PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
11159835-0	2001	Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells.	ribonucleic	43-54	metallothionein 2A	Homo sapiens	14-32
11024027-7	2001	Conversely, mutation of Ile(265) in MC3 (the corresponding residue of Tyr(268)) to Tyr displayed a gain of affinity for [d-Tyr(4)]MT-II, but not for Agouti protein, and a loss of affinity for [Nle(4)]Lys-gamma(2)-MSH as compared with wild-type MC3R.	D-tyrosine	121-126	metallothionein 2A	Homo sapiens	130-135
11127411-8	2000	In Northern blotting experiments, MT-II mRNA levels were induced over a wide range of Zn concentrations during 2-h exposures; specifcally, levels increased by 9- to 115-fold with exposure to 100 microM ZnCl, and by 16- to 311-fold with exposure to 200 microM ZnCl2.	Zinc	86-88	metallothionein 2A	Homo sapiens	34-39
11024027-7	2001	Conversely, mutation of Ile(265) in MC3 (the corresponding residue of Tyr(268)) to Tyr displayed a gain of affinity for [d-Tyr(4)]MT-II, but not for Agouti protein, and a loss of affinity for [Nle(4)]Lys-gamma(2)-MSH as compared with wild-type MC3R.	Isoleucine	24-27	metallothionein 2A	Homo sapiens	130-135
11188527-8	2000	Molecular mechanics calculations suggest that changes of even a single amino acid in lobster Cd3 beta N toward lobster Cd3 beta C-->N or in mammalian MT1 or MT2 toward Cd3 beta-MT3 (GIF) can destabilize their structures.	Nitrogen	102-103	metallothionein 2A	Homo sapiens	160-163
11127411-8	2000	In Northern blotting experiments, MT-II mRNA levels were induced over a wide range of Zn concentrations during 2-h exposures; specifcally, levels increased by 9- to 115-fold with exposure to 100 microM ZnCl, and by 16- to 311-fold with exposure to 200 microM ZnCl2.	zncl	202-206	metallothionein 2A	Homo sapiens	34-39
11127411-8	2000	In Northern blotting experiments, MT-II mRNA levels were induced over a wide range of Zn concentrations during 2-h exposures; specifcally, levels increased by 9- to 115-fold with exposure to 100 microM ZnCl, and by 16- to 311-fold with exposure to 200 microM ZnCl2.	zinc chloride	259-264	metallothionein 2A	Homo sapiens	34-39
10716192-6	2000	One to seven molar equivalents of zinc or of cadmium were added to metal-free human MT-2 at neutral pH, and the resulting complexes were measured by ESI mass spectrometry.	Cadmium	45-52	metallothionein 2A	Homo sapiens	84-88
11177190-4	2000	Our aim was to show whether measurement of T lymphocyte MT-2A mRNA, using a competitive reverse transcriptase (RT)--polymerase chain reaction (PCR) assay, could indicate Zn status in human subjects in a residential Zn-depletion study.	Zinc	170-172	metallothionein 2A	Homo sapiens	56-61
11177190-4	2000	Our aim was to show whether measurement of T lymphocyte MT-2A mRNA, using a competitive reverse transcriptase (RT)--polymerase chain reaction (PCR) assay, could indicate Zn status in human subjects in a residential Zn-depletion study.	Zinc	215-217	metallothionein 2A	Homo sapiens	56-61
11068946-1	2000	It has been difficult, so far, to obtain melatonin analogs possessing high selectivity for the respective melatonin receptors, mt1 and MT2.	Melatonin	41-50	metallothionein 2A	Homo sapiens	135-138
11068946-7	2000	On the contrary, it elicited only minimal MT2 receptor-mediated G protein activation, with a relative intrinsic activity of 0.16, and was also able to inhibit the melatonin-induced MT2 receptor-mediated G protein activation, with a pKB value of 7.4.	Melatonin	163-172	metallothionein 2A	Homo sapiens	181-184
11057756-5	2000	The data suggest that in human placental trophoblasts, a correlation may exist between MT2 receptor gene expression and the direct anti-proliferative action of melatonin.	Melatonin	160-169	metallothionein 2A	Homo sapiens	87-90
10920283-3	2000	In the present study, we investigated the therapeutic effect of the combination of vascular endothelial growth factor neutralizing antibody (VEGF Ab) and mitomycin C (MMC) on MT-2, a human gastric cancer xenograft.	Mitomycin	154-165	metallothionein 2A	Homo sapiens	175-179
10920283-3	2000	In the present study, we investigated the therapeutic effect of the combination of vascular endothelial growth factor neutralizing antibody (VEGF Ab) and mitomycin C (MMC) on MT-2, a human gastric cancer xenograft.	Mitomycin	167-170	metallothionein 2A	Homo sapiens	175-179
10842331-2	2000	We report the effects of melatonin on the cellular morphology of Chinese hamster ovary (CHO) cells transformed to express the human melatonin receptors, mt1 and MT2.	Melatonin	25-34	metallothionein 2A	Homo sapiens	161-164
11063602-4	2000	The affinities of the compounds for melatonin binding sites were evaluated in vitro in binding assays using chicken brain melatonin and the human mt(1) and MT(2) receptors expressed in HEK-293 cells.	Melatonin	36-45	metallothionein 2A	Homo sapiens	156-160
11063602-7	2000	The data highlighted the role of the methoxy group located in the ortho position to the ethylamido chain as compounds with picomolar affinities such as 14c were obtained (chicken brain, hmt(1), hMT(2) K(i) values = 0.02, 0.008, 0.069 nM, respectively).	Carbon-14	152-155	metallothionein 2A	Homo sapiens	194-199
11501155-2	2000	METHODS: An inducible system, MT-II regulatory system which allowed controlled expression of protein upon addition of ZnSO4(100 mumol/L) as an external inducer was used.	Zinc Sulfate	118-123	metallothionein 2A	Homo sapiens	30-35
10940647-14	2000	Increased expression of MT-1E, as well as MT-1X and MT-2A, protects against metal toxicity in PMC42 breast cancer cells.	Metals	76-81	metallothionein 2A	Homo sapiens	52-57
10738107-6	2000	In both NIH-mt1 and NIH-MT2 cells, melatonin pretreatment decreased cell proliferation and transformation.	Melatonin	35-44	metallothionein 2A	Homo sapiens	20-27
10716192-6	2000	One to seven molar equivalents of zinc or of cadmium were added to metal-free human MT-2 at neutral pH, and the resulting complexes were measured by ESI mass spectrometry.	Metals	67-72	metallothionein 2A	Homo sapiens	84-88
10506163-0	1999	Interactions of bismuth complexes with metallothionein(II).	Bismuth	16-23	metallothionein 2A	Homo sapiens	39-58
10968275-0	2000	Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors.	phenylalkylamide	32-48	metallothionein 2A	Homo sapiens	105-108
10567918-4	2000	Fluorescent MTII localized to the nucleus of digitonin-permeabilized human SCC25 carcinoma cells, consistent with its endogenous distribution in these cells.	Digitonin	45-54	metallothionein 2A	Homo sapiens	12-16
10567918-6	2000	Depletion of adenosine triphosphate (ATP) inhibited MTII nuclear localization, implying energy-dependent nuclear translocation or retention of MT.	Adenosine Triphosphate	13-35	metallothionein 2A	Homo sapiens	52-56
10567918-6	2000	Depletion of adenosine triphosphate (ATP) inhibited MTII nuclear localization, implying energy-dependent nuclear translocation or retention of MT.	Adenosine Triphosphate	37-40	metallothionein 2A	Homo sapiens	52-56
10542048-2	1999	This folded retro-alpha domain was able to bind Cd(II) in identical stoichiometries with the chemically synthesized alpha domain of metallothionein-2.	cd(ii)	48-54	metallothionein 2A	Homo sapiens	132-149
10205014-2	1999	GR128107 (3-(1-acetyl-3-methyl-piperidine)-5-methoxyindole) has previously been reported to be a competitive melatonin receptor antagonist in blocking melatonin inhibition of [3H]-dopamine release from rabbit retina, a response mediated by the MT2 receptor subtype.	GR 128107	0-8	metallothionein 2A	Homo sapiens	244-247
10471781-7	1999	Copper administration gave rise to substantially increased MT-1 mRNA, a slightly lower increase in MT-2 and also a significant increase in CP mRNA with similar kinetics.	Copper	0-6	metallothionein 2A	Homo sapiens	99-103
10403520-5	1999	The treatment of the two cell lines with 50 microM CdCl2 induced hsp72, hsp32 and metallothionein (MT-II) mRNAs, and the induction level of each mRNA did not differ in the two cell lines.	Cadmium Chloride	51-56	metallothionein 2A	Homo sapiens	82-97
10403520-5	1999	The treatment of the two cell lines with 50 microM CdCl2 induced hsp72, hsp32 and metallothionein (MT-II) mRNAs, and the induction level of each mRNA did not differ in the two cell lines.	Cadmium Chloride	51-56	metallothionein 2A	Homo sapiens	99-104
10403520-6	1999	However, the treatment with 20 microM CdCl2 induced the hsp72 and hsp32 mRNAs in A2780CP cells less than in A2780 cells, while the MT-II mRNA was induced to similar levels in the two cell lines.	Cadmium Chloride	38-43	metallothionein 2A	Homo sapiens	131-136
10405347-1	1999	In search for selective agonists at human melanocortin-4 receptor, proline-substituted analogs of MTII, a potent nonselective agonist at melanocortin receptors, were prepared by solid-phase syntheses and evaluated for their ability to bind and activate human MC-3, MC-4, and MC-5 receptors.	Proline	67-74	metallothionein 2A	Homo sapiens	98-102
10405347-1	1999	In search for selective agonists at human melanocortin-4 receptor, proline-substituted analogs of MTII, a potent nonselective agonist at melanocortin receptors, were prepared by solid-phase syntheses and evaluated for their ability to bind and activate human MC-3, MC-4, and MC-5 receptors.	MC-4	265-269	metallothionein 2A	Homo sapiens	98-102
10455277-1	1999	NIH3T3 fibroblast cells transfected with the full-length coding region of the MT2 human melatonin receptor stably expressed the receptor that is coupled to a pertussis toxin-sensitive G protein and exhibits high affinity for melatonin (K(I) = 261 pM).	Melatonin	88-97	metallothionein 2A	Homo sapiens	78-81
10455277-4	1999	MT2 melatonin receptors mediated incorporation of [35S]-GTPgammaS into isolated membranes via receptor catalyzed exchange of [35S]-GTPgammaS for GDP.	Sulfur-35	51-54	metallothionein 2A	Homo sapiens	0-3
10455277-4	1999	MT2 melatonin receptors mediated incorporation of [35S]-GTPgammaS into isolated membranes via receptor catalyzed exchange of [35S]-GTPgammaS for GDP.	Sulfur-35	126-129	metallothionein 2A	Homo sapiens	0-3
10455277-4	1999	MT2 melatonin receptors mediated incorporation of [35S]-GTPgammaS into isolated membranes via receptor catalyzed exchange of [35S]-GTPgammaS for GDP.	Guanosine Diphosphate	145-148	metallothionein 2A	Homo sapiens	0-3
10455277-9	1999	The other two mt1 antagonists used here, 4P-PDOT and N-[(2-phenyl-1H-indol-3-yl)ethyl]cyclobutanecarboxamide, behaved as partial agonists at the MT2 subtype, with relative intrinsic activities of 0.37 and 0.39, respectively.	n-[(2-phenyl-1h-indol-3-yl)ethyl]cyclobutanecarboxamide	53-108	metallothionein 2A	Homo sapiens	145-148
10381796-2	1999	At least three types of binding sites have been described for melatonin: the G-coupled, seven-transmembrane domain receptors mt1 and MT2 and a putative binding site called MT3.	Melatonin	62-71	metallothionein 2A	Homo sapiens	133-136
10420436-2	1999	In the present study, we describe the utility of a melanophore cell line from Xenopus laevis for exploring structure-activity relationships among novel melatonin analogues and report a novel MT2-selective agonist (IIK7) and MT2-selective receptor antagonist (K185).	K 185	259-263	metallothionein 2A	Homo sapiens	191-194
10420436-2	1999	In the present study, we describe the utility of a melanophore cell line from Xenopus laevis for exploring structure-activity relationships among novel melatonin analogues and report a novel MT2-selective agonist (IIK7) and MT2-selective receptor antagonist (K185).	K 185	259-263	metallothionein 2A	Homo sapiens	224-227
10420436-6	1999	A low concentration (10(-9) M) antagonizes melatonin inhibition of forskolin stimulation of cyclic AMP in NIH3T3 cells expressing human MT2 receptors, but has no effect in cells expressing mt1 receptors.	Melatonin	43-52	metallothionein 2A	Homo sapiens	136-139
10420436-6	1999	A low concentration (10(-9) M) antagonizes melatonin inhibition of forskolin stimulation of cyclic AMP in NIH3T3 cells expressing human MT2 receptors, but has no effect in cells expressing mt1 receptors.	Colforsin	67-76	metallothionein 2A	Homo sapiens	136-139
10420436-7	1999	In binding assays, K185 is 140-fold selective for the MT2 subtype.	K 185	19-23	metallothionein 2A	Homo sapiens	54-57
10205014-2	1999	GR128107 (3-(1-acetyl-3-methyl-piperidine)-5-methoxyindole) has previously been reported to be a competitive melatonin receptor antagonist in blocking melatonin inhibition of [3H]-dopamine release from rabbit retina, a response mediated by the MT2 receptor subtype.	3-(1-acetyl-3-methyl-piperidine)-5-methoxyindole	10-58	metallothionein 2A	Homo sapiens	244-247
10205014-18	1999	This suggestion is supported by the finding that GR128107, like melatonin, acted as a full agonist and inhibited forskolin-stimulation of cyclic AMP accumulation in NIH-3T3 cells expressing a high density of human mt1 or MT2 receptors.	GR 128107	49-57	metallothionein 2A	Homo sapiens	221-224
10205014-18	1999	This suggestion is supported by the finding that GR128107, like melatonin, acted as a full agonist and inhibited forskolin-stimulation of cyclic AMP accumulation in NIH-3T3 cells expressing a high density of human mt1 or MT2 receptors.	Colforsin	113-122	metallothionein 2A	Homo sapiens	221-224
18475903-9	1999	Mass spectral data are reported for metal-free MT 2A and Ag(n)-MT (n = 14-18).	Metals	36-41	metallothionein 2A	Homo sapiens	47-52
10366984-4	1999	The cells expressed Fas antigen was added to HepG2.2.15 cells expressing Fas Ligand together with fresh RPMI 1640 medium and incubated for 48-72 hours at 37 degrees C. The apoptosis in MT2 cells was detected by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL).	rpmi 1640 medium	104-120	metallothionein 2A	Homo sapiens	185-188
10366984-4	1999	The cells expressed Fas antigen was added to HepG2.2.15 cells expressing Fas Ligand together with fresh RPMI 1640 medium and incubated for 48-72 hours at 37 degrees C. The apoptosis in MT2 cells was detected by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL).	deoxyuridine triphosphate	258-262	metallothionein 2A	Homo sapiens	185-188
9893984-10	1999	Our data provide indirect evidence for the suggestion that the Cys-110 to Cys-117 octapeptide loop of human AGRP mimics the conformation of alpha-MSH, MT-II, and SHU-9119.	Cysteine	63-66	metallothionein 2A	Homo sapiens	151-156
9893984-10	1999	Our data provide indirect evidence for the suggestion that the Cys-110 to Cys-117 octapeptide loop of human AGRP mimics the conformation of alpha-MSH, MT-II, and SHU-9119.	Cysteine	74-77	metallothionein 2A	Homo sapiens	151-156
10608615-11	1999	Finally, in order to eliminate the class I molecules from the cell surface, we treated the MT-2 using a buffered citric acid solution (pH 3.8).	Citric Acid	113-124	metallothionein 2A	Homo sapiens	91-95
10085460-1	1999	NIH3T3 fibroblast cells transfected with the full-length coding regions of the mt1 and MT2 human melatonin receptors stably expressed the receptor, coupled to a pertussis-toxin-sensitive G protein and exhibiting high affinity for melatonin.	Melatonin	97-106	metallothionein 2A	Homo sapiens	87-90
10085460-2	1999	Both mt1 and MT2 melatonin receptors mediated the incorporation of [35S]GTPgammaS into isolated membranes via receptor-catalyzed exchange of [35S]GTPgammaS for GDP.	Sulfur-35	68-71	metallothionein 2A	Homo sapiens	13-16
10085460-2	1999	Both mt1 and MT2 melatonin receptors mediated the incorporation of [35S]GTPgammaS into isolated membranes via receptor-catalyzed exchange of [35S]GTPgammaS for GDP.	Sulfur-35	142-145	metallothionein 2A	Homo sapiens	13-16
10085460-2	1999	Both mt1 and MT2 melatonin receptors mediated the incorporation of [35S]GTPgammaS into isolated membranes via receptor-catalyzed exchange of [35S]GTPgammaS for GDP.	Guanosine Diphosphate	160-163	metallothionein 2A	Homo sapiens	13-16
10085460-7	1999	Two other mt1 antagonists, 4P-PDOT and N-[(2-phenyl-1H-indol-3-yl)ethyl]cyclobutanecarboxamide, behaved as partial agonists at the MT2 subtype, with relative intrinsic activities of 0.37 and 0.39, respectively.	n-[(2-phenyl-1h-indol-3-yl)ethyl]cyclobutanecarboxamide	39-94	metallothionein 2A	Homo sapiens	131-134
10447101-0	1999	Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-melanotropin.	Lactams	56-62	metallothionein 2A	Homo sapiens	49-54
10447101-2	1999	Replacement of His with Ala resulted in [Ala6]-MT-II with affinity and agonist potency at human MC3, MC4, and MC5 receptors similar to MT-II.	Histidine	15-18	metallothionein 2A	Homo sapiens	47-52
10447101-2	1999	Replacement of His with Ala resulted in [Ala6]-MT-II with affinity and agonist potency at human MC3, MC4, and MC5 receptors similar to MT-II.	Alanine	24-27	metallothionein 2A	Homo sapiens	47-52
10447101-5	1999	The nuclear magnetic resonance analysis of MT-II suggested involvement of Phe and Arg residues in H-bonds stabilizing the bent conformations of the peptide backbone.	Phenylalanine	74-77	metallothionein 2A	Homo sapiens	43-48
10447101-5	1999	The nuclear magnetic resonance analysis of MT-II suggested involvement of Phe and Arg residues in H-bonds stabilizing the bent conformations of the peptide backbone.	Arginine	82-85	metallothionein 2A	Homo sapiens	43-48
9545559-3	1998	The mRNA level of MT-II, a major isoform of MT genes, was more prominently increased than that of HSP70 when WISH cells were exposed to CdCl2 (5-15 microM, for 6 h).	Cadmium Chloride	136-141	metallothionein 2A	Homo sapiens	18-23
10696239-4	1998	Recently, the yeast two-hybrid system has identified hASNA-I as a cellular partner of metallothionein II suggesting an additional role in Zn homeostasis and cellular detoxification.	Zinc	138-140	metallothionein 2A	Homo sapiens	86-104
9790511-1	1998	By employing electron spin resonance spectroscopy, we examined the free radicals scavenging effects of hepatic metallothionein (MT) isoforms I and II (MTs-I and II) on four types of free radicals.	Free Radicals	67-80	metallothionein 2A	Homo sapiens	103-163
9790511-2	1998	Solutions of 0.15 mM of MT-I and 0.3 mM of MT-II were found to scavenge the 1,1-diphenyl-2-picrylhydrazyl radicals (1.30 x 10(15) spins/ml) completely.	1,1-diphenyl-2-picrylhydrazyl radicals	76-114	metallothionein 2A	Homo sapiens	43-48
9618428-4	1998	In Chinese hamster ovary cells expressing human mt1 or MT2 receptors, both melatonin and GR196429 dose-dependently inhibited forskolin-stimulated cAMP accumulation.	Melatonin	75-84	metallothionein 2A	Homo sapiens	55-58
9618428-4	1998	In Chinese hamster ovary cells expressing human mt1 or MT2 receptors, both melatonin and GR196429 dose-dependently inhibited forskolin-stimulated cAMP accumulation.	GR 196429	89-97	metallothionein 2A	Homo sapiens	55-58
9618428-4	1998	In Chinese hamster ovary cells expressing human mt1 or MT2 receptors, both melatonin and GR196429 dose-dependently inhibited forskolin-stimulated cAMP accumulation.	Colforsin	125-134	metallothionein 2A	Homo sapiens	55-58
12671304-5	1998	By employing electron spin resonance spectroscopy (ESR), we examined for the first time the free radical scavenging effects of MT-I and MT-II isoforms on four types of free radicals.	Free Radicals	92-104	metallothionein 2A	Homo sapiens	136-141
12671304-6	1998	Solutions of 0.15 mM of MT-I and 0.3 mM of MT-II scavenged the 1,1-diphenyl-2-picrylhydrazyl radicals completely.	1,1-diphenyl-2-picrylhydrazyl radicals	63-101	metallothionein 2A	Homo sapiens	43-48
12136178-2	1999	The results showed that MT-II promoter could be activated by the induction with 160 &mgr;mol/L Zn(2+) and the expression of Bcl-2 plays an important role in apoptosis of SGC7901 cells.	Adenosine Monophosphate	85-88	metallothionein 2A	Homo sapiens	24-29
12136178-2	1999	The results showed that MT-II promoter could be activated by the induction with 160 &mgr;mol/L Zn(2+) and the expression of Bcl-2 plays an important role in apoptosis of SGC7901 cells.	Zinc	99-101	metallothionein 2A	Homo sapiens	24-29
9545559-5	1998	Pretreatment of cells with 30 mM NAC significantly reduced both HSP70 and MT-II mRNA levels in the cells exposed to 50 microM CdCl2.	Cadmium Chloride	126-131	metallothionein 2A	Homo sapiens	74-79
9545559-10	1998	Taken together, NAC seems to have at least two concentration-dependent functions in WISH cells exposed to CdCl2; the low concentration of NAC can suppress the induction of HSP70 gene expression as well as the increase of lipid peroxidation via an antioxidant pathway, while the high concentration of NAC can suppress the induction of MT-II mRNA as well as cadmium-induced cell death.	Cadmium Chloride	106-111	metallothionein 2A	Homo sapiens	334-339
9006042-13	1997	These results suggest that TCP is uniquely involved in TMA-dependent methanogenesis, that this corrinoid protein is methylated by the substrate and demethylated by either isozyme of MT2, and that the predominant isozyme of MT2 found in TMA-grown cells is the favored participant in the TMA:CoM methyl transfer reaction.	4,4-dimethylcholesta-8,14-dien-3-ol	236-239	metallothionein 2A	Homo sapiens	223-226
9553716-3	1998	The canine MT-III had 2 insertions relative to known mammalian MT-I and MT-II: a threonine after the 4th amino acid and a block of 6 amino acids near the carboxyl terminus.	Threonine	81-90	metallothionein 2A	Homo sapiens	11-16
9666516-0	1998	Differential transactivation of human metallothionein-IIa in cisplatin-resistant and -sensitive cells.	Cisplatin	61-70	metallothionein 2A	Homo sapiens	38-57
9138684-9	1997	CdCl2 1 microM, ZnCl2 20-40 microM or HgCl2 2 microM pretreatment for 20 h induced MT-2 mRNA and total MT protein accumulation and had no effect on proliferation potential or metabolic activity, but significantly inhibited the ability of subsequent lipopolysaccharide treatment to induce the oxidative burst, increased adhesion to plastic, and MT-2 and interleukin-1 beta (IL-1 beta) mRNA accumulation.	Cadmium Chloride	0-5	metallothionein 2A	Homo sapiens	83-87
9138684-9	1997	CdCl2 1 microM, ZnCl2 20-40 microM or HgCl2 2 microM pretreatment for 20 h induced MT-2 mRNA and total MT protein accumulation and had no effect on proliferation potential or metabolic activity, but significantly inhibited the ability of subsequent lipopolysaccharide treatment to induce the oxidative burst, increased adhesion to plastic, and MT-2 and interleukin-1 beta (IL-1 beta) mRNA accumulation.	Cadmium Chloride	0-5	metallothionein 2A	Homo sapiens	344-348
9138684-9	1997	CdCl2 1 microM, ZnCl2 20-40 microM or HgCl2 2 microM pretreatment for 20 h induced MT-2 mRNA and total MT protein accumulation and had no effect on proliferation potential or metabolic activity, but significantly inhibited the ability of subsequent lipopolysaccharide treatment to induce the oxidative burst, increased adhesion to plastic, and MT-2 and interleukin-1 beta (IL-1 beta) mRNA accumulation.	zinc chloride	16-21	metallothionein 2A	Homo sapiens	83-87
9138684-9	1997	CdCl2 1 microM, ZnCl2 20-40 microM or HgCl2 2 microM pretreatment for 20 h induced MT-2 mRNA and total MT protein accumulation and had no effect on proliferation potential or metabolic activity, but significantly inhibited the ability of subsequent lipopolysaccharide treatment to induce the oxidative burst, increased adhesion to plastic, and MT-2 and interleukin-1 beta (IL-1 beta) mRNA accumulation.	zinc chloride	16-21	metallothionein 2A	Homo sapiens	344-348
9138684-9	1997	CdCl2 1 microM, ZnCl2 20-40 microM or HgCl2 2 microM pretreatment for 20 h induced MT-2 mRNA and total MT protein accumulation and had no effect on proliferation potential or metabolic activity, but significantly inhibited the ability of subsequent lipopolysaccharide treatment to induce the oxidative burst, increased adhesion to plastic, and MT-2 and interleukin-1 beta (IL-1 beta) mRNA accumulation.	Mercuric Chloride	38-43	metallothionein 2A	Homo sapiens	83-87
9138684-9	1997	CdCl2 1 microM, ZnCl2 20-40 microM or HgCl2 2 microM pretreatment for 20 h induced MT-2 mRNA and total MT protein accumulation and had no effect on proliferation potential or metabolic activity, but significantly inhibited the ability of subsequent lipopolysaccharide treatment to induce the oxidative burst, increased adhesion to plastic, and MT-2 and interleukin-1 beta (IL-1 beta) mRNA accumulation.	Mercuric Chloride	38-43	metallothionein 2A	Homo sapiens	344-348
9006042-10	1997	The TMA-MT polypeptides, when supplemented with purified methylcorrinoid:CoM methyltransferase (MT2), could effect the demethylation of TMA with the subsequent methylation of CoM and the production of dimethylamine at specific activities of up to 600 nmol/min/mg of TMA-MT protein.	4,4-dimethylcholesta-8,14-dien-3-ol	4-7	metallothionein 2A	Homo sapiens	96-99
9006042-10	1997	The TMA-MT polypeptides, when supplemented with purified methylcorrinoid:CoM methyltransferase (MT2), could effect the demethylation of TMA with the subsequent methylation of CoM and the production of dimethylamine at specific activities of up to 600 nmol/min/mg of TMA-MT protein.	4,4-dimethylcholesta-8,14-dien-3-ol	136-139	metallothionein 2A	Homo sapiens	96-99
9006042-10	1997	The TMA-MT polypeptides, when supplemented with purified methylcorrinoid:CoM methyltransferase (MT2), could effect the demethylation of TMA with the subsequent methylation of CoM and the production of dimethylamine at specific activities of up to 600 nmol/min/mg of TMA-MT protein.	dimethylamine	201-214	metallothionein 2A	Homo sapiens	96-99
9006042-10	1997	The TMA-MT polypeptides, when supplemented with purified methylcorrinoid:CoM methyltransferase (MT2), could effect the demethylation of TMA with the subsequent methylation of CoM and the production of dimethylamine at specific activities of up to 600 nmol/min/mg of TMA-MT protein.	4,4-dimethylcholesta-8,14-dien-3-ol	136-139	metallothionein 2A	Homo sapiens	96-99
9006042-12	1997	TMA-MT could interact with either isozyme of MT2 but had the greatest affinity for the A isozyme.	tma-mt	0-6	metallothionein 2A	Homo sapiens	45-48
9287296-3	1997	In addition, we also examined the effects of these same mutations on the binding affinity and potency of the structurally related agonists alpha-MSH, gamma-MSH, and Ac-Nle4-cyclic-[Asp5,His6,D-Phe7,Arg8,Trp9,Lys10]NH2 (MT-II).	ac-nle4-cyclic	165-179	metallothionein 2A	Homo sapiens	219-224
9342709-2	1997	Asn at position 4 conserved among all mammalian metallothionein-1 and metallothionein-2 is replaced by Asp in the canine metallothionein cDNA clone.	Asparagine	0-3	metallothionein 2A	Homo sapiens	70-87
9006042-13	1997	These results suggest that TCP is uniquely involved in TMA-dependent methanogenesis, that this corrinoid protein is methylated by the substrate and demethylated by either isozyme of MT2, and that the predominant isozyme of MT2 found in TMA-grown cells is the favored participant in the TMA:CoM methyl transfer reaction.	4,4-dimethylcholesta-8,14-dien-3-ol	236-239	metallothionein 2A	Homo sapiens	223-226
8774075-1	1996	Titration studies of Cd-binding alpha-fragment, the carboxyl-terminal half of human metallothionein-2, which was independently expressed in Escherichia coli as a Cd-binding form, with Cu were performed.	Cadmium	21-23	metallothionein 2A	Homo sapiens	84-101
8906826-2	1996	Here we show that M-T2 protein is secreted from infected cells as an N-linked glycoprotein, with both complex and hybrid or high mannose oligosaccharide chains.	mannose oligosaccharide	129-152	metallothionein 2A	Homo sapiens	18-22
8837045-4	1996	administration of ZnSO4 increases the synthesis of metallothionein I mRNA and metallothionein II mRNA.	Zinc Sulfate	18-23	metallothionein 2A	Homo sapiens	78-96
8774075-1	1996	Titration studies of Cd-binding alpha-fragment, the carboxyl-terminal half of human metallothionein-2, which was independently expressed in Escherichia coli as a Cd-binding form, with Cu were performed.	Cadmium	162-164	metallothionein 2A	Homo sapiens	84-101
8786322-7	1996	These bands were also recovered with CD21 precipitated from MT2 cells with C3d bound to Sepharose via the internal thioester, but were absent in CD21-expressing B cell lines.	Sepharose	88-97	metallothionein 2A	Homo sapiens	60-63
8852057-4	1996	Western blots indicated that metallothioneins-I and II eluted at 16% acetonitrile and metallothionein-III eluted at 37% acetonitrile.	acetonitrile	69-81	metallothionein 2A	Homo sapiens	29-54
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	Lactams	4-10	metallothionein 2A	Homo sapiens	36-48
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	Lactams	4-10	metallothionein 2A	Homo sapiens	50-55
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	Lactams	4-10	metallothionein 2A	Homo sapiens	136-141
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	ac-nle4-asp5-his6-d-phe7-arg8	76-105	metallothionein 2A	Homo sapiens	36-48
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	ac-nle4-asp5-his6-d-phe7-arg8	76-105	metallothionein 2A	Homo sapiens	50-55
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	alpha-msh4-10-nh2	117-134	metallothionein 2A	Homo sapiens	36-48
8637402-2	1996	The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro.	alpha-msh4-10-nh2	117-134	metallothionein 2A	Homo sapiens	50-55
7635826-11	1995	A likely mechanism is that the 29-kDa corrinoid is methylated by MMA and the methyl group is then transferred by the "A" isozyme of MT2 to CoM.	29-kda	31-37	metallothionein 2A	Homo sapiens	132-135
8720126-0	1995	Expression of human metallothionein-2 in Escherichia coli: cadmium tolerance of transformed cells.	Cadmium	59-66	metallothionein 2A	Homo sapiens	20-37
8720126-8	1995	It was demonstrated that human metallothionein-2 functioned for cadmium detoxification in E. coli.	Cadmium	64-71	metallothionein 2A	Homo sapiens	31-48
7635826-11	1995	A likely mechanism is that the 29-kDa corrinoid is methylated by MMA and the methyl group is then transferred by the "A" isozyme of MT2 to CoM.	Corrinoids	38-47	metallothionein 2A	Homo sapiens	132-135
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	metallothionein 2A	Homo sapiens	137-142
8664218-4	1995	Northern hybridization with human MT-IIa cDNA showed a significant increase in the gene expression of MT in the cells treated with 1,25(OH)2D3.	Calcitriol	131-142	metallothionein 2A	Homo sapiens	34-40
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	metallothionein 2A	Homo sapiens	197-202
7880833-1	1995	Rabbit liver metallothionein-2 is shown to form covalent bonds with the anticancer agent melphalan, in support of the hypothesis that covalent sequestration by metallothionein constitutes one mechanism for the cross-resistance acquired by cancer patients to therapeutic alkylating agents.	Melphalan	89-98	metallothionein 2A	Homo sapiens	13-30
7989768-2	1994	A 2-kB cDNA for the vitamin D receptor (VDR) was cloned in sense orientation into the plasmid pMEP4 (containing a cadmium-inducible metallothionein II promoter and a hygromycin-resistance selection gene) and transfected into monoblastoid U937 cells.	Cadmium	114-121	metallothionein 2A	Homo sapiens	132-150
7999084-0	1994	Metallothionein-II and ferritin H mRNA levels are increased in arsenite-exposed HeLa cells.	arsenite	63-71	metallothionein 2A	Homo sapiens	0-18
7999084-4	1994	Isolation and sequencing of three clones that showed a higher hybridization signal to RNA from arsenite-exposed cells, versus unexposed cells, revealed that two of the cDNAs coded for human ferritin H chain and the other coded for metallothionein-II.	arsenite	95-103	metallothionein 2A	Homo sapiens	231-249
34886787-6	2021	It is a melatonin receptor agonist (MT1 and MT2) and a 5-HT2C receptor antagonist.	Melatonin	8-17	metallothionein 2A	Homo sapiens	44-47
7920723-3	1994	Transcripts and Cd-binding proteins of expected size were observed in plants expressing either the 35S2-hMTII or the 35S2-hMTII/GUS gene, and in the latter plants a protein with GUS activity that was larger than the native GUS enzyme was observed.	Cadmium	16-18	metallothionein 2A	Homo sapiens	104-109
7920723-3	1994	Transcripts and Cd-binding proteins of expected size were observed in plants expressing either the 35S2-hMTII or the 35S2-hMTII/GUS gene, and in the latter plants a protein with GUS activity that was larger than the native GUS enzyme was observed.	Cadmium	16-18	metallothionein 2A	Homo sapiens	122-127
7920723-4	1994	Thus, plants expressing the hMTII-GUS gene synthesize a bifunctional protein, with both GUS and Cd-binding activity.	Cadmium	96-98	metallothionein 2A	Homo sapiens	28-33
8206390-0	1994	Interactions of nuclear proteins from uninduced, induced and superinduced HeLa cells with metal regulatory elements MRE3 and 4 of the human metallothionein IIa-encoding gene.	Metals	90-95	metallothionein 2A	Homo sapiens	140-159
7981453-5	1994	In this paper we report on the isolation of an estrogen receptor (ER) from a TAM stimulated tumor (MCF-7/MT2) which contains a point mutation that causes a tyrosine for aspartate substitution at amino acid 351 in the ligand binding domain.	Tamoxifen	77-80	metallothionein 2A	Homo sapiens	105-108
8432788-0	1993	Augmented induction by dexamethasone of metallothionein IIa messenger ribonucleic acid in fibroblasts from a patient with cortisol hyperreactive syndrome.	Dexamethasone	23-36	metallothionein 2A	Homo sapiens	40-59
8432788-1	1993	Northern blot analysis was used to investigate the effect of dexamethasone (Dex) or zinc on messenger RNA (mRNA) levels of metallothionein-IIa (MT-IIa) in fibroblasts from a patient with cortisol hyperreactive syndrome and from three normal subjects.	Dexamethasone	61-74	metallothionein 2A	Homo sapiens	123-142
8432788-1	1993	Northern blot analysis was used to investigate the effect of dexamethasone (Dex) or zinc on messenger RNA (mRNA) levels of metallothionein-IIa (MT-IIa) in fibroblasts from a patient with cortisol hyperreactive syndrome and from three normal subjects.	Dexamethasone	61-74	metallothionein 2A	Homo sapiens	144-150
8432788-1	1993	Northern blot analysis was used to investigate the effect of dexamethasone (Dex) or zinc on messenger RNA (mRNA) levels of metallothionein-IIa (MT-IIa) in fibroblasts from a patient with cortisol hyperreactive syndrome and from three normal subjects.	Dexamethasone	76-79	metallothionein 2A	Homo sapiens	123-142
8432788-1	1993	Northern blot analysis was used to investigate the effect of dexamethasone (Dex) or zinc on messenger RNA (mRNA) levels of metallothionein-IIa (MT-IIa) in fibroblasts from a patient with cortisol hyperreactive syndrome and from three normal subjects.	Dexamethasone	76-79	metallothionein 2A	Homo sapiens	144-150
8432788-2	1993	Dex was seen to increase MT-IIa mRNA levels and brought them to a maximum after 12 h. Zinc also increased the levels of MT-IIa mRNA and brought them to a maximum at 8 h after the addition.	Dexamethasone	0-3	metallothionein 2A	Homo sapiens	25-31
8432788-2	1993	Dex was seen to increase MT-IIa mRNA levels and brought them to a maximum after 12 h. Zinc also increased the levels of MT-IIa mRNA and brought them to a maximum at 8 h after the addition.	Dexamethasone	0-3	metallothionein 2A	Homo sapiens	120-126
8432788-3	1993	Dex as well as zinc caused a dose-related increase in MT-IIa mRNA levels.	Dexamethasone	0-3	metallothionein 2A	Homo sapiens	54-60
8432788-4	1993	Dex had a maximal inductive effect on MT-IIa at a concentration of 10(-6) mol/L and zinc at a concentration of 10(-4) mol/L.	Dexamethasone	0-3	metallothionein 2A	Homo sapiens	38-44
8432788-8	1993	These data indicated that the patient"s cells were hyperreactive to glucocorticoids as seen from the effect of Dex on the MT-IIa mRNA levels.	Dexamethasone	111-114	metallothionein 2A	Homo sapiens	122-128
1307930-2	1992	Synthetic antisense oligonucleotides (ODN), with sequence complementary to the messenger RNA coding for human metallothionein II, were prepared and tested for their ability to inhibit both constitutive- and cadmium-induced metallothionein protein synthesis in human Chang liver cells and hamster lung V79 cells in culture.	Oligonucleotides	20-36	metallothionein 2A	Homo sapiens	110-128
1307930-2	1992	Synthetic antisense oligonucleotides (ODN), with sequence complementary to the messenger RNA coding for human metallothionein II, were prepared and tested for their ability to inhibit both constitutive- and cadmium-induced metallothionein protein synthesis in human Chang liver cells and hamster lung V79 cells in culture.	Cadmium	207-214	metallothionein 2A	Homo sapiens	110-128
1385238-8	1992	The results from immunoblots, enzyme digestions and DEAE-Sephacell binding studies suggest that the unreduced MT2 antigen is a large protein composed of subunits which are connected by disulfide bonds.	2-diethylaminoethanol	52-56	metallothionein 2A	Homo sapiens	110-113
1385238-8	1992	The results from immunoblots, enzyme digestions and DEAE-Sephacell binding studies suggest that the unreduced MT2 antigen is a large protein composed of subunits which are connected by disulfide bonds.	sephacell	57-66	metallothionein 2A	Homo sapiens	110-113
1385238-8	1992	The results from immunoblots, enzyme digestions and DEAE-Sephacell binding studies suggest that the unreduced MT2 antigen is a large protein composed of subunits which are connected by disulfide bonds.	Disulfides	185-194	metallothionein 2A	Homo sapiens	110-113
1307915-1	1992	A synthetic antisense oligodeoxyribonucleotide with sequence complementary to the messenger RNA (mRNA) coding for human metallothionein (MT) II was prepared and tested for its ability to inhibit both constitutive- and cadmium-induced MT protein synthesis in neuroblastoma-IMR and Chang liver cells in culture.	Oligodeoxyribonucleotides	22-46	metallothionein 2A	Homo sapiens	120-143
1307915-1	1992	A synthetic antisense oligodeoxyribonucleotide with sequence complementary to the messenger RNA (mRNA) coding for human metallothionein (MT) II was prepared and tested for its ability to inhibit both constitutive- and cadmium-induced MT protein synthesis in neuroblastoma-IMR and Chang liver cells in culture.	Cadmium	218-225	metallothionein 2A	Homo sapiens	120-143
1544874-1	1992	When murine erythroleukemia (MEL) cells, containing the transferred rat c-myc gene under the control of human metallothionein II gene promoter, are induced to differentiate with dimethyl sulfoxide, the level of differentiation is dependent on the c-Myc level, which is modulated by the addition of Zn ions.	Dimethyl Sulfoxide	178-196	metallothionein 2A	Homo sapiens	110-128
1712546-0	1991	Aberrant MT2 positivity distinguishes follicular lymphoma from reactive follicular hyperplasia in B5- and formalin-fixed paraffin sections.	Formaldehyde	106-114	metallothionein 2A	Homo sapiens	9-12
1712546-0	1991	Aberrant MT2 positivity distinguishes follicular lymphoma from reactive follicular hyperplasia in B5- and formalin-fixed paraffin sections.	Paraffin	121-129	metallothionein 2A	Homo sapiens	9-12
1712546-5	1991	Ninety-two percent of the B5-fixed and 77% of the formalin-fixed lymphomas were MT2 positive.	Formaldehyde	50-58	metallothionein 2A	Homo sapiens	80-83
1712546-9	1991	The authors conclude that MT2 may be useful in distinguishing follicular lymphoma from follicular hyperplasia in paraffin sections.	paraffin sections	113-130	metallothionein 2A	Homo sapiens	26-29
1828514-5	1991	For example, the carbohydrate determinants recognized by MT2 (CD45RA) and 2B11 (CD45) were not or were very weakly expressed on germinal center cells, whereas the carbohydrate determinant recognized by MT3 (CD45RB) was not expressed on the majority of mantle zone B cells.	Carbohydrates	17-29	metallothionein 2A	Homo sapiens	57-60
2167380-0	1990	Amide proton exchange in human metallothionein-2 measured by nuclear magnetic resonance spectroscopy.	Amides	0-5	metallothionein 2A	Homo sapiens	31-48
2167380-1	1990	In human metallothionein-2, the exchange rate constants of ten amide protons were found to range from 1.7 x 10(-4) to 1 x 10(-1) min-1 at pH 6.3 and 8 degrees C. Most of these slowly exchanging protons could be associated with hydrogen bonds in secondary structure elements of the alpha-domain.	Amides	63-68	metallothionein 2A	Homo sapiens	9-26
2167380-1	1990	In human metallothionein-2, the exchange rate constants of ten amide protons were found to range from 1.7 x 10(-4) to 1 x 10(-1) min-1 at pH 6.3 and 8 degrees C. Most of these slowly exchanging protons could be associated with hydrogen bonds in secondary structure elements of the alpha-domain.	Hydrogen	227-235	metallothionein 2A	Homo sapiens	9-26
2223152-3	1990	[3H]TdR incorporation was also inhibited in MT-1 and MT-2 cells by treatment with bestatin.	Tritium	1-3	metallothionein 2A	Homo sapiens	53-57
2223152-3	1990	[3H]TdR incorporation was also inhibited in MT-1 and MT-2 cells by treatment with bestatin.	ubenimex	82-90	metallothionein 2A	Homo sapiens	53-57
2128185-4	1990	wt of 70 kd and a pl of 4.7 from the cell lysate of MT-2, a human T cell line constitutively expressing IL-2R, labeled metabolically with [35S]cysteine.	Sulfur-35	139-142	metallothionein 2A	Homo sapiens	52-56
2128185-4	1990	wt of 70 kd and a pl of 4.7 from the cell lysate of MT-2, a human T cell line constitutively expressing IL-2R, labeled metabolically with [35S]cysteine.	Cysteine	143-151	metallothionein 2A	Homo sapiens	52-56
2128185-5	1990	In contrast, only p75 was detected when the lysate of MT-2 cells surface-labeled with Na125I was immunoprecipitated with TU27 mAb.	na125i	86-92	metallothionein 2A	Homo sapiens	54-58
33809171-6	2021	MCF7-TamR cells overexpress messenger RNAs (mRNAs) for metallothionein 2A and ferritin heavy chain, and they are re-sensitized to Tam by inhibition of autophagy.	Tamoxifen	5-8	metallothionein 2A	Homo sapiens	55-73
23662831-1	2013	BACKGROUND AND AIMS: Metallothionein (MT)-1 and -2 are low-molecular weight, cysteine-rich, intracellular metal-binding proteins involved in diverse functions, such as metal homeostasis, cell cycle progression, cell differentiation, and carcinogenesis.	Cysteine	77-85	metallothionein 2A	Homo sapiens	21-50
23662831-1	2013	BACKGROUND AND AIMS: Metallothionein (MT)-1 and -2 are low-molecular weight, cysteine-rich, intracellular metal-binding proteins involved in diverse functions, such as metal homeostasis, cell cycle progression, cell differentiation, and carcinogenesis.	Metals	106-111	metallothionein 2A	Homo sapiens	21-50
23662831-1	2013	BACKGROUND AND AIMS: Metallothionein (MT)-1 and -2 are low-molecular weight, cysteine-rich, intracellular metal-binding proteins involved in diverse functions, such as metal homeostasis, cell cycle progression, cell differentiation, and carcinogenesis.	Metals	168-173	metallothionein 2A	Homo sapiens	21-50
7818178-0	1994	A polymorphic tetranucleotide repeat in the ovine metallothionein II gene.	tetranucleotide	14-29	metallothionein 2A	Homo sapiens	50-68
8134403-2	1994	By using synthetic oligonucleotides with sequences complementary to the mRNA coding for human metallothionein II, we have shown that (a) inhibition of metallothionein synthesis causes cells to die from metal toxicity, (b) metallothionein possesses an essential gene, and (c) modifications in oligonucleotide structures exhibit specificity in inhibiting metallothionein synthesis.	Oligonucleotides	19-35	metallothionein 2A	Homo sapiens	94-112
8134403-2	1994	By using synthetic oligonucleotides with sequences complementary to the mRNA coding for human metallothionein II, we have shown that (a) inhibition of metallothionein synthesis causes cells to die from metal toxicity, (b) metallothionein possesses an essential gene, and (c) modifications in oligonucleotide structures exhibit specificity in inhibiting metallothionein synthesis.	Oligonucleotides	19-34	metallothionein 2A	Homo sapiens	94-112
1458488-3	1992	LIF mRNA expression was enhanced by interleukin 2 or 12-O-tetradecanoylphorbol-13-acetate in MT-2 cells.	Tetradecanoylphorbol Acetate	53-89	metallothionein 2A	Homo sapiens	93-97
1529530-4	1992	The latter included induction of human metallothionein 2A (HMT2A) by phorbol ester and induction of IP-10 RNA by IFN-gamma.	Phorbol Esters	69-82	metallothionein 2A	Homo sapiens	39-57
1593628-2	1992	The comparison was based on complete sequence-specific 1H nuclear magnetic resonance assignments for human [Zn7]-metallothionein-2 obtained using the sequential assignment method.	Hydrogen	55-57	metallothionein 2A	Homo sapiens	113-130
1593628-4	1992	Only seven amide protons in [Zn7]- metallothionein-2 were found to have exchange rates lower than approximately 0.2 min-1 at pH 7.0 and 10 degrees C, which corresponds closely to the results of amide proton exchange studies with the [Cd7]- form of the protein.	Amides	11-16	metallothionein 2A	Homo sapiens	35-52
1593628-4	1992	Only seven amide protons in [Zn7]- metallothionein-2 were found to have exchange rates lower than approximately 0.2 min-1 at pH 7.0 and 10 degrees C, which corresponds closely to the results of amide proton exchange studies with the [Cd7]- form of the protein.	Amides	194-199	metallothionein 2A	Homo sapiens	35-52
1593628-5	1992	Finally, the 1H-1H distance constraints determined from nuclear Overhauser enhancement spectroscopy for human [Zn7]-metallothionein-2 were checked for compatibility with the [Cd7]-metallothionein-2 structure.	Hydrogen	13-15	metallothionein 2A	Homo sapiens	116-133
1593628-5	1992	Finally, the 1H-1H distance constraints determined from nuclear Overhauser enhancement spectroscopy for human [Zn7]-metallothionein-2 were checked for compatibility with the [Cd7]-metallothionein-2 structure.	Hydrogen	16-18	metallothionein 2A	Homo sapiens	116-133
2066364-0	1991	Amplification of the metallothionein-1 and metallothionein-2 genes in copper-resistant hepatoma cells.	Copper	70-76	metallothionein 2A	Homo sapiens	43-60
2066364-2	1991	The copper-resistant cell line HAC600, which is maintained in 600 microns copper, had increased steady-state mRNA levels for both the metallothionein-1 (MT-1) and the metallothionein-2 (MT-2) genes.	Copper	4-10	metallothionein 2A	Homo sapiens	167-184
2066364-2	1991	The copper-resistant cell line HAC600, which is maintained in 600 microns copper, had increased steady-state mRNA levels for both the metallothionein-1 (MT-1) and the metallothionein-2 (MT-2) genes.	Copper	4-10	metallothionein 2A	Homo sapiens	186-190
2388267-6	1990	The polypeptide-to-metal co-ordinative bonds in human metallothionein-2 are identical to those in the previously determined solution structures of rat metallothionein-2 and rabbit metallothionein-2a, and the polypeptide conformations in the three proteins are also closely similar.	Metals	19-24	metallothionein 2A	Homo sapiens	54-71
2388267-6	1990	The polypeptide-to-metal co-ordinative bonds in human metallothionein-2 are identical to those in the previously determined solution structures of rat metallothionein-2 and rabbit metallothionein-2a, and the polypeptide conformations in the three proteins are also closely similar.	Metals	19-24	metallothionein 2A	Homo sapiens	151-168
20504644-6	1990	Furthermore, we probed the poly A(+) RNA with (32)P-labeled 180 base pair BamH1/PvuII restriction fragment containing the cDNA for human MTII from the phMT-II(3) plasmid.	Phosphorus-32	46-51	metallothionein 2A	Homo sapiens	137-141
34932329-1	2022	The effects of the neurohormone melatonin are mediated by the activation of the GPCRs MT1 and MT2 in a variety of tissues.	Melatonin	32-41	metallothionein 2A	Homo sapiens	94-97
34932329-2	2022	Crystal structures suggest ligand access to the orthosteric binding site of MT1 and MT2 receptors through a lateral channel between transmembrane (TM) helices IV and V. We investigated the feasibility of this lipophilic entry route for 2-iodomelatonin, a nonselective agonist with a slower dissociation rate from the MT2 receptor, applying enhanced sampling simulations and free-energy calculations.	2-iodomelatonin	236-251	metallothionein 2A	Homo sapiens	84-87
34607253-4	2021	Melatonin, a hormone secreted from the pineal gland, is a melatonin receptor 1A (MT1) and 1B (MT2) agonist and influences the function of diverse systems.	Melatonin	0-9	metallothionein 2A	Homo sapiens	94-97
34612067-4	2021	We detected the mRNA and protein expression of the melatonin MT2 but not the MT1 receptor in native human and guinea pig airway smooth muscle and cultured human airway smooth muscle (HASM) cells by RT-PCR, immunoblotting, and immunohistochemistry.	Melatonin	51-60	metallothionein 2A	Homo sapiens	61-64
34612067-5	2021	Activation of melatonin MT2 receptors with either pharmacological concentrations of melatonin (10 - 100 microM) or the non-selective MT1/MT2 agonist ramelteon (10 microM) significantly inhibited forskolin-stimulated cAMP accumulation in HASM cells, which was reversed by the Galphai protein inhibitor pertussis toxin or knockdown of the MT2 receptor by its specific siRNA.	Melatonin	14-23	metallothionein 2A	Homo sapiens	24-27
34612067-5	2021	Activation of melatonin MT2 receptors with either pharmacological concentrations of melatonin (10 - 100 microM) or the non-selective MT1/MT2 agonist ramelteon (10 microM) significantly inhibited forskolin-stimulated cAMP accumulation in HASM cells, which was reversed by the Galphai protein inhibitor pertussis toxin or knockdown of the MT2 receptor by its specific siRNA.	Melatonin	84-93	metallothionein 2A	Homo sapiens	24-27
34612067-5	2021	Activation of melatonin MT2 receptors with either pharmacological concentrations of melatonin (10 - 100 microM) or the non-selective MT1/MT2 agonist ramelteon (10 microM) significantly inhibited forskolin-stimulated cAMP accumulation in HASM cells, which was reversed by the Galphai protein inhibitor pertussis toxin or knockdown of the MT2 receptor by its specific siRNA.	ramelteon	149-158	metallothionein 2A	Homo sapiens	24-27
34612067-5	2021	Activation of melatonin MT2 receptors with either pharmacological concentrations of melatonin (10 - 100 microM) or the non-selective MT1/MT2 agonist ramelteon (10 microM) significantly inhibited forskolin-stimulated cAMP accumulation in HASM cells, which was reversed by the Galphai protein inhibitor pertussis toxin or knockdown of the MT2 receptor by its specific siRNA.	Colforsin	195-204	metallothionein 2A	Homo sapiens	24-27
34612067-5	2021	Activation of melatonin MT2 receptors with either pharmacological concentrations of melatonin (10 - 100 microM) or the non-selective MT1/MT2 agonist ramelteon (10 microM) significantly inhibited forskolin-stimulated cAMP accumulation in HASM cells, which was reversed by the Galphai protein inhibitor pertussis toxin or knockdown of the MT2 receptor by its specific siRNA.	Cyclic AMP	216-220	metallothionein 2A	Homo sapiens	24-27
34732414-5	2021	RESULTS: Treatment of cells with ZnCl2 effectively induced MT1A and MT2A mRNA expression, and interestingly suppressed mRNA expression of CDH1, which was induced by 1,25(OH)2D3 in both cell lines.	zinc chloride	33-38	metallothionein 2A	Homo sapiens	68-72
34851477-8	2022	The expressions of genes were significantly increased in the cancer tissues than in non-cancerous tissues in RCC sub-types and there was a significant correlation between Cd levels and expression of genes VEGF, MT2A, P38 and JNK in chRCC group.	Cadmium	171-173	metallothionein 2A	Homo sapiens	211-215
34816281-8	2022	In addition, progesterone (P4) secretion and cell viability were promoted in luteal cells treated with serotonin, and the stimulatory effects were blocked by luzindole (a non-selective MT1 and MT2 antagonist).	Serotonin	103-112	metallothionein 2A	Homo sapiens	193-196
34816281-8	2022	In addition, progesterone (P4) secretion and cell viability were promoted in luteal cells treated with serotonin, and the stimulatory effects were blocked by luzindole (a non-selective MT1 and MT2 antagonist).	luzindole	158-167	metallothionein 2A	Homo sapiens	193-196
34816281-9	2022	Finally, the expressions of MT1 and MT2 were augmented by serotonin in luteal cells.	Serotonin	58-67	metallothionein 2A	Homo sapiens	36-39
34732414-5	2021	RESULTS: Treatment of cells with ZnCl2 effectively induced MT1A and MT2A mRNA expression, and interestingly suppressed mRNA expression of CDH1, which was induced by 1,25(OH)2D3 in both cell lines.	Calcitriol	165-176	metallothionein 2A	Homo sapiens	68-72
34623211-8	2021	hMT2 treatment was able to reverse the effects of paraquat.	Paraquat	50-58	metallothionein 2A	Homo sapiens	0-4
34623211-11	2021	Paraquat treatment also led to reduction of dopaminergic neurons while their numbers showed an increase following hMT2 treatment.Conclusion: Paraquat has been identified as one of the pesticides that can cause the death of dopaminergic neurons and affect dopamine biosynthesis.	Paraquat	0-8	metallothionein 2A	Homo sapiens	114-118
34623211-11	2021	Paraquat treatment also led to reduction of dopaminergic neurons while their numbers showed an increase following hMT2 treatment.Conclusion: Paraquat has been identified as one of the pesticides that can cause the death of dopaminergic neurons and affect dopamine biosynthesis.	Paraquat	141-149	metallothionein 2A	Homo sapiens	114-118
34623211-11	2021	Paraquat treatment also led to reduction of dopaminergic neurons while their numbers showed an increase following hMT2 treatment.Conclusion: Paraquat has been identified as one of the pesticides that can cause the death of dopaminergic neurons and affect dopamine biosynthesis.	Dopamine	255-263	metallothionein 2A	Homo sapiens	114-118
34623211-12	2021	Treatment with exogenous hMT2 could reverse the effects of paraquat in the zebrafish brain.	Paraquat	59-67	metallothionein 2A	Homo sapiens	25-29
34189835-7	2021	Gene expression of metallothionein 2A was remarkably enhanced by Pb nanoparticle exposure in dTHP-1 cells.	Lead	65-67	metallothionein 2A	Homo sapiens	19-37
34477370-0	2021	An Integrated Mass Spectrometry and Molecular Dynamics Simulations Approach Reveals the Spatial Organization Impact of Metal-Binding Sites on the Stability of Metal-Depleted Metallothionein-2 Species.	Metals	119-124	metallothionein 2A	Homo sapiens	174-191
34477370-0	2021	An Integrated Mass Spectrometry and Molecular Dynamics Simulations Approach Reveals the Spatial Organization Impact of Metal-Binding Sites on the Stability of Metal-Depleted Metallothionein-2 Species.	Metals	159-164	metallothionein 2A	Homo sapiens	174-191
34477370-7	2021	The thermodynamics properties of Zn(II) (un)binding to MT2 are found to differ from those of Cd(II), justifying their distinctive roles.	zn(ii)	33-39	metallothionein 2A	Homo sapiens	55-58
34690701-3	2021	The two subtypes of human melatonin receptors, termed MT1 and MT2, utilize overlapping signaling pathways although biased signaling properties have been reported in some cellular systems.	Melatonin	26-35	metallothionein 2A	Homo sapiens	62-65
34072023-5	2021	A Zn concentration was especially decreased in the blood of smoking AP patients with the AA genotype for SNP rs11640851 in the MT1A gene and the GC genotype for SNP rs10636 in MT2A, compared to non-smokers with AP, which was accompanied by an increase in the value of the Cu/Zn ratio.	Zinc	2-4	metallothionein 2A	Homo sapiens	176-180
34354246-1	2021	Melatonin receptors (MT1 and MT2) transduce inhibitory signaling by melatonin (N-acetyl-5-methoxytryptamine), which is associated with sleep induction and circadian rhythm modulation.	Melatonin	0-9	metallothionein 2A	Homo sapiens	29-32
34354246-1	2021	Melatonin receptors (MT1 and MT2) transduce inhibitory signaling by melatonin (N-acetyl-5-methoxytryptamine), which is associated with sleep induction and circadian rhythm modulation.	Melatonin	68-77	metallothionein 2A	Homo sapiens	29-32
34354246-1	2021	Melatonin receptors (MT1 and MT2) transduce inhibitory signaling by melatonin (N-acetyl-5-methoxytryptamine), which is associated with sleep induction and circadian rhythm modulation.	Melatonin	79-107	metallothionein 2A	Homo sapiens	29-32
34091948-16	2021	The receptor that mediates MEL function is most likely similar to the mammalian MT2, because injecting the competitive MT2 antagonist luzindole blocked MEL function, and MEL injection after luzindole treatment restored MT function.	luzindole	134-143	metallothionein 2A	Homo sapiens	119-122
35420022-1	2022	Melatonin is a neurohormone that modulates several physiological functions in mammals through the activation of melatonin receptor type 1 and 2 (MT1 and MT2).	Melatonin	0-9	metallothionein 2A	Homo sapiens	153-156
35188390-2	2022	Here, by deploying the Chemical Linkage of Peptide onto Scaffolds strategy, we replaced the lactam cyclization of melanotan II (MT-II), a potent and unselective agonist of human MCRs (hMCRs), with different xylene-derived thioethers.	Lactams	92-98	metallothionein 2A	Homo sapiens	128-133
35478275-2	2022	Selective MT2 Agonists Derived from 5,6-Dihydroindolo(2,1-a)isoquinolines and Related Systems.	5,6-dihydroindolo(2,1-a)isoquinolines	36-73	metallothionein 2A	Homo sapiens	10-13
35478275-9	2022	Substitution of oxygen for carbon at position 5 gives the indolo(1,2-c)benzoxazines 33, 36 a and b, that bind strongly to the human receptors, 33, 36 b being potent agonists at the melatonin receptors, but do not discriminate between hMT1 and hMT2.	indolo(1,2-c)benzoxazines	58-83	metallothionein 2A	Homo sapiens	243-247
35133682-5	2022	Current evidence suggests that melatonin and some of its metabolites inhibit both, melanogenesis (via reducing tyrosinase activity) and melanocyte proliferation by stimulating melatonin membrane receptors (MT1, MT2).	Melatonin	31-40	metallothionein 2A	Homo sapiens	211-214
35188390-2	2022	Here, by deploying the Chemical Linkage of Peptide onto Scaffolds strategy, we replaced the lactam cyclization of melanotan II (MT-II), a potent and unselective agonist of human MCRs (hMCRs), with different xylene-derived thioethers.	Xylenes	207-213	metallothionein 2A	Homo sapiens	128-133
35188390-2	2022	Here, by deploying the Chemical Linkage of Peptide onto Scaffolds strategy, we replaced the lactam cyclization of melanotan II (MT-II), a potent and unselective agonist of human MCRs (hMCRs), with different xylene-derived thioethers.	Sulfides	222-232	metallothionein 2A	Homo sapiens	128-133
34910685-3	2022	Furthermore, the patterns of melatonin membrane receptors (MT1 and MT2) expression were consistent with those of GnRH and LH expression in the CL of pregnant sows; the relative levels of MT1 and MT2 in the early- and mid- stages were significantly higher than those in the later-stage (P < 0.01).	Melatonin	29-38	metallothionein 2A	Homo sapiens	67-70
35075546-0	2022	Bioreduction and bioremoval of hexavalent chromium by genetically engineered strains (Escherichia coli MT2A and Escherichia coli MT3).	Chromium	42-50	metallothionein 2A	Homo sapiens	103-107
35075546-3	2022	In this study, we used recombinant strains created by cloning the human metallothioneins MT2A and MT3 into Escherichia coli Jm109 to assess the removal and reduction of hexavalent chromium (Cr(VI)) from aqueous solutions.	Chromium	180-188	metallothionein 2A	Homo sapiens	89-93
35075546-4	2022	MT2A was the most effective strain in both Cr(VI) removal (89% in 25 mg/L Cr(VI)) and Cr(VI) reduction (76% in 25 mg/L Cr(VI)).	Chromium	74-76	metallothionein 2A	Homo sapiens	0-4
35075546-4	2022	MT2A was the most effective strain in both Cr(VI) removal (89% in 25 mg/L Cr(VI)) and Cr(VI) reduction (76% in 25 mg/L Cr(VI)).	chromium hexavalent ion	86-92	metallothionein 2A	Homo sapiens	0-4
35075546-4	2022	MT2A was the most effective strain in both Cr(VI) removal (89% in 25 mg/L Cr(VI)) and Cr(VI) reduction (76% in 25 mg/L Cr(VI)).	chromium hexavalent ion	119-124	metallothionein 2A	Homo sapiens	0-4
35075546-5	2022	The amount of Cr adsorbed per dry cell by the MT2A strain was 22 mg/g.	Chromium	14-16	metallothionein 2A	Homo sapiens	46-50
35075546-10	2022	When all of the experimental data was combined, it was determined that both MT2A and MT3 were effective in removing Cr(VI) from aqueous solutions, but MT2A was more effective, indicating that MT2A may be employed as a biotechnological tool.	chromium hexavalent ion	116-122	metallothionein 2A	Homo sapiens	76-80
35075546-10	2022	When all of the experimental data was combined, it was determined that both MT2A and MT3 were effective in removing Cr(VI) from aqueous solutions, but MT2A was more effective, indicating that MT2A may be employed as a biotechnological tool.	chromium hexavalent ion	116-122	metallothionein 2A	Homo sapiens	192-196
34910685-6	2022	Additionally, the effects of melatonin on luteal GnRH and LH production, were blocked by luzindole, a nonselective MT1 and MT2 receptor antagonist.	luzindole	89-98	metallothionein 2A	Homo sapiens	123-126
34986763-3	2022	Melatonin interacts with melatonin receptors MT1 and MT2 but it was also revealed that melatonin is a strong antioxidant and it also has a role in regulation of cell cycle.	Melatonin	0-9	metallothionein 2A	Homo sapiens	53-56
34986763-3	2022	Melatonin interacts with melatonin receptors MT1 and MT2 but it was also revealed that melatonin is a strong antioxidant and it also has a role in regulation of cell cycle.	Melatonin	87-96	metallothionein 2A	Homo sapiens	53-56
2692787-1	1989	When murine erythroleukemia (MEL) cells, having the transferred rat c-myc gene under the control of human metallothionein II gene promoter, are induced to differentiate with dimethyl sulfoxide (DMSO), the level of differentiation is dependent on the c-myc levels which are modulated by the Zn++ ion.	Dimethyl Sulfoxide	174-192	metallothionein 2A	Homo sapiens	106-124
4012806-1	1985	Metabolic fate of cadmium bound to metallothionein polymers.	Cadmium	18-25	metallothionein 2A	Homo sapiens	35-50
2892785-1	1987	The MT-2, derived from an adult T-cell leukaemia (ATL) cell, the Molt-4F, a human T-cell line, and the Isk, an EB virus-transformed B-cell line, were found to have high-affinity receptors for somatostatin, a cyclic tetradecapeptide that inhibits the release of substances such as growth hormone, TSH, glucagon, insulin, secretin, gastrin and cholecystokinin.	cyclic tetradecapeptide	208-231	metallothionein 2A	Homo sapiens	4-8
3731358-2	1986	Synthesis of a nonacosapeptide corresponding to the N-terminal sequence 1-29 (beta-fragment) of human liver metallothionein II (hMT II) and its heavy metal-binding properties.	Metals	108-113	metallothionein 2A	Homo sapiens	128-134
2684368-2	1989	Adult T-cell Leukemia cell lines MT-1, MT-2, KH-2 and MT-2 stimulated by phorbol 12-myristate 13-acetate (PMA) were used as target cells in immunofluorescence microscopy (IF) examination with positive rates as 0.20% (2/965), 0.62% (6/965), 0.20% (2/965) and 0.51 (5/965) respectively.	Tetradecanoylphorbol Acetate	73-104	metallothionein 2A	Homo sapiens	39-43
2684368-2	1989	Adult T-cell Leukemia cell lines MT-1, MT-2, KH-2 and MT-2 stimulated by phorbol 12-myristate 13-acetate (PMA) were used as target cells in immunofluorescence microscopy (IF) examination with positive rates as 0.20% (2/965), 0.62% (6/965), 0.20% (2/965) and 0.51 (5/965) respectively.	Tetradecanoylphorbol Acetate	73-104	metallothionein 2A	Homo sapiens	54-58
2684368-2	1989	Adult T-cell Leukemia cell lines MT-1, MT-2, KH-2 and MT-2 stimulated by phorbol 12-myristate 13-acetate (PMA) were used as target cells in immunofluorescence microscopy (IF) examination with positive rates as 0.20% (2/965), 0.62% (6/965), 0.20% (2/965) and 0.51 (5/965) respectively.	Tetradecanoylphorbol Acetate	106-109	metallothionein 2A	Homo sapiens	39-43
2684368-2	1989	Adult T-cell Leukemia cell lines MT-1, MT-2, KH-2 and MT-2 stimulated by phorbol 12-myristate 13-acetate (PMA) were used as target cells in immunofluorescence microscopy (IF) examination with positive rates as 0.20% (2/965), 0.62% (6/965), 0.20% (2/965) and 0.51 (5/965) respectively.	Tetradecanoylphorbol Acetate	106-109	metallothionein 2A	Homo sapiens	54-58
2974926-4	1988	Dexamethasone treatment of these human cell types caused a dose-dependent increase in hMTII mRNA levels, whereas no effect on hCPII mRNA levels was observed.	Dexamethasone	0-13	metallothionein 2A	Homo sapiens	86-91
2974926-6	1988	Dexamethasone (10(-6) M) induced hMTII but not hCPII mRNA in CEM C7 cells, whereas neither hMTII nor hCPII mRNA was induced in ICR-27 cells.	Dexamethasone	0-13	metallothionein 2A	Homo sapiens	33-38
3780677-3	1986	Conversely, metallothionein IIa (MTIIa) mRNA levels in these cells are raised by Dex.	Dexamethasone	81-84	metallothionein 2A	Homo sapiens	12-31
3780677-3	1986	Conversely, metallothionein IIa (MTIIa) mRNA levels in these cells are raised by Dex.	Dexamethasone	81-84	metallothionein 2A	Homo sapiens	33-38
3719032-4	1986	DEAE A-25 anion exchange chromatography revealed that human fetal hepatic MT-1 and MT-2 elute similarly to native newborn and cadmium-induced adult rat liver MT, MT-1 and MT-2.	deae a	0-6	metallothionein 2A	Homo sapiens	60-87
33519498-10	2020	Moreover, the presence of membrane MT1 and MT2 receptors was identified in HK-2 cells and their ligand, ramelteon, turned out to mimic melatonin action on both HIF-1alpha and sirtuin 1 levels.	ramelteon	104-113	metallothionein 2A	Homo sapiens	43-46
3990797-4	1985	Transcription of the mRNA for human MT2A is induced by glucocorticoids or metal ions and the regulatory elements have been mapped by promoter-fusion experiments.	Metals	74-79	metallothionein 2A	Homo sapiens	36-40
3990797-5	1985	We now show that the rate of transcription of MT2A is the same on treatment with interferon or dexamethasone, but that the mRNA accumulates much faster with dexamethasone, indicating that post-transcriptional events are important in the latter case.	Dexamethasone	95-108	metallothionein 2A	Homo sapiens	46-50
6526271-4	1984	Most of the mutations in MT-II processed gene are silent except that the amino acid glycine (GGT) at position 10 is changed to serine (AGT) due to a transition.	amino acid glycine	73-91	metallothionein 2A	Homo sapiens	25-30
6526271-4	1984	Most of the mutations in MT-II processed gene are silent except that the amino acid glycine (GGT) at position 10 is changed to serine (AGT) due to a transition.	Serine	127-133	metallothionein 2A	Homo sapiens	25-30
6526271-5	1984	Both MT-I and MT-II processed genes possess poly(A) sequences of 21 and 17 nucleotides, respectively, 3" to the consensus AATAAA sequence.	Poly A	44-51	metallothionein 2A	Homo sapiens	14-19
6089206-6	1984	Analysis of RNA from somatic cell hybrids indicated that hybrids that contained human chromosome 16 expressed both human MT1 and MT2 mRNA, and this expression is regulated by both heavy metal ions and glucocorticoid hormones.	Metals	186-191	metallothionein 2A	Homo sapiens	129-132
6640789-2	1983	Synthesis of a hexacosapeptide corresponding to the C-terminal sequence 36-61 of human metallothionein II (hMT II) and determination of its heavy metal binding activity.	Metals	87-92	metallothionein 2A	Homo sapiens	107-113
7142174-4	1982	Four 113Cd resonances were observed, three of which had identical chemical shifts to those assigned to the four-metal cluster in human liver metallothionein-2 under the same pH and buffer conditions.	Cadmium, isotope of mass 113	5-10	metallothionein 2A	Homo sapiens	141-158
33682410-1	2021	To develop potent and orally bioavailable melatonin receptor (MT1 and MT2) agonists, a novel series of 5-6-5 tricyclic derivatives was designed, synthesized, and evaluated.	5-6-5 tricyclic	103-118	metallothionein 2A	Homo sapiens	70-73
33451856-3	2021	Here we aim to study the specific role of each melatonin receptor (MT1 and MT2) subtype in melatonin regulation of circadian CBT and its possible relationship with depressive-like behaviors.	Melatonin	47-56	metallothionein 2A	Homo sapiens	75-78
33451856-3	2021	Here we aim to study the specific role of each melatonin receptor (MT1 and MT2) subtype in melatonin regulation of circadian CBT and its possible relationship with depressive-like behaviors.	Melatonin	91-100	metallothionein 2A	Homo sapiens	75-78
3987895-2	1985	The Cd-binding ability of the beta-fragment was much stronger than that of cysteine as thionein and synthetic alpha-fragment corresponding to the C-terminal sequence 30-61 of human liver metallothionein II.	Cadmium	4-6	metallothionein 2A	Homo sapiens	187-205
6667529-2	1983	Synthesis of cysteine-containing peptide fragments related to human hepatic metallothionein II (hMT II) and determination of their heavy metal-binding properties.	Cysteine	13-21	metallothionein 2A	Homo sapiens	96-102
6667529-2	1983	Synthesis of cysteine-containing peptide fragments related to human hepatic metallothionein II (hMT II) and determination of their heavy metal-binding properties.	Metals	76-81	metallothionein 2A	Homo sapiens	96-102
33559028-3	2021	The altered expression levels of a small number of proteins displaying a temporal response may provide the best indication of the underlying mechanism; more well-known copper response proteins including the metal binding metallothioneins (MT1X, MT1F, MT2A) and antioxidant response proteins including Heme oxygenase were upregulated to a similar level in both copper concentrations and so are less likely to underpin this phenomenon.The temporal response proteins include Granulins, AN1-type zinc finger protein 2A (ZFAND2A), and the heat shock proteins (HSPA6 and HSPA1B).	Copper	168-174	metallothionein 2A	Homo sapiens	251-255
33546749-10	2021	Melatonin inhibited the expression of binding immunoglobulin protein (BiP) through the regulation of MT2/Sp1-dependent microRNA-597-5p.	Melatonin	0-9	metallothionein 2A	Homo sapiens	101-104
33546749-12	2021	CONCLUSION: Melatonin induced the efflux of intracellular cholesterol through ABCA1 to decrease apoptosis of UCB-MSCs via an MT2-dependent BiP/NRF1 pathway.	Melatonin	12-21	metallothionein 2A	Homo sapiens	125-128
33546749-12	2021	CONCLUSION: Melatonin induced the efflux of intracellular cholesterol through ABCA1 to decrease apoptosis of UCB-MSCs via an MT2-dependent BiP/NRF1 pathway.	Cholesterol	58-69	metallothionein 2A	Homo sapiens	125-128
33203660-1	2021	Integrated in silico chemical clustering and melatonin receptor molecular modeling combined with in vitro 2-[125I]-iodomelatonin competition binding were used to identify carbamate insecticides with affinity for hMT1 and hMT2 melatonin receptors.	Carbamates	171-180	metallothionein 2A	Homo sapiens	221-225
33467427-4	2021	Interestingly, both Mt-I and Mt-II showed high activity in polyethylene with productivities between 3.17 x 106 g/molMt h to 5.06 x 106 g/molMt h, activities were very close to each other with 100% TIBA, but Mt-II/borate-II became more active when TEA was more than 50% in cocatalyst.	Polyethylene	59-71	metallothionein 2A	Homo sapiens	29-34
33467427-4	2021	Interestingly, both Mt-I and Mt-II showed high activity in polyethylene with productivities between 3.17 x 106 g/molMt h to 5.06 x 106 g/molMt h, activities were very close to each other with 100% TIBA, but Mt-II/borate-II became more active when TEA was more than 50% in cocatalyst.	Polyethylene	59-71	metallothionein 2A	Homo sapiens	207-212
33467427-4	2021	Interestingly, both Mt-I and Mt-II showed high activity in polyethylene with productivities between 3.17 x 106 g/molMt h to 5.06 x 106 g/molMt h, activities were very close to each other with 100% TIBA, but Mt-II/borate-II became more active when TEA was more than 50% in cocatalyst.	triethylaluminum	247-250	metallothionein 2A	Homo sapiens	29-34
33467427-4	2021	Interestingly, both Mt-I and Mt-II showed high activity in polyethylene with productivities between 3.17 x 106 g/molMt h to 5.06 x 106 g/molMt h, activities were very close to each other with 100% TIBA, but Mt-II/borate-II became more active when TEA was more than 50% in cocatalyst.	cocatalyst	272-282	metallothionein 2A	Homo sapiens	29-34
33467427-7	2021	In PE, the active center fractions [C*]/[Zr] of Mt-I/borate were higher than that of Mt-II/borate and average chain propagation rate constant (kp) value slightly decreased with the increase of TEA/TIBA ratio, but the Mt-II/borate systems showed higher kp 1007 kp (L/mol s).	triethylaluminum	193-196	metallothionein 2A	Homo sapiens	217-222
33519498-10	2020	Moreover, the presence of membrane MT1 and MT2 receptors was identified in HK-2 cells and their ligand, ramelteon, turned out to mimic melatonin action on both HIF-1alpha and sirtuin 1 levels.	Melatonin	135-144	metallothionein 2A	Homo sapiens	43-46
33122816-11	2020	Especially for MSTO-211H cell presenting low initial MT2A levels, a strong induction of MT2A expression could be observed during cisplatin treatment, indicating a cell line-specific and platin-dependent adaption mechanism.	Cisplatin	129-138	metallothionein 2A	Homo sapiens	88-92
33048779-2	2021	While the melatonin receptor subtype, MT3, has been identified in amphibian animals and birds, in humans and other mammals, melatonin acts through, MT1 and MT2 receptor subtypes which are expressed in human ovaries.	Melatonin	124-133	metallothionein 2A	Homo sapiens	156-159
32638210-0	2020	MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells.	Oxaliplatin	14-25	metallothionein 2A	Homo sapiens	0-4
32638210-9	2020	Knockdown of MT2A in HT29 OR cells improved sensitivity to Oxaliplatin, while ectopic overexpression of MT2A conferred HT29 cells relative resistance to Oxaliplatin.	Oxaliplatin	59-70	metallothionein 2A	Homo sapiens	13-17
32638210-9	2020	Knockdown of MT2A in HT29 OR cells improved sensitivity to Oxaliplatin, while ectopic overexpression of MT2A conferred HT29 cells relative resistance to Oxaliplatin.	Oxaliplatin	153-164	metallothionein 2A	Homo sapiens	104-108
32638210-11	2020	BARD1 overexpression partially restored the compromised Oxaliplatin resistance elicited by MT2A deficiency in terms of both cell proliferation and viability.	Oxaliplatin	56-67	metallothionein 2A	Homo sapiens	91-95
32638210-12	2020	Our data highlighted the critical contributions of MT2A-BARD1/BRCA1 in Oxaliplatin resistance in colorectal cancer cells.	Oxaliplatin	71-82	metallothionein 2A	Homo sapiens	51-55
32934681-4	2020	The present results showed that melatonin enhanced the melatonin receptors (MT1 and MT2) expression in Schwann cells.	Melatonin	32-41	metallothionein 2A	Homo sapiens	84-87
32934681-4	2020	The present results showed that melatonin enhanced the melatonin receptors (MT1 and MT2) expression in Schwann cells.	Melatonin	55-64	metallothionein 2A	Homo sapiens	84-87
33146651-8	2020	Cd-exposed cells accumulate Cd in a dose-dependent manner and upregulate MT2A accordingly (up to 15-fold induction upon 5 muM CdCl2 treatment for 72 h).	Cadmium	0-2	metallothionein 2A	Homo sapiens	73-77
33146651-8	2020	Cd-exposed cells accumulate Cd in a dose-dependent manner and upregulate MT2A accordingly (up to 15-fold induction upon 5 muM CdCl2 treatment for 72 h).	Cadmium Chloride	126-131	metallothionein 2A	Homo sapiens	73-77
33146651-9	2020	5 muM Cd exposure for 72 h decreased cell number to 60%, an effect that was aggravated by MT2A depletion (cell number reduced to 30%) indicating additive effects.	Cadmium	6-8	metallothionein 2A	Homo sapiens	90-94
33146651-10	2020	In conclusion, our data suggest that DMT1 and ZIP14 are required for Cd uptake into human placental cells that upregulate MT2A to store and detoxify the metal.	Cadmium	69-71	metallothionein 2A	Homo sapiens	122-126
33146651-10	2020	In conclusion, our data suggest that DMT1 and ZIP14 are required for Cd uptake into human placental cells that upregulate MT2A to store and detoxify the metal.	Metals	153-158	metallothionein 2A	Homo sapiens	122-126
33122816-12	2020	Additionally, a MT2A-dependent cellular evasion of apoptosis during cisplatin could be observed, leading to three different MT based phenotypes.	Cisplatin	68-77	metallothionein 2A	Homo sapiens	16-20
33122816-13	2020	MSTO-211H cells showed lower apoptosis rates at an increased expression level of MT2A after cisplatin treatment (from sixfold to fourfold).	Cisplatin	92-101	metallothionein 2A	Homo sapiens	81-85
33122816-16	2020	Knockdown of MT2A expression levels resulted in significantly induced apoptotic rates during cisplatin treatment with strongest induction of apoptosis in each of the MPM cell lines, but in different markedness.	Cisplatin	93-102	metallothionein 2A	Homo sapiens	13-17
33122816-18	2020	The present study showed MT2A to be part of the underlying mechanism of cisplatin resistance in MPM.	Cisplatin	72-81	metallothionein 2A	Homo sapiens	25-29
33122816-20	2020	We could prove the inhibition of MT2A as a powerful tool to boost response rates to cisplatin-based therapy in vitro.	Cisplatin	84-93	metallothionein 2A	Homo sapiens	33-37
32786475-1	2020	Here, using human metallothionein (MT2) as an example, we describe an improved strategy based on differential alkylation coupled to MS, assisted by zinc probe monitoring, for identification of cysteine-rich binding sites with nanomolar and picomolar metal affinity utilizing IAM and NEM reagents.	Cysteine	193-201	metallothionein 2A	Homo sapiens	35-38
32786475-1	2020	Here, using human metallothionein (MT2) as an example, we describe an improved strategy based on differential alkylation coupled to MS, assisted by zinc probe monitoring, for identification of cysteine-rich binding sites with nanomolar and picomolar metal affinity utilizing IAM and NEM reagents.	Metals	18-23	metallothionein 2A	Homo sapiens	35-38
32786475-5	2020	The methodology presented might be applied not only for MT2 but to identify metal binding sites in other Cys-containing proteins.	Metals	76-81	metallothionein 2A	Homo sapiens	56-59
32786475-5	2020	The methodology presented might be applied not only for MT2 but to identify metal binding sites in other Cys-containing proteins.	Cysteine	105-108	metallothionein 2A	Homo sapiens	56-59
32806409-3	2020	The results showed that incorporating a complex microbial agent at 0.8% (w/w) on the 0th and 11th day (group MT2) effectively degraded doxycycline with a final degradation rate of 46.83 +- 0.55%.	Doxycycline	135-146	metallothionein 2A	Homo sapiens	109-112
32000994-9	2020	Melatonin acts through melatonin receptors MT1 and MT2 and the gene for MT1 (MTNR1A) is polymorphic in buffaloes.	Melatonin	0-9	metallothionein 2A	Homo sapiens	51-54
33073191-5	2020	Furthermore, using camptothecin as the cytotoxic drug, camptothecin-MT-II (compound 1) can effectively inhibit A375 melanoma cell growth with an IC50 of 16 nM.	Camptothecin	19-31	metallothionein 2A	Homo sapiens	68-73
32223750-14	2020	CONCLUSIONS: Human dental pulp abundantly expressed melatonin and its receptors MT1 and MT2 in the odontoblastic layers and pulpal connective tissue layers.	Melatonin	52-61	metallothionein 2A	Homo sapiens	88-91
32532115-2	2020	In this work, we utilized mass spectrometry-based lipidomic approaches to investigate the action of Asp-49 Ca2+-dependent secreted phospholipase A2 (sPLA2) (MT-III) and Lys-49 sPLA2 (MT-II), two group IIA phospholipase A2s isolated from the venom of the snake Bothrops asper, on human peripheral blood monocytes.	Aspartic Acid	100-103	metallothionein 2A	Homo sapiens	157-162
32234648-9	2020	This could indicate a stimulatory effect of melatonin on testicular (i.e., steroidogenesis and spermatogenesis) and epididymal (i.e., spermatozoa maturation) function in male roe deer through the MT1 and MT2 receptors.	Melatonin	44-53	metallothionein 2A	Homo sapiens	204-207
32234648-10	2020	Our results form the basis for further studies into the detailed mechanism of action of melatonin through MT1 and MT2 receptors for optimal reproductive activity in male roe deer and other mammals.	Melatonin	88-97	metallothionein 2A	Homo sapiens	114-117
32105962-6	2020	The results showed that the binding affinities of CdTe QDs and plasma proteins depend on the nature of the protein and follow the order of fibrinogen (FIB)> plasminogen (PLG) > thrombin (TM) > metallothionein-II (MT-II) > human serum albumin (HSA).	cadmium telluride	50-54	metallothionein 2A	Homo sapiens	193-211
32105962-6	2020	The results showed that the binding affinities of CdTe QDs and plasma proteins depend on the nature of the protein and follow the order of fibrinogen (FIB)> plasminogen (PLG) > thrombin (TM) > metallothionein-II (MT-II) > human serum albumin (HSA).	cadmium telluride	50-54	metallothionein 2A	Homo sapiens	213-218
31693784-1	2020	The long-anticipated high-resolution structures of the human melatonin G protein-coupled receptors MT1 and MT2 , involved in establishing and maintaining circadian rhythm, were obtained in complex with two melatonin analogs and two approved anti-insomnia and antidepression drugs using X-ray free-electron laser serial femtosecond crystallography.	Melatonin	61-70	metallothionein 2A	Homo sapiens	107-110
31693784-1	2020	The long-anticipated high-resolution structures of the human melatonin G protein-coupled receptors MT1 and MT2 , involved in establishing and maintaining circadian rhythm, were obtained in complex with two melatonin analogs and two approved anti-insomnia and antidepression drugs using X-ray free-electron laser serial femtosecond crystallography.	Melatonin	206-215	metallothionein 2A	Homo sapiens	107-110
31693784-6	2020	The role of receptor oligomerization is further discussed in light of the differential interaction of MT1 and MT2 with GPR50, a regulatory melatonin coreceptor.	Melatonin	139-148	metallothionein 2A	Homo sapiens	110-113
32004937-4	2020	Quinazoline and phthalazine rings proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands.	Quinazolines	0-11	metallothionein 2A	Homo sapiens	94-97
32597135-10	2020	The third SNP, rs1610216 (MT2A -209A/G), has been studied for association with type 2 diabetes, cardiomyopathy, hyperglycaemia, and Zn concentrations.	Zinc	132-134	metallothionein 2A	Homo sapiens	26-30
32597135-11	2020	Metallothionein concentrations and MT2A polymorphisms have a potential to be used as biomarkers of metal exposure and clinical markers of a number of chronic diseases.	Metals	99-104	metallothionein 2A	Homo sapiens	35-39
32118583-5	2020	Moreover, two most potent agonists, including 21 and a close derivative of melatonin, 28, had dramatically reduced arrestin recruitment at MT2, while compound 37 was devoid of Gi signaling at MT1, implying biased signaling.	Melatonin	75-84	metallothionein 2A	Homo sapiens	139-142
32004937-4	2020	Quinazoline and phthalazine rings proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands.	phthalazine	16-27	metallothionein 2A	Homo sapiens	94-97
32004937-6	2020	However, the presence of two nitrogen atoms resulted in compounds with lower affinity for both MT1 and MT2, in comparison with the parent compound, balanced by the exhibition of good pharmacokinetic properties.	Nitrogen	29-37	metallothionein 2A	Homo sapiens	103-106
31560946-6	2020	Melatonin activates its cognate membrane receptors, MT1 and MT2, which are present in numerous ocular tissues, including the aqueous-humor-producing ciliary processes.	Melatonin	0-9	metallothionein 2A	Homo sapiens	60-63
31877423-7	2020	Specifically, the case studies reviewed herein utilized the melatonin analog and melatonergic MT1 and MT2 receptor agonist, Agomelatine.	agomelatine	124-135	metallothionein 2A	Homo sapiens	102-105
31442321-4	2019	Among them, melatonin MT1 and MT2 receptors are the best characterized melatonin targets, mediating melatonin effects in a variety of tissues.	Melatonin	71-80	metallothionein 2A	Homo sapiens	30-33
31624901-13	2019	Ex vivo, islet Mt1 and Mt2 mRNA and MT1 and MT2 protein levels were downregulated after culture with glucose at 10-30 mmol/l vs 2-5 mmol/l, in association with increased insulin secretion.	Glucose	101-108	metallothionein 2A	Homo sapiens	23-26
31624901-13	2019	Ex vivo, islet Mt1 and Mt2 mRNA and MT1 and MT2 protein levels were downregulated after culture with glucose at 10-30 mmol/l vs 2-5 mmol/l, in association with increased insulin secretion.	Glucose	101-108	metallothionein 2A	Homo sapiens	44-47
31624901-14	2019	In human islets, mRNA levels of MT1E, MT1X and MT2A were downregulated by stimulation with physiological and supraphysiological levels of glucose.	Glucose	138-145	metallothionein 2A	Homo sapiens	47-51
31893123-1	2020	Melatonin is a neurohormone that translates the circadian rhythm to the peripheral organs through a series of binding sites identified as G protein-coupled receptors MT1 and MT2.	Melatonin	0-9	metallothionein 2A	Homo sapiens	174-177
31451998-4	2019	In this review, the underlying anticancer mechanisms of Melatonin such as stimulation of apoptosis, Melatonin receptors (MT1 and MT2) stimulation, paro-survival signal regulation, the hindering of angiogenesis, epigenetic alteration and metastasis have been discussed with recent findings.	Melatonin	56-65	metallothionein 2A	Homo sapiens	129-132
31587393-3	2019	We have previously detected the existence of melatonin-synthesizing enzymes and melatonin receptors MT1 and MT2 in the ram reproductive tract, thus, in order to start to elucidate melatonin catabolism in these organs, we have investigated the presence of the melatonin-catabolizing enzymes indoleamine 2,3-dioxygenase (IDO, both IDO1 and IDO2 isoforms) and myeloperoxidase (MPO) in testis, epididymis and accessory glands.	Melatonin	80-89	metallothionein 2A	Homo sapiens	108-111
31587393-3	2019	We have previously detected the existence of melatonin-synthesizing enzymes and melatonin receptors MT1 and MT2 in the ram reproductive tract, thus, in order to start to elucidate melatonin catabolism in these organs, we have investigated the presence of the melatonin-catabolizing enzymes indoleamine 2,3-dioxygenase (IDO, both IDO1 and IDO2 isoforms) and myeloperoxidase (MPO) in testis, epididymis and accessory glands.	Melatonin	80-89	metallothionein 2A	Homo sapiens	108-111
31587393-3	2019	We have previously detected the existence of melatonin-synthesizing enzymes and melatonin receptors MT1 and MT2 in the ram reproductive tract, thus, in order to start to elucidate melatonin catabolism in these organs, we have investigated the presence of the melatonin-catabolizing enzymes indoleamine 2,3-dioxygenase (IDO, both IDO1 and IDO2 isoforms) and myeloperoxidase (MPO) in testis, epididymis and accessory glands.	Melatonin	80-89	metallothionein 2A	Homo sapiens	108-111
31542717-2	2019	Specifically, the substituted amino moiety containing mono or poly alkoxy group(s) with various positions and groups were mainly explored to understand the structure-activity relationships for the cytotoxic activity against three human cancer cell lines (K562, Jurkat, and MT-2) and human peripheral blood mononuclear cells (PBMC).	Amino Acids	30-35	metallothionein 2A	Homo sapiens	273-277
31408847-6	2019	Treatment of porcine embryo with melatonin significantly increased formation rates of blastocysts and their total cell numbers, and also upregulated the expression of Nrf2/ARE signaling and apoptosis-related genes (MT2, Nrf2, UCHL, HO-1, SOD1, and Bcl-2).	Melatonin	33-42	metallothionein 2A	Homo sapiens	215-218
31914295-10	2019	Conclusion:Serum melatonin levels in PTC patients were higher than those in MNG and control groups, which may be associated with low malignancy of PTC; melatonin inhibits PTC metastasis, which exerts anti-PTC metastasis mainly through MT2 receptors.	Melatonin	17-26	metallothionein 2A	Homo sapiens	235-238
31914295-10	2019	Conclusion:Serum melatonin levels in PTC patients were higher than those in MNG and control groups, which may be associated with low malignancy of PTC; melatonin inhibits PTC metastasis, which exerts anti-PTC metastasis mainly through MT2 receptors.	Melatonin	152-161	metallothionein 2A	Homo sapiens	235-238
31408847-7	2019	Furthermore, the expression of proteins (Nrf2 and MT2) was also upregulated in the melatonin-treated group.	Melatonin	83-92	metallothionein 2A	Homo sapiens	50-53
31029764-1	2019	Melatonin (MLT), a neuromodulator mainly acting through two G-protein coupled receptors MT1 and MT2, regulates many brain functions, including circadian rhythms, mood, pain and sleep.	Melatonin	0-9	metallothionein 2A	Homo sapiens	96-99
31019305-3	2019	Here we report X-ray free electron laser (XFEL) structures of the human MT2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon6 at resolutions of 2.8 A and 3.3 A, respectively, along with two structures of function-related mutants: H2085.46A (superscripts represent the Ballesteros-Weinstein residue numbering nomenclature7) and N862.50D, obtained in complex with 2-PMT.	2-phenylmelatonin	114-131	metallothionein 2A	Homo sapiens	72-75
31012003-3	2019	The inhibitory effect of exogenous melatonin was due to its interaction with the membrane receptors MT1 and MT2.	Melatonin	35-44	metallothionein 2A	Homo sapiens	108-111
31019305-3	2019	Here we report X-ray free electron laser (XFEL) structures of the human MT2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon6 at resolutions of 2.8 A and 3.3 A, respectively, along with two structures of function-related mutants: H2085.46A (superscripts represent the Ballesteros-Weinstein residue numbering nomenclature7) and N862.50D, obtained in complex with 2-PMT.	2-phenylmelatonin	133-138	metallothionein 2A	Homo sapiens	72-75
31019305-3	2019	Here we report X-ray free electron laser (XFEL) structures of the human MT2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon6 at resolutions of 2.8 A and 3.3 A, respectively, along with two structures of function-related mutants: H2085.46A (superscripts represent the Ballesteros-Weinstein residue numbering nomenclature7) and N862.50D, obtained in complex with 2-PMT.	ramelteon6	144-154	metallothionein 2A	Homo sapiens	72-75
31019305-3	2019	Here we report X-ray free electron laser (XFEL) structures of the human MT2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon6 at resolutions of 2.8 A and 3.3 A, respectively, along with two structures of function-related mutants: H2085.46A (superscripts represent the Ballesteros-Weinstein residue numbering nomenclature7) and N862.50D, obtained in complex with 2-PMT.	2-phenylmelatonin	391-396	metallothionein 2A	Homo sapiens	72-75
31019305-4	2019	Comparison of the structures of MT2 with a published structure8 of MT1 reveals that, despite conservation of the orthosteric ligand-binding site residues, there are notable conformational variations as well as differences in [3H]melatonin dissociation kinetics that provide insights into the selectivity between melatonin receptor subtypes.	Tritium	226-228	metallothionein 2A	Homo sapiens	32-35
31019305-4	2019	Comparison of the structures of MT2 with a published structure8 of MT1 reveals that, despite conservation of the orthosteric ligand-binding site residues, there are notable conformational variations as well as differences in [3H]melatonin dissociation kinetics that provide insights into the selectivity between melatonin receptor subtypes.	Melatonin	229-238	metallothionein 2A	Homo sapiens	32-35
31019305-4	2019	Comparison of the structures of MT2 with a published structure8 of MT1 reveals that, despite conservation of the orthosteric ligand-binding site residues, there are notable conformational variations as well as differences in [3H]melatonin dissociation kinetics that provide insights into the selectivity between melatonin receptor subtypes.	Melatonin	312-321	metallothionein 2A	Homo sapiens	32-35
31019306-2	2019	Melatonin is formed in the pineal gland in a light-regulated manner4 by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates sleep and wakefulness5 by activating two high-affinity G-protein-coupled receptors, type 1A (MT1) and type 1B (MT2)3,6.	Melatonin	0-9	metallothionein 2A	Homo sapiens	264-267
30593827-9	2019	Pretreated AF-MSCs with non-selective MT1/MT2 receptors antagonist, luzindole and selective MT2 receptor antagonist, 4-P-PDOT diminished melatonin-induced increase in dopaminergic neuronal markers and phosphorylated ERK but did not diminish increase in phosphorylated CaMKII by melatonin.	Melatonin	278-287	metallothionein 2A	Homo sapiens	92-95
30935147-4	2019	The low and moderate treatment with Cd induced lipid peroxidation and oxidatively modified proteins and DNA, as well as enhanced the expression of MT1 and MT2 in the liver, whereas the co-administration of AE completely prevented almost all of these effects.	Cadmium	36-38	metallothionein 2A	Homo sapiens	155-158
30593827-9	2019	Pretreated AF-MSCs with non-selective MT1/MT2 receptors antagonist, luzindole and selective MT2 receptor antagonist, 4-P-PDOT diminished melatonin-induced increase in dopaminergic neuronal markers and phosphorylated ERK but did not diminish increase in phosphorylated CaMKII by melatonin.	4-p	117-120	metallothionein 2A	Homo sapiens	92-95
30717701-10	2019	TSA (0.2 mol/L, 0.8 mol/L) and SAHA (1 mumol/L, 2 mumol/L) suppressed the expression of FOXO3A and MT2.	trichostatin A	0-3	metallothionein 2A	Homo sapiens	99-102
30593827-9	2019	Pretreated AF-MSCs with non-selective MT1/MT2 receptors antagonist, luzindole and selective MT2 receptor antagonist, 4-P-PDOT diminished melatonin-induced increase in dopaminergic neuronal markers and phosphorylated ERK but did not diminish increase in phosphorylated CaMKII by melatonin.	Melatonin	137-146	metallothionein 2A	Homo sapiens	42-45
30593827-9	2019	Pretreated AF-MSCs with non-selective MT1/MT2 receptors antagonist, luzindole and selective MT2 receptor antagonist, 4-P-PDOT diminished melatonin-induced increase in dopaminergic neuronal markers and phosphorylated ERK but did not diminish increase in phosphorylated CaMKII by melatonin.	Melatonin	137-146	metallothionein 2A	Homo sapiens	92-95
30717701-10	2019	TSA (0.2 mol/L, 0.8 mol/L) and SAHA (1 mumol/L, 2 mumol/L) suppressed the expression of FOXO3A and MT2.	Vorinostat	31-35	metallothionein 2A	Homo sapiens	99-102
30301827-9	2019	Mechanistically, MZF1 was upregulated in both GC and GES-1 cells by MT2A ectopically expressed or induced upon treatment with a garlic-derived compound, diallyl trisulfide (DATS).	diallyl trisulfide	153-171	metallothionein 2A	Homo sapiens	68-72
30853999-2	2019	Antiviral activity of the flavonoids was assessed by analyzing HIV-1 p24 core protein levels in the supernatants of HIV-1 infected MT-4 and MT-2 cell cultures.	Flavonoids	26-36	metallothionein 2A	Homo sapiens	140-144
30853999-3	2019	The compounds showed mild to weak cytotoxic activities on the host cells; herbacitrin was the strongest in this regard (CC50=27.8 and 63.64 muM on MT-4 and MT-2 cells, respectively).	HERBACITRIN	74-85	metallothionein 2A	Homo sapiens	156-160
31317905-1	2019	Agomelatine is an antidepressant agent with an innovative unique pharmacodynamic profile, including melatonergic receptor agonism (MT1 / MT2) and antagonistic effects on serotonergic 5-HT2C receptors.	agomelatine	0-11	metallothionein 2A	Homo sapiens	137-140
30420986-7	2018	By mutating selected residues and motifs in MT-3 to the corresponding MT-2 amino acids, we dissected key roles in modulating cluster dynamic and metal exchange rates, in increasing the Cu(i)-affinity in MT-3 N-terminal beta-domain and/or modulating the higher stability of the Zn(ii)-thiolate cluster in MT-2 beta-domain.	zn(ii)-thiolate	277-292	metallothionein 2A	Homo sapiens	70-74
30420986-4	2018	Metallothionein-3 (MT-3) has been shown to possess the most pronounced Cu-thionein character forming Cu(i)-containing species more favorably than metallothionein-2 (MT-2), which possesses the strongest Zn-thionein character.	zn-thionein	202-213	metallothionein 2A	Homo sapiens	146-163
30466987-8	2018	It is for the first time we report that the molecular mechanism of actions of melatonin and plant adaptogens are alike, all adaptogens tested activated the melatonin signaling pathway by acting through two G-protein-coupled membrane receptors MT1 and MT2 and upregulation of the ligand-specific nuclear receptor RORA, which plays a role in intellectual disability, neurological disorders, retinopathy, hypertension, dyslipidemia, and cancer, which are common in aging.	Melatonin	78-87	metallothionein 2A	Homo sapiens	251-254
30420986-4	2018	Metallothionein-3 (MT-3) has been shown to possess the most pronounced Cu-thionein character forming Cu(i)-containing species more favorably than metallothionein-2 (MT-2), which possesses the strongest Zn-thionein character.	zn-thionein	202-213	metallothionein 2A	Homo sapiens	165-169
30420986-7	2018	By mutating selected residues and motifs in MT-3 to the corresponding MT-2 amino acids, we dissected key roles in modulating cluster dynamic and metal exchange rates, in increasing the Cu(i)-affinity in MT-3 N-terminal beta-domain and/or modulating the higher stability of the Zn(ii)-thiolate cluster in MT-2 beta-domain.	Metals	145-150	metallothionein 2A	Homo sapiens	70-74
30420986-7	2018	By mutating selected residues and motifs in MT-3 to the corresponding MT-2 amino acids, we dissected key roles in modulating cluster dynamic and metal exchange rates, in increasing the Cu(i)-affinity in MT-3 N-terminal beta-domain and/or modulating the higher stability of the Zn(ii)-thiolate cluster in MT-2 beta-domain.	cuprous ion	185-190	metallothionein 2A	Homo sapiens	70-74
30420986-7	2018	By mutating selected residues and motifs in MT-3 to the corresponding MT-2 amino acids, we dissected key roles in modulating cluster dynamic and metal exchange rates, in increasing the Cu(i)-affinity in MT-3 N-terminal beta-domain and/or modulating the higher stability of the Zn(ii)-thiolate cluster in MT-2 beta-domain.	cuprous ion	185-190	metallothionein 2A	Homo sapiens	304-308
30466987-8	2018	It is for the first time we report that the molecular mechanism of actions of melatonin and plant adaptogens are alike, all adaptogens tested activated the melatonin signaling pathway by acting through two G-protein-coupled membrane receptors MT1 and MT2 and upregulation of the ligand-specific nuclear receptor RORA, which plays a role in intellectual disability, neurological disorders, retinopathy, hypertension, dyslipidemia, and cancer, which are common in aging.	Melatonin	156-165	metallothionein 2A	Homo sapiens	251-254
30014556-5	2018	COMMENT: Agomelatine, a naphthalene analog of melatonin, is a novel melatonergic drug with a longer half-life and a comparatively greater affinity for MT1 and MT2 melatonin receptors than melatonin itself.	Melatonin	46-55	metallothionein 2A	Homo sapiens	159-162
30221266-5	2018	The accumulation of Cd in maternal tissues (e.g. placenta, maternal blood, and mammary glands) induces the synthesis of MTs, preferably MT2, in an attempt to sequester the metal to avoid toxicity.	Cadmium	20-22	metallothionein 2A	Homo sapiens	136-139
30014556-5	2018	COMMENT: Agomelatine, a naphthalene analog of melatonin, is a novel melatonergic drug with a longer half-life and a comparatively greater affinity for MT1 and MT2 melatonin receptors than melatonin itself.	agomelatine	9-20	metallothionein 2A	Homo sapiens	159-162
30014556-5	2018	COMMENT: Agomelatine, a naphthalene analog of melatonin, is a novel melatonergic drug with a longer half-life and a comparatively greater affinity for MT1 and MT2 melatonin receptors than melatonin itself.	Melatonin	163-172	metallothionein 2A	Homo sapiens	159-162
28707298-2	2018	Among the multiple effects attributed to melatonin, we will focus here on those that are dependent on the activation of the two mammalian MT1 and MT2 melatonin receptors.	Melatonin	41-50	metallothionein 2A	Homo sapiens	146-149
29882686-12	2018	Additionally, the gene expression of metallothionein 2A (MT2A) was enhanced in the ZnO, CuO, and Bi2O3 exposed cells.	Zinc Oxide	83-86	metallothionein 2A	Homo sapiens	37-55
29882686-12	2018	Additionally, the gene expression of metallothionein 2A (MT2A) was enhanced in the ZnO, CuO, and Bi2O3 exposed cells.	Zinc Oxide	83-86	metallothionein 2A	Homo sapiens	57-61
29882686-12	2018	Additionally, the gene expression of metallothionein 2A (MT2A) was enhanced in the ZnO, CuO, and Bi2O3 exposed cells.	cupric oxide	88-91	metallothionein 2A	Homo sapiens	37-55
29882686-12	2018	Additionally, the gene expression of metallothionein 2A (MT2A) was enhanced in the ZnO, CuO, and Bi2O3 exposed cells.	cupric oxide	88-91	metallothionein 2A	Homo sapiens	57-61
29882686-12	2018	Additionally, the gene expression of metallothionein 2A (MT2A) was enhanced in the ZnO, CuO, and Bi2O3 exposed cells.	bi2o3	97-102	metallothionein 2A	Homo sapiens	37-55
29882686-12	2018	Additionally, the gene expression of metallothionein 2A (MT2A) was enhanced in the ZnO, CuO, and Bi2O3 exposed cells.	bi2o3	97-102	metallothionein 2A	Homo sapiens	57-61
29882686-14	2018	The enhancement of HO-1, IL-8, and MT2A gene expressions was related to the cytotoxic activity of metal oxide nanoparticles.	metal oxide	98-109	metallothionein 2A	Homo sapiens	35-39
30227688-6	2018	Melatonin administration, reducing oxidative stress and directly acting on its membrane receptors, melatonin thyroid hormone receptors (MT1 and MT2), displays effects on the earliest phases of pregnancy and during the whole gestational period.	Melatonin	0-9	metallothionein 2A	Homo sapiens	144-147
29861447-0	2018	Stimulatory Effects of Melatonin on Porcine In Vitro Maturation Are Mediated by MT2 Receptor.	Melatonin	23-32	metallothionein 2A	Homo sapiens	80-83
29988433-9	2018	Predicted metagenomics indicated the underrepresentation in MT2 of eight genes involved in pathways of butyrate biosynthesis, notably including paths from glutamate as well as pyruvate.	Butyrates	103-111	metallothionein 2A	Homo sapiens	60-63
29988433-9	2018	Predicted metagenomics indicated the underrepresentation in MT2 of eight genes involved in pathways of butyrate biosynthesis, notably including paths from glutamate as well as pyruvate.	Glutamic Acid	155-164	metallothionein 2A	Homo sapiens	60-63
29988433-9	2018	Predicted metagenomics indicated the underrepresentation in MT2 of eight genes involved in pathways of butyrate biosynthesis, notably including paths from glutamate as well as pyruvate.	Pyruvic Acid	176-184	metallothionein 2A	Homo sapiens	60-63
29464840-1	2018	Recent investigations of our group established that melatonin modulates hormone secretion of pancreatic islets via melatonin receptor types MT1 and MT2.	Melatonin	52-61	metallothionein 2A	Homo sapiens	148-151
29464840-8	2018	These data suggest the following: i) cell-type-specific density of MT1 and MT2 receptors in human pancreatic islets, which should be considered in context of the hormone secretion of islets, ii) the influence of diabetes on density of MT1 and MT2 as well as iii) the differential impact of melatonin on somatostatin secretion of nondiabetic and type 2 diabetic islets.	Melatonin	290-299	metallothionein 2A	Homo sapiens	75-78
29861447-2	2018	The fact that melatonin modulates the functions of porcine granulosa cells via the MT2 receptor suggests the possibility of MT2 receptor-mediation for melatonin to promote cumulus expansion of porcine cumulus-oocyte complexes (COCs).	Melatonin	14-23	metallothionein 2A	Homo sapiens	83-86
29861447-2	2018	The fact that melatonin modulates the functions of porcine granulosa cells via the MT2 receptor suggests the possibility of MT2 receptor-mediation for melatonin to promote cumulus expansion of porcine cumulus-oocyte complexes (COCs).	Melatonin	151-160	metallothionein 2A	Homo sapiens	124-127
29861447-10	2018	In conclusion, our results indicate that the MT2 receptor mediated the stimulatory effects of melatonin on porcine cumulus expansion and subsequent embryo development.	Melatonin	94-103	metallothionein 2A	Homo sapiens	45-48
29277070-10	2018	Additionally, the stimulatory effects of melatonin were blocked by luzindole, a non-selective MT1 and MT2 receptor antagonist, or partially blocked by a selective MT2 ligand, 4-phenyl-2-propionamidotetralin (4P-PDOT).	Melatonin	41-50	metallothionein 2A	Homo sapiens	102-105
29595267-4	2018	The THQ ring proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands, which resulted as more polar bioisosteres of their tetralin analogs.	1,2,3,4-tetrahydroquinoline	4-7	metallothionein 2A	Homo sapiens	73-76
29595267-4	2018	The THQ ring proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands, which resulted as more polar bioisosteres of their tetralin analogs.	tetralin	137-145	metallothionein 2A	Homo sapiens	73-76
29595267-5	2018	Potent partial agonists, with subnanomolar binding affinity for the MT2 receptor, were obtained, and a new series of THQ derivatives is presented.	1,2,3,4-tetrahydroquinoline	117-120	metallothionein 2A	Homo sapiens	68-71
29561927-4	2018	Recent discoveries indicate that Zn(ii) ions are bound with MT2 with the range from nano- to picomolar affinity, which determines its cellular zinc buffering properties that are demonstrated by the presence of partially Zn(ii)-depleted MT2 species.	Zinc	33-39	metallothionein 2A	Homo sapiens	60-63
29561927-4	2018	Recent discoveries indicate that Zn(ii) ions are bound with MT2 with the range from nano- to picomolar affinity, which determines its cellular zinc buffering properties that are demonstrated by the presence of partially Zn(ii)-depleted MT2 species.	Zinc	33-39	metallothionein 2A	Homo sapiens	236-239
29561927-4	2018	Recent discoveries indicate that Zn(ii) ions are bound with MT2 with the range from nano- to picomolar affinity, which determines its cellular zinc buffering properties that are demonstrated by the presence of partially Zn(ii)-depleted MT2 species.	Zinc	220-226	metallothionein 2A	Homo sapiens	60-63
29561927-7	2018	Here, we describe the Zn(ii) binding mechanism in human MT2 with high resolution with respect to particular Zn(ii) binding sites, and provide structural insights into Zn(ii)-depleted MT species.	Zinc	22-28	metallothionein 2A	Homo sapiens	56-59
29561927-7	2018	Here, we describe the Zn(ii) binding mechanism in human MT2 with high resolution with respect to particular Zn(ii) binding sites, and provide structural insights into Zn(ii)-depleted MT species.	Zinc	108-114	metallothionein 2A	Homo sapiens	56-59
29561927-7	2018	Here, we describe the Zn(ii) binding mechanism in human MT2 with high resolution with respect to particular Zn(ii) binding sites, and provide structural insights into Zn(ii)-depleted MT species.	Zinc	108-114	metallothionein 2A	Homo sapiens	56-59
29561927-15	2018	This study provides a comprehensive overview of the crosstalk of structural and zinc buffering related-to-thermodynamics properties of partially metal-saturated mammalian MT2 and sheds more light on other MT proteins and zinc homeostasis.	Metals	145-150	metallothionein 2A	Homo sapiens	171-174
29285799-4	2018	Melatonin effects were mediated through MT2 melatonin receptors, MEK1/2, and MEK5.	Melatonin	0-9	metallothionein 2A	Homo sapiens	40-43
29149494-0	2018	Inhibiting MT2-TFE3-dependent autophagy enhances melatonin-induced apoptosis in tongue squamous cell carcinoma.	Melatonin	49-58	metallothionein 2A	Homo sapiens	11-14
29277070-10	2018	Additionally, the stimulatory effects of melatonin were blocked by luzindole, a non-selective MT1 and MT2 receptor antagonist, or partially blocked by a selective MT2 ligand, 4-phenyl-2-propionamidotetralin (4P-PDOT).	luzindole	67-76	metallothionein 2A	Homo sapiens	102-105
29277070-11	2018	The data support the presence of MT1 and MT2 in porcine CL and a regulatory role for melatonin in luteal function through MT1 and MT2-mediated signal transduction pathways.	Melatonin	85-94	metallothionein 2A	Homo sapiens	130-133
29854276-5	2018	The known heavy metal detoxifying effect of MT-I and MT-II may be the reason for heavy metal drug resistance of various cancers including MPM.	Metals	16-21	metallothionein 2A	Homo sapiens	53-58
29854276-5	2018	The known heavy metal detoxifying effect of MT-I and MT-II may be the reason for heavy metal drug resistance of various cancers including MPM.	Metals	87-92	metallothionein 2A	Homo sapiens	53-58
29277070-10	2018	Additionally, the stimulatory effects of melatonin were blocked by luzindole, a non-selective MT1 and MT2 receptor antagonist, or partially blocked by a selective MT2 ligand, 4-phenyl-2-propionamidotetralin (4P-PDOT).	Melatonin	41-50	metallothionein 2A	Homo sapiens	163-166
29471847-2	2018	Metallothionein-II (MTII) is a metal-binding protein known for its neuroprotective effect by directly stimulating the growth of axons after injury.	Metals	31-36	metallothionein 2A	Homo sapiens	0-18
29471847-2	2018	Metallothionein-II (MTII) is a metal-binding protein known for its neuroprotective effect by directly stimulating the growth of axons after injury.	Metals	31-36	metallothionein 2A	Homo sapiens	20-24
29699692-1	2018	The melatonin receptor subfamily is composed of three members, MT1 and MT2, which are binding to melatonin, and GPR50, which shows high sequence homology to MT1 and MT2 but does not bind to melatonin or any other known ligand.	Melatonin	97-106	metallothionein 2A	Homo sapiens	71-74
29710712-5	2018	In the mammalian brains, the effects of melatonin are mainly relayed by two of its receptors, melatonin receptor type 1a (MT1) and 1b (MT2).	Melatonin	40-49	metallothionein 2A	Homo sapiens	135-138
29437149-4	2018	Metallothionein-2 relaxes ASMCs via transgelin-2 (TG2) and induces dephosphorylation of myosin phosphatase target subunit 1 (MYPT1).	asmcs	26-31	metallothionein 2A	Homo sapiens	0-17
29154938-6	2018	The assessments confirmed the nature of the agonistic ligands but showed that 4-phenyl-2-propionamidotetralin, a described antagonist, is a biased partial agonist at MT2 with poorer affinity for MT1.	4-phenyl-2-propionamidotetralin	78-109	metallothionein 2A	Homo sapiens	166-169
29320872-0	2018	Correction to: Bai et al., Melatonin promotes self-renewal of nestin-positive pancreatic stem cells through activation of the MT2/ERK/SMAD/nestin axis.	Melatonin	27-36	metallothionein 2A	Homo sapiens	126-129
29699692-1	2018	The melatonin receptor subfamily is composed of three members, MT1 and MT2, which are binding to melatonin, and GPR50, which shows high sequence homology to MT1 and MT2 but does not bind to melatonin or any other known ligand.	Melatonin	4-13	metallothionein 2A	Homo sapiens	71-74
28507149-11	2017	Collectively, this study uncovers an important role for XAF1-MT2A antagonism as a linchpin to govern cell fate under various stressful conditions including heavy metal exposure.	Metals	162-167	metallothionein 2A	Homo sapiens	61-65
29699692-1	2018	The melatonin receptor subfamily is composed of three members, MT1 and MT2, which are binding to melatonin, and GPR50, which shows high sequence homology to MT1 and MT2 but does not bind to melatonin or any other known ligand.	Melatonin	4-13	metallothionein 2A	Homo sapiens	165-168
28865957-6	2017	This study focused on designing an MT2a construct of recombinant human MT2a to determine the Zn(II) binding profile of MT2a in vitro.	Zinc	93-99	metallothionein 2A	Homo sapiens	35-39
28865957-6	2017	This study focused on designing an MT2a construct of recombinant human MT2a to determine the Zn(II) binding profile of MT2a in vitro.	Zinc	93-99	metallothionein 2A	Homo sapiens	71-75
28865957-6	2017	This study focused on designing an MT2a construct of recombinant human MT2a to determine the Zn(II) binding profile of MT2a in vitro.	Zinc	93-99	metallothionein 2A	Homo sapiens	71-75
28865957-7	2017	We analyzed the pH dependence of Zn-MT2a speciation from electrospray ionization mass spectral data.	Zinc	33-35	metallothionein 2A	Homo sapiens	36-40
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	Zinc	21-27	metallothionein 2A	Homo sapiens	74-78
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	Zinc	21-27	metallothionein 2A	Homo sapiens	179-183
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	cysteine thiols	55-70	metallothionein 2A	Homo sapiens	74-78
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	Metals	125-130	metallothionein 2A	Homo sapiens	74-78
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	Zinc	158-164	metallothionein 2A	Homo sapiens	179-183
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	zn4s11	172-178	metallothionein 2A	Homo sapiens	179-183
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	cysteinyl thiols	211-227	metallothionein 2A	Homo sapiens	74-78
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	Zinc	158-164	metallothionein 2A	Homo sapiens	179-183
28865957-8	2017	At physiological pH, Zn(II) is terminally bound to the cysteine thiols of MT2a, making bead-like structures (non-cooperative metal binding), while at low pH, Zn(II) formed Zn4S11-MT2a clusters involving bridged cysteinyl thiols to the Zn(II) (cooperative metal binding).	Metals	255-260	metallothionein 2A	Homo sapiens	74-78
28865957-9	2017	The Zn(II) binding profile of MT2a was compared to Zn(II) binding profile of human kidney MT1a, which was reported in literature, and found that the Zn(II) binding profile of MT2a is similar to that of MT1a.	Zinc	4-10	metallothionein 2A	Homo sapiens	30-34
28865957-9	2017	The Zn(II) binding profile of MT2a was compared to Zn(II) binding profile of human kidney MT1a, which was reported in literature, and found that the Zn(II) binding profile of MT2a is similar to that of MT1a.	Zinc	4-10	metallothionein 2A	Homo sapiens	175-179
28865957-10	2017	The facility of forming bead-like structures at physiological pH for Zn5-MT2a means that Zn7-MT2a can donate up to two Zn(II) to Zn-dependent enzymes.	Zinc	69-71	metallothionein 2A	Homo sapiens	73-77
28865957-10	2017	The facility of forming bead-like structures at physiological pH for Zn5-MT2a means that Zn7-MT2a can donate up to two Zn(II) to Zn-dependent enzymes.	Zinc	69-71	metallothionein 2A	Homo sapiens	93-97
28865957-10	2017	The facility of forming bead-like structures at physiological pH for Zn5-MT2a means that Zn7-MT2a can donate up to two Zn(II) to Zn-dependent enzymes.	Zinc	89-91	metallothionein 2A	Homo sapiens	73-77
28865957-10	2017	The facility of forming bead-like structures at physiological pH for Zn5-MT2a means that Zn7-MT2a can donate up to two Zn(II) to Zn-dependent enzymes.	Zinc	89-91	metallothionein 2A	Homo sapiens	93-97
29088301-1	2017	The mammalian retina harbors a circadian clockwork that regulates vision and promotes healthiness of retinal neurons, mainly through directing the rhythmic release of the neurohormones dopamine-acting on dopamine D4 receptors-and melatonin-acting on MT1 and MT2 receptors.	Dopamine	185-193	metallothionein 2A	Homo sapiens	258-261
29088301-1	2017	The mammalian retina harbors a circadian clockwork that regulates vision and promotes healthiness of retinal neurons, mainly through directing the rhythmic release of the neurohormones dopamine-acting on dopamine D4 receptors-and melatonin-acting on MT1 and MT2 receptors.	Melatonin	230-239	metallothionein 2A	Homo sapiens	258-261
28827538-6	2017	Co-expression of the melatonin binding MT2 receptor with GPR61, GPR62 or GPR135 has several consequences such as (i) the formation of receptor heteromers, (ii) the inhibition of melatonin-induced ss-arrestin2 recruitment to MT2 and (iii) the decrease of elevated cAMP levels upon melatonin stimulation in cells expressing spontaneously active GPR61 and GPR62.	Melatonin	21-30	metallothionein 2A	Homo sapiens	39-42
28827538-6	2017	Co-expression of the melatonin binding MT2 receptor with GPR61, GPR62 or GPR135 has several consequences such as (i) the formation of receptor heteromers, (ii) the inhibition of melatonin-induced ss-arrestin2 recruitment to MT2 and (iii) the decrease of elevated cAMP levels upon melatonin stimulation in cells expressing spontaneously active GPR61 and GPR62.	Melatonin	21-30	metallothionein 2A	Homo sapiens	224-227
28827538-6	2017	Co-expression of the melatonin binding MT2 receptor with GPR61, GPR62 or GPR135 has several consequences such as (i) the formation of receptor heteromers, (ii) the inhibition of melatonin-induced ss-arrestin2 recruitment to MT2 and (iii) the decrease of elevated cAMP levels upon melatonin stimulation in cells expressing spontaneously active GPR61 and GPR62.	Cyclic AMP	263-267	metallothionein 2A	Homo sapiens	39-42
28827538-6	2017	Co-expression of the melatonin binding MT2 receptor with GPR61, GPR62 or GPR135 has several consequences such as (i) the formation of receptor heteromers, (ii) the inhibition of melatonin-induced ss-arrestin2 recruitment to MT2 and (iii) the decrease of elevated cAMP levels upon melatonin stimulation in cells expressing spontaneously active GPR61 and GPR62.	Melatonin	178-187	metallothionein 2A	Homo sapiens	39-42
28827538-6	2017	Co-expression of the melatonin binding MT2 receptor with GPR61, GPR62 or GPR135 has several consequences such as (i) the formation of receptor heteromers, (ii) the inhibition of melatonin-induced ss-arrestin2 recruitment to MT2 and (iii) the decrease of elevated cAMP levels upon melatonin stimulation in cells expressing spontaneously active GPR61 and GPR62.	Melatonin	178-187	metallothionein 2A	Homo sapiens	224-227
28188799-8	2017	The backbone of the polysaccharide moiety of MTW was the same as MT2-A (Li et al.	Polysaccharides	20-34	metallothionein 2A	Homo sapiens	65-70
29173474-13	2018	New evidence is that MT2A -5A/G SNP was associated with decreased placental Fe levels in non-smokers.	Iron	76-78	metallothionein 2A	Homo sapiens	21-25
29102176-0	2017	Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands.	naphtho	43-50	metallothionein 2A	Homo sapiens	120-123
29102176-0	2017	Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands.	quinolinocyclopentane	56-77	metallothionein 2A	Homo sapiens	120-123
28956121-8	2017	Blockade of MT1 and/or MT2 receptors with luzindole or 4-P-PDOT was unable to reverse the enhancing effects of melatonin on both cytotoxicity, caspase-3 activation and the amount of apoptotic cells evoked by the chemotherapeutic agents, whereas when MT3 receptors were blocked with prazosin, the synergistic effect of melatonin with chemotherapy on cytotoxicity and apoptosis was reversed.	luzindole	42-51	metallothionein 2A	Homo sapiens	23-26
28027439-2	2017	Using an integrated pharmacoinformatics based screening approach, we have identified these insecticides to be structural mimics of the neurohormone melatonin and were able to bind to the putative melatonin binding sites in MT1 and MT2 melatonin receptors in silico.	Melatonin	196-205	metallothionein 2A	Homo sapiens	231-234
28131805-7	2017	In contrast, ddC treatment of rapidly dividing MT-2 and Jurkat cells resulted in a dose-dependent decrease in mtDNA.	Zalcitabine	13-16	metallothionein 2A	Homo sapiens	47-51
28070874-3	2017	Therefore, we attempted to determine whether a defective provirus could transmit during the co-culture of HTLV-1 uninfected human T-cell line, Jurkat, with MT-2 cells treated with mitomycin C.	Mitomycin	180-191	metallothionein 2A	Homo sapiens	156-160
28027439-5	2017	In the presence of GTP (100 muM), which decouples the G-protein linked receptors to modulate signaling, the apparent efficacy of carbaryl and carbofuran for 2-[125I]-iodomelatonin binding for the hMT1 melatonin receptor was not affected but significantly decreased for the hMT2 melatonin receptor compatible with receptor antagonist/inverse agonist and agonist efficacy, respectively.	Carbofuran	142-152	metallothionein 2A	Homo sapiens	273-277
28587098-6	2017	MT2 was highly upregulated by Zn2+ in both cell cultures, while MT3 was not affected, and no other metal had an effect on either MT2 or MT3.	Zinc	30-34	metallothionein 2A	Homo sapiens	0-3
28335493-1	2017	Some melatonin functions in mammals are exerted through MT1 and MT2 receptors.	Melatonin	5-14	metallothionein 2A	Homo sapiens	64-67
28027439-3	2017	Carbaryl and carbofuran then were tested for competition with 2-[125I]-iodomelatonin (300 pM) binding to hMT1 or hMT2 receptors stably expressed in CHO cells.	2-[125i]-iodomelatonin	62-84	metallothionein 2A	Homo sapiens	113-117
28027439-4	2017	Carbaryl and carbofuran showed higher affinity for competition with 2-[125I]-iodomelatonin binding to the hMT2 compared to the hMT1 melatonin receptor (33 and 35-fold difference, respectively) as predicted by the molecular modeling.	Carbaryl	0-8	metallothionein 2A	Homo sapiens	106-110
28027439-4	2017	Carbaryl and carbofuran showed higher affinity for competition with 2-[125I]-iodomelatonin binding to the hMT2 compared to the hMT1 melatonin receptor (33 and 35-fold difference, respectively) as predicted by the molecular modeling.	Carbofuran	13-23	metallothionein 2A	Homo sapiens	106-110
28027439-4	2017	Carbaryl and carbofuran showed higher affinity for competition with 2-[125I]-iodomelatonin binding to the hMT2 compared to the hMT1 melatonin receptor (33 and 35-fold difference, respectively) as predicted by the molecular modeling.	2-[125i]-iodomelatonin	68-90	metallothionein 2A	Homo sapiens	106-110
28027439-5	2017	In the presence of GTP (100 muM), which decouples the G-protein linked receptors to modulate signaling, the apparent efficacy of carbaryl and carbofuran for 2-[125I]-iodomelatonin binding for the hMT1 melatonin receptor was not affected but significantly decreased for the hMT2 melatonin receptor compatible with receptor antagonist/inverse agonist and agonist efficacy, respectively.	Carbaryl	129-137	metallothionein 2A	Homo sapiens	273-277
29085556-4	2017	MT-I and MT-II have been considered polyvalent proteins whose main function is to maintain cellular homeostasis of essential metals such as zinc and copper, but other functions have also been considered: detoxification of heavy metals, regulation of gene expression, processes of inflammation, and protection against free radicals generated by oxidative stress.	Copper	149-155	metallothionein 2A	Homo sapiens	9-14
28131094-5	2017	Besides, sulphonamide 11b showed the most important MT2 selectivity of this series (167 folds) while methyl and ethyl-ureas 11f and 11g represented the most potent melatonergic ligands of this study.	sulphonamide 11b	9-25	metallothionein 2A	Homo sapiens	52-55
27919824-4	2017	In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes.	Melatonin	49-58	metallothionein 2A	Homo sapiens	96-99
29085556-4	2017	MT-I and MT-II have been considered polyvalent proteins whose main function is to maintain cellular homeostasis of essential metals such as zinc and copper, but other functions have also been considered: detoxification of heavy metals, regulation of gene expression, processes of inflammation, and protection against free radicals generated by oxidative stress.	Free Radicals	317-330	metallothionein 2A	Homo sapiens	9-14
27504868-1	2016	Agomelatine is an antidepressant drug with moderate agonistic action at the melatonine receptor MT1 and weak effect at MT2.	agomelatine	0-11	metallothionein 2A	Homo sapiens	119-122
29898451-6	2017	Melatonin acts mainly on the MT1 and MT2 receptors, which are present in the SCN, to regulate physiological and neuroendocrine functions including circadian entrainment, referred to as a chronobiotic effect.	Melatonin	0-9	metallothionein 2A	Homo sapiens	37-40
29376995-3	2017	Besides the effect on suprachiasmatic nucleus, a relevant role in the mechanism of action of agomelatine plays its special functionally selective (with regard to intracellular signaling pathways) interaction with heteromeric complexes of serotonin 5-NT2S and melatonin MT2 receptors in the hippocampus and cerebral cortex.	agomelatine	93-104	metallothionein 2A	Homo sapiens	269-272
27744593-8	2016	The results revealed that mean MT-1A and MT-2A mRNAs and MT-1/2 proteins were up-regulated in H-Cd group (p &lt; 0.05).	h-cd	94-98	metallothionein 2A	Homo sapiens	41-46
27477115-9	2016	In conclusion, the study demonstrated that melatonin mediated proliferation, apoptosis, and steroidogenesis in porcine granulosa cells predominantly through the activation of melatonin receptor MT2 in vitro, which provided evidence of the beneficial role of melatonin as well as its functional mechanism in porcine granulosa cells in vitro.	Melatonin	43-52	metallothionein 2A	Homo sapiens	194-197
27698681-4	2016	Melatonin mediates its actions through MT1/MT2 melatonin receptors on the cell membrane and also through RZR/ROR nuclear orphan receptors.	Melatonin	0-9	metallothionein 2A	Homo sapiens	43-46
27477115-0	2016	Melatonin modulates the functions of porcine granulosa cells via its membrane receptor MT2 in vitro.	Melatonin	0-9	metallothionein 2A	Homo sapiens	87-90
27477115-9	2016	In conclusion, the study demonstrated that melatonin mediated proliferation, apoptosis, and steroidogenesis in porcine granulosa cells predominantly through the activation of melatonin receptor MT2 in vitro, which provided evidence of the beneficial role of melatonin as well as its functional mechanism in porcine granulosa cells in vitro.	Melatonin	175-184	metallothionein 2A	Homo sapiens	194-197
27608012-2	2016	For many years, most studies evaluating the effects of MT2A have focused on reactive oxygen species (ROS), as second messengers that lead to oxidative stress injury of cells and tissues.	Reactive Oxygen Species	76-99	metallothionein 2A	Homo sapiens	55-59
27314307-11	2016	These results indicate a potential modulating role of melatonin via the MT2 receptor on abnormal osteogenic and chondrogenic differentiaation in patients with AIS.	Melatonin	54-63	metallothionein 2A	Homo sapiens	72-75
27608012-2	2016	For many years, most studies evaluating the effects of MT2A have focused on reactive oxygen species (ROS), as second messengers that lead to oxidative stress injury of cells and tissues.	Reactive Oxygen Species	101-104	metallothionein 2A	Homo sapiens	55-59
26908771-8	2016	RPTEC/TERT1 cells overexpressing MT2A were less susceptible towards cadmium chloride-induced cytotoxicity and hypoxia-induced apoptosis, both models for increased generation of reactive oxygen species.	Cadmium Chloride	68-84	metallothionein 2A	Homo sapiens	33-37
26908771-8	2016	RPTEC/TERT1 cells overexpressing MT2A were less susceptible towards cadmium chloride-induced cytotoxicity and hypoxia-induced apoptosis, both models for increased generation of reactive oxygen species.	Reactive Oxygen Species	177-200	metallothionein 2A	Homo sapiens	33-37
27391761-6	2016	Treatment with 1.0 ng/mL of melatonin also significantly elevated MT2, SOD1, and GPX4 while lowering FASL, CHOP, and GRP78 mRNA abundance compared to the untreated control.	Melatonin	28-37	metallothionein 2A	Homo sapiens	66-69
27374080-7	2016	Chick embryo chorioallantoic membrane invasion assays demonstrated that cells transfected with WT MT2-MMP were more invasive than cells transfected with control vector, treated with GM6001, or transfected with the E260A mutant.	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	182-188	metallothionein 2A	Homo sapiens	98-101
26801633-0	2016	Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-kappaB Activation.	diallyl trisulfide	49-67	metallothionein 2A	Homo sapiens	27-45
25515626-1	2016	The present study analysed the involvement of melatonin, acting via its receptors (MT1 and MT2), in ram sperm functionality.	Melatonin	46-55	metallothionein 2A	Homo sapiens	91-94
25515626-5	2016	In conclusion, melatonin exerts a modulating effect on ram sperm functionality, primarily via activation of the MT2 receptor.	Melatonin	15-24	metallothionein 2A	Homo sapiens	112-115
26801633-0	2016	Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-kappaB Activation.	Docetaxel	127-136	metallothionein 2A	Homo sapiens	27-45
26801633-3	2016	The present study investigated the effect of diallyl trisulfide (DATS), a garlic-derived compound, and docetaxel (DOC) on regulation of MT2A in relation to NF-kappaB in GC cells.	diallyl trisulfide	45-63	metallothionein 2A	Homo sapiens	136-140
26801633-3	2016	The present study investigated the effect of diallyl trisulfide (DATS), a garlic-derived compound, and docetaxel (DOC) on regulation of MT2A in relation to NF-kappaB in GC cells.	diallyl trisulfide	65-69	metallothionein 2A	Homo sapiens	136-140
26801633-3	2016	The present study investigated the effect of diallyl trisulfide (DATS), a garlic-derived compound, and docetaxel (DOC) on regulation of MT2A in relation to NF-kappaB in GC cells.	Docetaxel	103-112	metallothionein 2A	Homo sapiens	136-140
26801633-3	2016	The present study investigated the effect of diallyl trisulfide (DATS), a garlic-derived compound, and docetaxel (DOC) on regulation of MT2A in relation to NF-kappaB in GC cells.	Docetaxel	114-117	metallothionein 2A	Homo sapiens	136-140
26801633-5	2016	The anti-GC effect of DATS was attributable to its capacity to epigenetically upregulate MT2A, which in turn enhanced transcription of IkappaB-alpha to suppress NF-kappaB activation in GC cells.	diallyl trisulfide	22-26	metallothionein 2A	Homo sapiens	89-93
26801633-6	2016	The combination of DATS with DOC exhibited a synergistic anti-GC activity accompanied by MT2A upregulation and NF-kappaB inactivation.	Docetaxel	29-32	metallothionein 2A	Homo sapiens	89-93
26801633-7	2016	Histopathologic analysis of GC specimens from patients showed a significant increase in MT2A expression following DOC treatment.	Docetaxel	114-117	metallothionein 2A	Homo sapiens	88-92
26801633-9	2016	INNOVATION AND CONCLUSION: We conclude that DATS exerts its anti-GC activity and enhances chemosensitivity of GC to DOC by epigenetic upregulation of MT2A to attenuate NF-kappaB signaling.	diallyl trisulfide	44-48	metallothionein 2A	Homo sapiens	150-154
26801633-9	2016	INNOVATION AND CONCLUSION: We conclude that DATS exerts its anti-GC activity and enhances chemosensitivity of GC to DOC by epigenetic upregulation of MT2A to attenuate NF-kappaB signaling.	Docetaxel	116-119	metallothionein 2A	Homo sapiens	150-154
27229348-3	2016	METHODS: We evaluated a group of 24 nondepressed patients with a diagnosis of the behavioral variant of FTD, in order to determine the effectiveness on apathy of agomelatine, an antidepressant with MT1 and MT2 receptor agonism and 5-HT2C receptor antagonism; the latter leads to an increase in prefrontal dopaminergic and noradrenergic tone.	agomelatine	162-173	metallothionein 2A	Homo sapiens	206-209
27092136-4	2016	MT2 microplates (Biolog(TM)) method is traditionally used for bacteria identification and the evaluation of their ability to utilize different carbon substrates.	Carbon	143-149	metallothionein 2A	Homo sapiens	0-3
26867681-6	2016	Both dimethyl phthalate (DMP) and DEHP were correlated with higher MT and MT-2A expression, while diethyl phthalate (DEP) was also positively correlated with MT-1A and FATP1 expression in female infants.	dimethyl phthalate	5-23	metallothionein 2A	Homo sapiens	74-79
26867681-6	2016	Both dimethyl phthalate (DMP) and DEHP were correlated with higher MT and MT-2A expression, while diethyl phthalate (DEP) was also positively correlated with MT-1A and FATP1 expression in female infants.	dimethyl phthalate	25-28	metallothionein 2A	Homo sapiens	74-79
26867681-6	2016	Both dimethyl phthalate (DMP) and DEHP were correlated with higher MT and MT-2A expression, while diethyl phthalate (DEP) was also positively correlated with MT-1A and FATP1 expression in female infants.	Diethylhexyl Phthalate	34-38	metallothionein 2A	Homo sapiens	74-79
27010900-1	2016	Our recent ultrastructural study of human parotid glands revealed that the melatonin receptors, MT1 and MT2, are localised in the plasma cell membranes of acinar and ductal cells but also, and intriguingly, predominantly in acinar secretory granules, giving rise to the working hypothesis that secretory granules are a part of a transcytotic transport system for melatonin.	Melatonin	75-84	metallothionein 2A	Homo sapiens	104-107
27829983-6	2016	The literature reviewed here indicates that PD is associated with impaired brain expression of melatonin and its receptors MT1 and MT2.	Melatonin	95-104	metallothionein 2A	Homo sapiens	131-134
26961605-7	2016	Further analysis of a library of zinc complexes showed that zinc(II) bis(diethyldithiocarbamate) activated the MTF-1/MRE pathway but not the Nrf2/ARE pathway, increased MT-1A, MT-1E, and MT-2A mRNA levels, and induced metallothionein proteins.	zinc(ii) bis(diethyldithiocarbamate)	60-96	metallothionein 2A	Homo sapiens	187-192
26820449-1	2016	Following our research for new melatonergic ligands, herein we report the design, synthesis and biological evaluation of new series of naphthofuranic derivatives as MT1 and MT2 ligands.	naphthofuranic derivatives	135-161	metallothionein 2A	Homo sapiens	173-176
26514204-2	2016	Melatonin activates two high-affinity G protein-coupled receptors, termed MT1 and MT2, to exert beneficial actions in sleep and circadian abnormality, mood disorders, learning and memory, neuroprotection, drug abuse, and cancer.	Melatonin	0-9	metallothionein 2A	Homo sapiens	82-85
26446034-7	2015	Using repeated-measures ANOVA, MT-2A gene expression and fold change were found to be higher in the ZT group (P = 0.025 and P = 0.016, respectively) compared to the NT group, specifically at Day 2 (40 +- 18 % increase from baseline, P = 0.011), despite no significant increase in plasma zinc concentration.	zt	100-102	metallothionein 2A	Homo sapiens	31-36
26529669-7	2015	RESULTS: Minor alleles of rs28366003 and rs10636 near the MT2A gene were associated with lower urinary Cd, Cu, and Zn.	Copper	107-109	metallothionein 2A	Homo sapiens	58-62
26529669-7	2015	RESULTS: Minor alleles of rs28366003 and rs10636 near the MT2A gene were associated with lower urinary Cd, Cu, and Zn.	Zinc	115-117	metallothionein 2A	Homo sapiens	58-62
26444951-2	2015	Because agomelatine acts as a MT1 and MT2 agonist and as a 5HT2c antagonist, this study was designed to assess the efficacy of agomelatine in treating depressive symptoms in PD patients, and the potential changes both in sleep quality and motor symptoms.	agomelatine	8-19	metallothionein 2A	Homo sapiens	38-41
26594907-3	2016	The present study aimed to evaluate the genetic effects of the polymorphism of MT2A (single nucleotide polymorphism rs10636; Cx2192;G) on blood Pb levels (BLL) of workers from car battery factories who are chronically exposed to the metal.	Lead	144-146	metallothionein 2A	Homo sapiens	79-83
26594907-3	2016	The present study aimed to evaluate the genetic effects of the polymorphism of MT2A (single nucleotide polymorphism rs10636; Cx2192;G) on blood Pb levels (BLL) of workers from car battery factories who are chronically exposed to the metal.	Metals	233-238	metallothionein 2A	Homo sapiens	79-83
26529669-7	2015	RESULTS: Minor alleles of rs28366003 and rs10636 near the MT2A gene were associated with lower urinary Cd, Cu, and Zn.	Cadmium	103-105	metallothionein 2A	Homo sapiens	58-62
26547260-10	2015	Treatment with YM155 combined with the STAT3 inhibitor S3I-201 significantly suppressed cell proliferation compared to that with either YM155 or S3I-201 in MT-2 cells, indicating that STAT3 may play a role in tolerance of MT-2 cells to YM155 and that STAT3 may therefore be a therapeutic target for YM155-resistant ATL cells.	YM 155	15-20	metallothionein 2A	Homo sapiens	156-160
26547260-10	2015	Treatment with YM155 combined with the STAT3 inhibitor S3I-201 significantly suppressed cell proliferation compared to that with either YM155 or S3I-201 in MT-2 cells, indicating that STAT3 may play a role in tolerance of MT-2 cells to YM155 and that STAT3 may therefore be a therapeutic target for YM155-resistant ATL cells.	YM 155	15-20	metallothionein 2A	Homo sapiens	222-226
26375382-1	2015	The reaction of cadmium-binding human metallothionein-2A (Cd7MT) and N-ethylmaleimide (NEM) is investigated by electrospray ionization-ion mobility-mass spectrometry (ESI IM-MS).	Ethylmaleimide	69-85	metallothionein 2A	Homo sapiens	38-56
26375382-1	2015	The reaction of cadmium-binding human metallothionein-2A (Cd7MT) and N-ethylmaleimide (NEM) is investigated by electrospray ionization-ion mobility-mass spectrometry (ESI IM-MS).	Cadmium	16-23	metallothionein 2A	Homo sapiens	38-56
25851638-1	2015	Tasimelteon ([1R-trans]-N-[(2-[2,3-dihydro-4-benzofuranyl] cyclopropyl) methyl] propanamide), a novel dual melatonin receptor agonist that demonstrates specificity and high affinity for melatonin receptor types 1 and 2 (MT1 and MT2 receptors), is the first treatment approved by the US Food and Drug Administration for Non-24-Hour Sleep-Wake Disorder.	[1r-trans]-n-[(2-[2,3-dihydro-4-benzofuranyl] cyclopropyl) methyl] propanamide	13-91	metallothionein 2A	Homo sapiens	228-231
26334942-0	2015	Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines.	1-benzyl-2-acylaminomethyl-tetrahydroquinolines	97-144	metallothionein 2A	Homo sapiens	28-31
26334942-5	2015	Structural optimization resulted in N-[(1-benzyl-1,2,3,4-tetrahydro-5-methoxyquinolin-2-yl)methyl]propionamide (UCM1014), with picomolar MT2 binding affinity (K(i) = 0.001 nM), more than 10000-fold selectivity over the MT1 receptor, and a full agonist profile (GTPgammaS test), being the most potent MT2-selective full agonist reported to date.	UCM1014	36-110	metallothionein 2A	Homo sapiens	137-140
26334942-5	2015	Structural optimization resulted in N-[(1-benzyl-1,2,3,4-tetrahydro-5-methoxyquinolin-2-yl)methyl]propionamide (UCM1014), with picomolar MT2 binding affinity (K(i) = 0.001 nM), more than 10000-fold selectivity over the MT1 receptor, and a full agonist profile (GTPgammaS test), being the most potent MT2-selective full agonist reported to date.	UCM1014	36-110	metallothionein 2A	Homo sapiens	300-303
26331226-2	2015	The effects of melatonin on insulin secretion are mediated through the melatonin receptors (MT1 and MT2).	Melatonin	15-24	metallothionein 2A	Homo sapiens	100-103
26283214-9	2015	This attenuating effect was prevented by pre-incubation with luzindole, an antagonist of the melatonin MT1/MT2 receptors.	luzindole	61-70	metallothionein 2A	Homo sapiens	107-110
26283214-11	2015	MT2 knockdown by siRNA abrogated the anti-inflammatory effect exerted by melatonin.	Melatonin	73-82	metallothionein 2A	Homo sapiens	0-3
26283214-12	2015	From these findings, we propose that melatonin exerts its protective effects on methamphetamine-induced neuroinflammation through the membrane receptor, at least in part MT2 subtype, in the SH-SY5Y neuroblastoma cell line.	Melatonin	37-46	metallothionein 2A	Homo sapiens	170-173
26283214-12	2015	From these findings, we propose that melatonin exerts its protective effects on methamphetamine-induced neuroinflammation through the membrane receptor, at least in part MT2 subtype, in the SH-SY5Y neuroblastoma cell line.	Methamphetamine	80-95	metallothionein 2A	Homo sapiens	170-173
25833399-9	2015	This effect of melatonin appears to be mediated via its MT1 and MT2 receptors.	Melatonin	15-24	metallothionein 2A	Homo sapiens	64-67
25833399-3	2015	The purpose of this study was to determine melatonin-synthesizing enzymes, arylalkylamine N-acetyltransferase (AANAT) and hydroxyindole O-methyltransferase (HIOMT), and melatonin receptors (MT1 and MT2) expression throughout pregnancy as well as the role of melatonin and its receptors in villous trophoblast syncytialization.	Melatonin	43-52	metallothionein 2A	Homo sapiens	198-201
26109726-5	2015	A Nox inhibitor, diphenylene iodonium, and antioxidants such as N-acetyl cysteine blocked proliferation of MT1 and MT2 cells.	diphenyleneiodonium	17-37	metallothionein 2A	Homo sapiens	115-118
26109726-5	2015	A Nox inhibitor, diphenylene iodonium, and antioxidants such as N-acetyl cysteine blocked proliferation of MT1 and MT2 cells.	Acetylcysteine	64-81	metallothionein 2A	Homo sapiens	115-118
26512337-6	2015	Recently, more potent melatonin analogs (selective melatonin-1 (MT1) and melatonin-2 (MT2) receptor agonists) with prolonged effects and slow-release melatonin preparations have been developed.	Melatonin	22-31	metallothionein 2A	Homo sapiens	86-89
25900616-2	2015	The goal of this study was to identify the -5 A/G (rs28366003) single-nucleotide polymorphism (SNP) in the core promoter region of the MT2A gene, and to investigate its effect on allele-specific gene expression and Cd, Zn, Cu and Ni content in sinonasal inverted papilloma tissue (IP), with non-cancerous sinonasal mucosa (NCM) as a control.	Cadmium	215-217	metallothionein 2A	Homo sapiens	135-139
25804888-10	2015	Increased transcript expression of metallothioneins, MT1A and MT2A and the stress response genes HMOX1 (690%) and HIF1A (247%) occurred in CATLE cells possibly in adaptation to chronic arsenic exposure.	Arsenic	185-192	metallothionein 2A	Homo sapiens	62-66
25900616-2	2015	The goal of this study was to identify the -5 A/G (rs28366003) single-nucleotide polymorphism (SNP) in the core promoter region of the MT2A gene, and to investigate its effect on allele-specific gene expression and Cd, Zn, Cu and Ni content in sinonasal inverted papilloma tissue (IP), with non-cancerous sinonasal mucosa (NCM) as a control.	Zinc	219-221	metallothionein 2A	Homo sapiens	135-139
25900616-2	2015	The goal of this study was to identify the -5 A/G (rs28366003) single-nucleotide polymorphism (SNP) in the core promoter region of the MT2A gene, and to investigate its effect on allele-specific gene expression and Cd, Zn, Cu and Ni content in sinonasal inverted papilloma tissue (IP), with non-cancerous sinonasal mucosa (NCM) as a control.	Copper	223-225	metallothionein 2A	Homo sapiens	135-139
25900616-13	2015	The results obtained in this study suggest that the -5 A/G SNP in the MT2A gene may have an effect on allele-specific gene expression and toxic metal accumulation in sinonasal inverted papilloma.	Metals	144-149	metallothionein 2A	Homo sapiens	70-74
25218889-0	2015	Interaction study of arsenic (III and V) ions with metallothionein gene (MT2A) fragment.	Arsenic	21-28	metallothionein 2A	Homo sapiens	73-77
25511253-5	2015	Hence, Zn-MT3 showed the highest reactivity, in agreement with its high Cu-thionein character, whereas Zn-MT2 exhibited the lowest reactivity, in line with its high Zn-thionein character.	zn-thionein	165-176	metallothionein 2A	Homo sapiens	106-109
25511253-6	2015	The reactivity of the Zn-loaded forms of MT1 and MT4 is intermediate between those of MT3 and MT2.	Zinc	22-24	metallothionein 2A	Homo sapiens	94-97
25702644-5	2015	Therefore, the anti-apoptotic effect of melatonin requires the simultaneous, independent interaction with high (MT1/MT2) and low (calmodulin) affinity targets, eliciting two independent signal transduction pathways converging into Bax sequestration and inactivation.	Melatonin	40-49	metallothionein 2A	Homo sapiens	116-119
25702644-6	2015	MT1/MT2 vs. lipoxygenase pathways are activated by 10(-9) vs. 10(-5)M melatonin, respectively; the anti-apoptotic effect of melatonin is achieved at 10(-5)M, but drops to 10(-9)M upon addition of exogenous 5-HETE, revealing that lipoxygenase activation is the rate-limiting pathway.	Melatonin	70-79	metallothionein 2A	Homo sapiens	4-7
25702644-6	2015	MT1/MT2 vs. lipoxygenase pathways are activated by 10(-9) vs. 10(-5)M melatonin, respectively; the anti-apoptotic effect of melatonin is achieved at 10(-5)M, but drops to 10(-9)M upon addition of exogenous 5-HETE, revealing that lipoxygenase activation is the rate-limiting pathway.	Melatonin	124-133	metallothionein 2A	Homo sapiens	4-7
25702644-6	2015	MT1/MT2 vs. lipoxygenase pathways are activated by 10(-9) vs. 10(-5)M melatonin, respectively; the anti-apoptotic effect of melatonin is achieved at 10(-5)M, but drops to 10(-9)M upon addition of exogenous 5-HETE, revealing that lipoxygenase activation is the rate-limiting pathway.	5-hydroxy-6,8,11,14-eicosatetraenoic acid	206-212	metallothionein 2A	Homo sapiens	4-7
25757565-6	2015	Exposure of HEK293 cells stably expressing recombinant MT1 or MT2 receptors to Abeta lead to a 40% reduction in [(125)I]iodomelatonin binding to MT1.	iodomelatonin	120-133	metallothionein 2A	Homo sapiens	62-65
25808318-5	2015	HEK cells overexpressing MT-2A demonstrated reduced oxygen consumption and lower cellular ATP levels.	Oxygen	52-58	metallothionein 2A	Homo sapiens	25-30
25808318-5	2015	HEK cells overexpressing MT-2A demonstrated reduced oxygen consumption and lower cellular ATP levels.	Adenosine Triphosphate	90-93	metallothionein 2A	Homo sapiens	25-30
25585597-0	2015	Melatonin influences somatostatin secretion from human pancreatic delta-cells via MT1 and MT2 receptors.	Melatonin	0-9	metallothionein 2A	Homo sapiens	90-93
25528336-2	2015	Concomitant insertion of a hydroxymethyl in the beta-acetamide position and aliphatic groups in C-3 position produced a positive effect on both melatonin (MT1, MT2) and serotonin (5-HT2C) binding affinities.	beta-acetamide	48-62	metallothionein 2A	Homo sapiens	160-163
25528336-5	2015	Finally, the acetamide modulation has led to methyl thiourea 11h, with a weak MT2 selectivity.	acetamide	13-22	metallothionein 2A	Homo sapiens	78-81
25370199-4	2015	For HuFtH, unstored Fe(III) ions trigger the oxidation of Cu-MT2 with concomitant Cu(I) release.	hufth	4-9	metallothionein 2A	Homo sapiens	61-64
25370199-4	2015	For HuFtH, unstored Fe(III) ions trigger the oxidation of Cu-MT2 with concomitant Cu(I) release.	ferric sulfate	20-27	metallothionein 2A	Homo sapiens	61-64
25370199-4	2015	For HuFtH, unstored Fe(III) ions trigger the oxidation of Cu-MT2 with concomitant Cu(I) release.	cuprous ion	82-87	metallothionein 2A	Homo sapiens	61-64
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Aspartic Acid	52-55	metallothionein 2A	Homo sapiens	37-41
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Histidine	56-59	metallothionein 2A	Homo sapiens	37-41
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Deuterium	60-61	metallothionein 2A	Homo sapiens	37-41
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Phenylalanine	62-65	metallothionein 2A	Homo sapiens	37-41
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Arginine	66-69	metallothionein 2A	Homo sapiens	37-41
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Tryptophan	70-73	metallothionein 2A	Homo sapiens	37-41
26095376-1	2015	An alpha-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective.	Lysine	74-77	metallothionein 2A	Homo sapiens	37-41
25479338-0	2014	Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.	isoquinolinones	57-72	metallothionein 2A	Homo sapiens	76-79
25479338-1	2014	A series of substituted isoquinolinones were synthesized and their binding affinities and functional activities towards human melatonin MT1 and MT2 receptors were evaluated.	isoquinolinones	24-39	metallothionein 2A	Homo sapiens	144-147
25479338-2	2014	Structure-activity relationship analysis revealed that substituted isoquinolinones bearing a 3-methoxybenzyloxyl group at C5, C6 or C7 position respectively (C5&gt;C6&gt;C7 in terms of their potency) conferred effective binding and selectivity toward the MT2 receptor, with 15b as the most potent compound.	isoquinolinones	67-82	metallothionein 2A	Homo sapiens	255-258
25479338-2	2014	Structure-activity relationship analysis revealed that substituted isoquinolinones bearing a 3-methoxybenzyloxyl group at C5, C6 or C7 position respectively (C5&gt;C6&gt;C7 in terms of their potency) conferred effective binding and selectivity toward the MT2 receptor, with 15b as the most potent compound.	3-methoxybenzyloxyl	93-112	metallothionein 2A	Homo sapiens	255-258
25479338-3	2014	Most of the tested compounds were MT2-selective agonists as revealed in receptor-mediated cAMP inhibition, intracellular Ca2+ mobilization and phosphorylation of extracellular signal-regulated protein kinases.	Cyclic AMP	90-94	metallothionein 2A	Homo sapiens	34-37
25479338-4	2014	Intriguingly, compounds 7e and 7f bearing a 4-methoxybenzyloxyl group or 4-methylbenzyloxyl at C6 behaved as weak MT2-selective antagonists.	4-methoxybenzyloxyl	44-63	metallothionein 2A	Homo sapiens	114-117
25479338-4	2014	Intriguingly, compounds 7e and 7f bearing a 4-methoxybenzyloxyl group or 4-methylbenzyloxyl at C6 behaved as weak MT2-selective antagonists.	4-methylbenzyloxyl	73-91	metallothionein 2A	Homo sapiens	114-117
25479338-5	2014	These results suggest that substituted isoquinolinones represent a novel family of MT2-selective melatonin ligands.	isoquinolinones	39-54	metallothionein 2A	Homo sapiens	83-86
25479338-5	2014	These results suggest that substituted isoquinolinones represent a novel family of MT2-selective melatonin ligands.	Melatonin	97-106	metallothionein 2A	Homo sapiens	83-86
25023005-1	2014	Melatonin, the popular hormone of the darkness, is primarily synthesized in the pineal gland, and acts classically through the G-protein coupled plasma membrane melatonin receptors MT1 and MT2, respectively.	Melatonin	0-9	metallothionein 2A	Homo sapiens	189-192
25347033-0	2014	1,4-disubstituted-[1,2,3]triazolyl-containing analogues of MT-II: design, synthesis, conformational analysis, and biological activity.	1,4-disubstituted-[1,2,3]triazolyl	0-34	metallothionein 2A	Homo sapiens	59-64
25347033-5	2014	Herein we report the design, synthesis, conformational analysis, and functional biological activity of a series of i-to-i+5 1,4- and 4,1-disubstituted [1,2,3]triazole-bridged cyclopeptides derived from MT-II, the homodetic Asp(5) to Lys(10) side chain-to-side chain bridged heptapeptide, an extensively studied agonist of melanocortin receptors.	1,4- and 4,1	124-136	metallothionein 2A	Homo sapiens	202-207
25347033-5	2014	Herein we report the design, synthesis, conformational analysis, and functional biological activity of a series of i-to-i+5 1,4- and 4,1-disubstituted [1,2,3]triazole-bridged cyclopeptides derived from MT-II, the homodetic Asp(5) to Lys(10) side chain-to-side chain bridged heptapeptide, an extensively studied agonist of melanocortin receptors.	Peptides, Cyclic	175-188	metallothionein 2A	Homo sapiens	202-207
25232966-5	2014	Among the 25 synthesized HHIPs, some of them containing methylenedioxy (series 2) and 8-chloro-7-methoxy substituents (series 4) on the benzene ring revealed affinity for the MT1 and/or the MT2 receptors within the nanomolar range or low micromolar.	Benzene	136-143	metallothionein 2A	Homo sapiens	190-193
24930835-6	2014	Furthermore, the methylenedioxy HHIPs 2d (N-phenylacetamide) and 2f (N,N-diethylacetamide), exhibited high selectivity at MT1 or MT2 receptors, respectively, when compared with melatonin.	acetanilide	42-59	metallothionein 2A	Homo sapiens	129-132
25277428-5	2014	Certain melatonin actions are mediated by receptors that belong to the superfamily of G-protein-coupled receptors (GPCRs), the MT1 and MT2 membrane.	Melatonin	8-17	metallothionein 2A	Homo sapiens	135-138
24595738-0	2014	Cadmium-resistance mechanism in the bacteria Cupriavidus metallidurans CH34 and Pseudomonas putida mt2.	Cadmium	0-7	metallothionein 2A	Homo sapiens	99-102
24595738-1	2014	Cupriavidus metallidurans CH34 and Pseudomonas putida mt2 were used as cadmium (Cd)-resistant and -sensitive bacteria, respectively, to study Cd uptake, sorption, intracellular accumulation, metallothionein (MT) induction, and bioremediation potential of both isolates.	Cadmium	71-78	metallothionein 2A	Homo sapiens	54-57
24595738-3	2014	Addition of N,N"-dicyclohexylcarbodiimide (DCCD) and 2,4-dinitrophenol (DNP) along with Cd resulted in more cell growth in mt2 (OD578 = 0.71) compared with CH34 (OD578 = 0.34).	Dicyclohexylcarbodiimide	12-41	metallothionein 2A	Homo sapiens	123-126
24595738-3	2014	Addition of N,N"-dicyclohexylcarbodiimide (DCCD) and 2,4-dinitrophenol (DNP) along with Cd resulted in more cell growth in mt2 (OD578 = 0.71) compared with CH34 (OD578 = 0.34).	Dicyclohexylcarbodiimide	43-47	metallothionein 2A	Homo sapiens	123-126
24595738-3	2014	Addition of N,N"-dicyclohexylcarbodiimide (DCCD) and 2,4-dinitrophenol (DNP) along with Cd resulted in more cell growth in mt2 (OD578 = 0.71) compared with CH34 (OD578 = 0.34).	2,4-Dinitrophenol	53-70	metallothionein 2A	Homo sapiens	123-126
24595738-3	2014	Addition of N,N"-dicyclohexylcarbodiimide (DCCD) and 2,4-dinitrophenol (DNP) along with Cd resulted in more cell growth in mt2 (OD578 = 0.71) compared with CH34 (OD578 = 0.34).	2,4-Dinitrophenol	72-75	metallothionein 2A	Homo sapiens	123-126
24595738-3	2014	Addition of N,N"-dicyclohexylcarbodiimide (DCCD) and 2,4-dinitrophenol (DNP) along with Cd resulted in more cell growth in mt2 (OD578 = 0.71) compared with CH34 (OD578 = 0.34).	Cadmium	88-90	metallothionein 2A	Homo sapiens	123-126
24595738-5	2014	Greater Cd interaction with the cell surface was observed in mt2 cells compared with CH34 cells.	Cadmium	8-10	metallothionein 2A	Homo sapiens	61-64
24595738-7	2014	Intracellular Cd uptake was observed in even killed mt2 cells (7.11 +- 0.05 mug L(-1) at 5 h) compared with CH34 cells (2.50 +- 0.08 mug L(-1) at 5 h).	Cadmium	14-16	metallothionein 2A	Homo sapiens	52-55
24595738-10	2014	mt2 was able to remove 80 mg L(-1) of Cd after 8 days from original industrial effluent, which was more than Cd removal by mt2 from distilled water (i.e. 77 mg L(-1) after 8 days).	Cadmium	38-40	metallothionein 2A	Homo sapiens	0-3
24595738-10	2014	mt2 was able to remove 80 mg L(-1) of Cd after 8 days from original industrial effluent, which was more than Cd removal by mt2 from distilled water (i.e. 77 mg L(-1) after 8 days).	Cadmium	109-111	metallothionein 2A	Homo sapiens	123-126
24595738-10	2014	mt2 was able to remove 80 mg L(-1) of Cd after 8 days from original industrial effluent, which was more than Cd removal by mt2 from distilled water (i.e. 77 mg L(-1) after 8 days).	Water	142-147	metallothionein 2A	Homo sapiens	123-126
24595738-11	2014	Cd did not induce any MT in CH34, but it did so in mt2 (14 kDa), which was thought to be a Cd-resistance mechanism operative in mt2.	Cadmium	0-2	metallothionein 2A	Homo sapiens	51-54
24595738-11	2014	Cd did not induce any MT in CH34, but it did so in mt2 (14 kDa), which was thought to be a Cd-resistance mechanism operative in mt2.	Cadmium	0-2	metallothionein 2A	Homo sapiens	128-131
24595738-11	2014	Cd did not induce any MT in CH34, but it did so in mt2 (14 kDa), which was thought to be a Cd-resistance mechanism operative in mt2.	Cadmium	91-93	metallothionein 2A	Homo sapiens	51-54
24595738-11	2014	Cd did not induce any MT in CH34, but it did so in mt2 (14 kDa), which was thought to be a Cd-resistance mechanism operative in mt2.	Cadmium	91-93	metallothionein 2A	Homo sapiens	128-131
25157674-0	2014	The -5 A/G single-nucleotide polymorphism in the core promoter region of MT2A and its effect on allele-specific gene expression and Cd, Zn and Cu levels in laryngeal cancer.	Cadmium	132-134	metallothionein 2A	Homo sapiens	73-77
25157674-0	2014	The -5 A/G single-nucleotide polymorphism in the core promoter region of MT2A and its effect on allele-specific gene expression and Cd, Zn and Cu levels in laryngeal cancer.	Zinc	136-138	metallothionein 2A	Homo sapiens	73-77
25157674-0	2014	The -5 A/G single-nucleotide polymorphism in the core promoter region of MT2A and its effect on allele-specific gene expression and Cd, Zn and Cu levels in laryngeal cancer.	Copper	143-145	metallothionein 2A	Homo sapiens	73-77
25157674-3	2014	The aim of this study was to determine the -5 A/G (rs28366003) single-nucleotide polymorphism (SNP) in the core promoter region of the MT2A gene and to investigate its effect on allele-specific gene expression and Cd, Zn and Cu content in squamous cell laryngeal cancer (SCC) and non-cancerous laryngeal mucosa (NCM) as a control.	Zinc	218-220	metallothionein 2A	Homo sapiens	135-139
25157674-3	2014	The aim of this study was to determine the -5 A/G (rs28366003) single-nucleotide polymorphism (SNP) in the core promoter region of the MT2A gene and to investigate its effect on allele-specific gene expression and Cd, Zn and Cu content in squamous cell laryngeal cancer (SCC) and non-cancerous laryngeal mucosa (NCM) as a control.	Copper	225-227	metallothionein 2A	Homo sapiens	135-139
25157674-10	2014	The Spearman rank correlation results showed that the MT2A expression and Cd, Zn, Cu levels were negatively correlated.	Cadmium	74-76	metallothionein 2A	Homo sapiens	54-58
25157674-10	2014	The Spearman rank correlation results showed that the MT2A expression and Cd, Zn, Cu levels were negatively correlated.	Zinc	78-80	metallothionein 2A	Homo sapiens	54-58
25157674-10	2014	The Spearman rank correlation results showed that the MT2A expression and Cd, Zn, Cu levels were negatively correlated.	Copper	82-84	metallothionein 2A	Homo sapiens	54-58
25157674-11	2014	Results obtained in this study suggest that -5 A/G SNP in MT2A gene may have an effect on allele-specific gene expression and accumulation of metal levels in laryngeal cancer.	Metals	142-147	metallothionein 2A	Homo sapiens	58-62
24724693-3	2014	The recent demonstration of the existence of heteromeric complexes of MT1 and MT2 with 5-HT2C receptors at the cellular level may explain how these two properties of agomelatine translate into a synergistic action that, for example, leads to increases in hippocampal proliferation, maturation and survival through modulation of multiple cellular pathways (increase in trophic factors, synaptic remodelling, glutamate signalling) and key targets (early genes, kinases).	Glutamic Acid	407-416	metallothionein 2A	Homo sapiens	78-81
24930835-6	2014	Furthermore, the methylenedioxy HHIPs 2d (N-phenylacetamide) and 2f (N,N-diethylacetamide), exhibited high selectivity at MT1 or MT2 receptors, respectively, when compared with melatonin.	N,N-diethylacetamide	69-89	metallothionein 2A	Homo sapiens	129-132
24930835-6	2014	Furthermore, the methylenedioxy HHIPs 2d (N-phenylacetamide) and 2f (N,N-diethylacetamide), exhibited high selectivity at MT1 or MT2 receptors, respectively, when compared with melatonin.	Melatonin	177-186	metallothionein 2A	Homo sapiens	129-132
24930835-7	2014	It seems that the methylenedioxy group on the indene ring system and the N-acetamide substituent are important structural features to bind selectively MT1 or MT2 subtypes.	indene	46-52	metallothionein 2A	Homo sapiens	158-161
24930835-7	2014	It seems that the methylenedioxy group on the indene ring system and the N-acetamide substituent are important structural features to bind selectively MT1 or MT2 subtypes.	n-acetamide	73-84	metallothionein 2A	Homo sapiens	158-161
24754452-12	2014	2005, 240, 301), and this approach was used to assign metal ion binding sites for human metallothionein protein MT-2a (Chen, S. H.; Russell, W. K.; Russell, D. H. Anal.	Metals	54-59	metallothionein 2A	Homo sapiens	112-117
24636462-3	2014	Here we explored in a group of 62 CFS subjects the impact on fatigue levels of agomelatine, an antidepressant with agonist activity at melatonin receptors (MT1 and MT2) and antagonist activity at serotoninergic 2C receptors (5HT2C).	agomelatine	79-90	metallothionein 2A	Homo sapiens	164-167
24918957-0	2014	Metal-induced conformational changes of human metallothionein-2A: a combined theoretical and experimental study of metal-free and partially metalated intermediates.	Metals	0-5	metallothionein 2A	Homo sapiens	46-64
24918957-1	2014	Electrospray ionization ion mobility mass spectrometry (ESI IM-MS) and molecular dynamics (MD) simulations reveal new insights into metal-induced conformational changes and the mechanism for metalation of human metallothionein-2A (MT), an intrinsically disordered protein.	Metals	132-137	metallothionein 2A	Homo sapiens	211-229
23719026-6	2014	The melatonin MT1/MT2 agonist and 5-HT(2C) antagonist, agomelatine, which is effective in the short- and long-term treatment of depression, exemplifies the former approach, while evidence-based polypharmacy is illustrated by the adjunctive use of second-generation antipsychotics with serotonin reuptake inhibitors for treatment of resistant depression.	Melatonin	4-13	metallothionein 2A	Homo sapiens	18-21
23719026-6	2014	The melatonin MT1/MT2 agonist and 5-HT(2C) antagonist, agomelatine, which is effective in the short- and long-term treatment of depression, exemplifies the former approach, while evidence-based polypharmacy is illustrated by the adjunctive use of second-generation antipsychotics with serotonin reuptake inhibitors for treatment of resistant depression.	agomelatine	55-66	metallothionein 2A	Homo sapiens	18-21
23719026-6	2014	The melatonin MT1/MT2 agonist and 5-HT(2C) antagonist, agomelatine, which is effective in the short- and long-term treatment of depression, exemplifies the former approach, while evidence-based polypharmacy is illustrated by the adjunctive use of second-generation antipsychotics with serotonin reuptake inhibitors for treatment of resistant depression.	Serotonin	285-294	metallothionein 2A	Homo sapiens	18-21
24766542-3	2014	Agomelatine is an antidepressant approved by the European Agency; it is a melatonergic agonist (MT1 and MT2 receptors) and a 5-HT2C antagonist indicated in the treatment of major depressive episodes.	agomelatine	0-11	metallothionein 2A	Homo sapiens	104-107
24680813-1	2014	A homogeneous glycopeptide with a molecular weight of 1.61x10(5)Da, termed as MT2-A, was isolated from crude mannatide by DEAE-52 cellulose column and Sephacryl S-300 gel column.	polyactin A	109-118	metallothionein 2A	Homo sapiens	78-83
24680813-1	2014	A homogeneous glycopeptide with a molecular weight of 1.61x10(5)Da, termed as MT2-A, was isolated from crude mannatide by DEAE-52 cellulose column and Sephacryl S-300 gel column.	2-diethylaminoethanol	122-126	metallothionein 2A	Homo sapiens	78-83
24680813-1	2014	A homogeneous glycopeptide with a molecular weight of 1.61x10(5)Da, termed as MT2-A, was isolated from crude mannatide by DEAE-52 cellulose column and Sephacryl S-300 gel column.	Cellulose	130-139	metallothionein 2A	Homo sapiens	78-83
24680813-1	2014	A homogeneous glycopeptide with a molecular weight of 1.61x10(5)Da, termed as MT2-A, was isolated from crude mannatide by DEAE-52 cellulose column and Sephacryl S-300 gel column.	sephacryl s	151-162	metallothionein 2A	Homo sapiens	78-83
24680813-2	2014	The polysaccharide moiety of MT2-A was mainly composed of mannose and trace amount of glucose.	Polysaccharides	4-18	metallothionein 2A	Homo sapiens	29-34
24680813-2	2014	The polysaccharide moiety of MT2-A was mainly composed of mannose and trace amount of glucose.	Mannose	58-65	metallothionein 2A	Homo sapiens	29-34
24680813-2	2014	The polysaccharide moiety of MT2-A was mainly composed of mannose and trace amount of glucose.	Glucose	86-93	metallothionein 2A	Homo sapiens	29-34
24680813-5	2014	Based on the experimental results, it was concluded that the polysaccharide moiety of MT2-A had a backbone of (1 6)-alpha-D-mannopyranose residues, which highly branched at O-2 position of (1 2,6)-alpha-D-mannopyranose residues.	Polysaccharides	61-75	metallothionein 2A	Homo sapiens	86-91
24680813-5	2014	Based on the experimental results, it was concluded that the polysaccharide moiety of MT2-A had a backbone of (1 6)-alpha-D-mannopyranose residues, which highly branched at O-2 position of (1 2,6)-alpha-D-mannopyranose residues.	(1 6)-alpha-d-mannopyranose	110-137	metallothionein 2A	Homo sapiens	86-91
24680813-5	2014	Based on the experimental results, it was concluded that the polysaccharide moiety of MT2-A had a backbone of (1 6)-alpha-D-mannopyranose residues, which highly branched at O-2 position of (1 2,6)-alpha-D-mannopyranose residues.	(1 2,6)-alpha-d-mannopyranose	189-218	metallothionein 2A	Homo sapiens	86-91
24724723-1	2014	The pineal gland hormone melatonin exerts its regulatory roles in a variety of physiological and pathological responses through two G protein-coupled receptors, melatonin receptor type 1 (MT1) and melatonin receptor type 2 (MT2), which have been recognized as promising targets in the treatment of a number of human diseases and disorders.	Melatonin	25-34	metallothionein 2A	Homo sapiens	224-227
24228714-1	2014	Numerous physiological functions of the pineal gland hormone melatonin are mediated via activation of two G-protein-coupled receptors, MT1 and MT2.	Melatonin	61-70	metallothionein 2A	Homo sapiens	143-146
24650091-3	2014	In a transfected INS-1 cell line overexpressing the human MT2 receptor (hMT2-INS-1), melatonin treatment induced even stronger depressive effects on calcium/calmodulin-dependent kinase 2d and IV (Camk2d, CamkIV) transcripts during 3-isobutyl-1-methylxanthine (IBMX) treatment than in normal INS-1 cells, indicating a crucial influence of melatonin receptor density on transcript-level regulation.	Melatonin	85-94	metallothionein 2A	Homo sapiens	58-61
24650091-3	2014	In a transfected INS-1 cell line overexpressing the human MT2 receptor (hMT2-INS-1), melatonin treatment induced even stronger depressive effects on calcium/calmodulin-dependent kinase 2d and IV (Camk2d, CamkIV) transcripts during 3-isobutyl-1-methylxanthine (IBMX) treatment than in normal INS-1 cells, indicating a crucial influence of melatonin receptor density on transcript-level regulation.	Melatonin	85-94	metallothionein 2A	Homo sapiens	72-76
24650091-4	2014	In addition, melatonin induced a significant downregulation of calmodulin (Calm1) in IBMX-treated hMT2-INS-1 cells.	Melatonin	13-22	metallothionein 2A	Homo sapiens	98-102
24228714-2	2014	The melatonergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and TIK-301, are high-affinity nonselective MT1/MT2 agonists.	agomelatine	52-63	metallothionein 2A	Homo sapiens	197-200
24560278-5	2014	This study evaluated the effects of zinc supplementation on zinc status and expression of the zinc-dependent MT1F and MT2A genes in patients with atherosclerosis treated with rosuvastatin.	Rosuvastatin Calcium	175-187	metallothionein 2A	Homo sapiens	118-122
24559479-0	2014	pH-dependent coordination of Pb2+ to metallothionein2: structures and insight into lead detoxification.	Lead	29-33	metallothionein 2A	Homo sapiens	37-53
24559479-6	2014	The O-donor ligand in Pb7-MT2(II) was identified as the carboxyl groups of the aspartic acid residues at positions 2 and 56.	Aspartic Acid	79-92	metallothionein 2A	Homo sapiens	26-29
24417958-1	2014	Herein we describe the synthesis of novel tricyclic analogues issued from the rigidification of the methoxy group of the benzofuranic analogue of melatonin as MT1 and MT2 ligands.	Melatonin	146-155	metallothionein 2A	Homo sapiens	167-170
24333911-0	2014	False positives in Biolog EcoPlates  and MT2 MicroPlates  caused by calcium.	Calcium	68-75	metallothionein 2A	Homo sapiens	41-44
24417958-1	2014	Herein we describe the synthesis of novel tricyclic analogues issued from the rigidification of the methoxy group of the benzofuranic analogue of melatonin as MT1 and MT2 ligands.	benzofuranic	121-133	metallothionein 2A	Homo sapiens	167-170
24356796-9	2014	Proteomic analysis of one of the commonly seen fluorescing regions showed the possibility for some dyes to recognize Zn and Cu bound to metallothionein 2.	Zinc	117-119	metallothionein 2A	Homo sapiens	136-153
24356796-9	2014	Proteomic analysis of one of the commonly seen fluorescing regions showed the possibility for some dyes to recognize Zn and Cu bound to metallothionein 2.	Copper	124-126	metallothionein 2A	Homo sapiens	136-153
24117008-3	2014	EXPERIMENTAL APPROACH: We characterized [(3)H]-melatonin binding to the hMT1 and hMT2 receptors expressed in a range of cell lines and obtained new insights into the molecular pharmacology of melatonin receptors.	Melatonin	47-56	metallothionein 2A	Homo sapiens	81-85
24117008-4	2014	KEY RESULTS: The binding of [(3)H]-melatonin to the hMT1 and hMT2 receptors displayed two sites on the saturation curves.	Tritium	28-35	metallothionein 2A	Homo sapiens	61-65
24117008-4	2014	KEY RESULTS: The binding of [(3)H]-melatonin to the hMT1 and hMT2 receptors displayed two sites on the saturation curves.	Melatonin	35-44	metallothionein 2A	Homo sapiens	61-65
24117008-7	2014	CONCLUSIONS AND IMPLICATIONS: hMT1 and hMT2 receptors spontaneously exist in two states when expressed in cell lines; these states can be probed by [(3)H]-melatonin binding.	Melatonin	155-164	metallothionein 2A	Homo sapiens	39-43
24251671-12	2014	Blockade of MT2 receptors by luzindole, significantly attenuated melatonin- and L-tryptophan-induced protection and increased the speed of ulcer healing and these effects were accompanied by an increase in the GBF and luminal content of NO suggesting that melatonin exhibits gastroprotection and hyperemia via activation of MT2 receptors and release of NO.	luzindole	29-38	metallothionein 2A	Homo sapiens	12-15
24251671-12	2014	Blockade of MT2 receptors by luzindole, significantly attenuated melatonin- and L-tryptophan-induced protection and increased the speed of ulcer healing and these effects were accompanied by an increase in the GBF and luminal content of NO suggesting that melatonin exhibits gastroprotection and hyperemia via activation of MT2 receptors and release of NO.	Melatonin	65-74	metallothionein 2A	Homo sapiens	12-15
24251671-12	2014	Blockade of MT2 receptors by luzindole, significantly attenuated melatonin- and L-tryptophan-induced protection and increased the speed of ulcer healing and these effects were accompanied by an increase in the GBF and luminal content of NO suggesting that melatonin exhibits gastroprotection and hyperemia via activation of MT2 receptors and release of NO.	Tryptophan	80-92	metallothionein 2A	Homo sapiens	12-15
24251671-12	2014	Blockade of MT2 receptors by luzindole, significantly attenuated melatonin- and L-tryptophan-induced protection and increased the speed of ulcer healing and these effects were accompanied by an increase in the GBF and luminal content of NO suggesting that melatonin exhibits gastroprotection and hyperemia via activation of MT2 receptors and release of NO.	Melatonin	256-265	metallothionein 2A	Homo sapiens	12-15
24251671-15	2014	Evidence is provided that exogenous melatonin and that converted from its precursor, L-tryptophan, attenuates acute gastric lesions and accelerates ulcer healing via interaction with MT2 receptors due to an enhancement of gastric microcirculation, probably mediated by NO and PG derived from NOS and COX-1 and COX-2 overexpression and activity.	Melatonin	36-45	metallothionein 2A	Homo sapiens	183-186
24251671-15	2014	Evidence is provided that exogenous melatonin and that converted from its precursor, L-tryptophan, attenuates acute gastric lesions and accelerates ulcer healing via interaction with MT2 receptors due to an enhancement of gastric microcirculation, probably mediated by NO and PG derived from NOS and COX-1 and COX-2 overexpression and activity.	Tryptophan	85-97	metallothionein 2A	Homo sapiens	183-186
24251671-15	2014	Evidence is provided that exogenous melatonin and that converted from its precursor, L-tryptophan, attenuates acute gastric lesions and accelerates ulcer healing via interaction with MT2 receptors due to an enhancement of gastric microcirculation, probably mediated by NO and PG derived from NOS and COX-1 and COX-2 overexpression and activity.	pg	276-278	metallothionein 2A	Homo sapiens	183-186
25555862-2	2014	PATIENTS AND METHODS: The MT2A-838G/C was examined in 287 patients with coronary heart disease (CHD group) and 226 healthy controls (control group) by using mono-labeled fluorescent probes.	Mono-S	157-161	metallothionein 2A	Homo sapiens	26-30
25084796-2	2014	Ramelteon has few adverse effects and higher affinity for MT1 and MT2 receptors than melatonin.	ramelteon	0-9	metallothionein 2A	Homo sapiens	66-69
24142542-7	2014	CONCLUSIONS: According to our results, it is concluded that for the first time, the expression of MT2 receptor in gastric adenocarcinoma tissues which was in parallel with breast and colon cancer studies and high expression of this receptor in the marginal tissues indicate refractory mechanism which shows the defending role of melatonin in the GI system.	Melatonin	329-338	metallothionein 2A	Homo sapiens	98-101
25711117-1	2014	Ramelteon is a novel hypnotic characterized by its action as a melatonin receptor (MT1/MT2) agonist.	ramelteon	0-9	metallothionein 2A	Homo sapiens	87-90
24314750-6	2014	Agomelatine is a novel antidepressant which acts as melatonin MT1 and MT2 receptor agonist and serotonin 5Ht2C receptor antagonist.	agomelatine	0-11	metallothionein 2A	Homo sapiens	70-73
24314750-11	2014	Since one of the many causes of sleep disruption in epilepsy is circadian rhythm disturbances and sleep promoting and circadian effects of melatonin is attributed to the MT1 and MT2 subtypes of human melatonin receptors, agomelatine may also have a promising effect on epilepsy induced sleep disruptions.	Melatonin	139-148	metallothionein 2A	Homo sapiens	178-181
24031039-0	2013	Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.	agomelatine	60-71	metallothionein 2A	Homo sapiens	100-103
25126521-7	2014	Likewise, a significant increase in the heavy metal responsive gene MT2A was observed following exposure to Cd.	Metals	46-51	metallothionein 2A	Homo sapiens	68-72
25126521-7	2014	Likewise, a significant increase in the heavy metal responsive gene MT2A was observed following exposure to Cd.	Cadmium	108-110	metallothionein 2A	Homo sapiens	68-72
24343836-4	2013	Agomelatine was recently added to the list of available antidepressant drugs; it is a novel antidepressant that works on melatonergic (MT1 and MT2), 5-HT 2B and 5-HT2C receptors.	agomelatine	0-11	metallothionein 2A	Homo sapiens	143-146
23686423-5	2013	Moreover, histiocytes from THRLBCL strongly expressed metal-binding proteins like MT2A, by which histiocytes of THRLBCL can be distinguished from the other histiocyte subsets investigated.	thrlbcl	27-34	metallothionein 2A	Homo sapiens	82-86
23686423-5	2013	Moreover, histiocytes from THRLBCL strongly expressed metal-binding proteins like MT2A, by which histiocytes of THRLBCL can be distinguished from the other histiocyte subsets investigated.	Metals	54-59	metallothionein 2A	Homo sapiens	82-86
23686423-5	2013	Moreover, histiocytes from THRLBCL strongly expressed metal-binding proteins like MT2A, by which histiocytes of THRLBCL can be distinguished from the other histiocyte subsets investigated.	thrlbcl	112-119	metallothionein 2A	Homo sapiens	82-86
23686423-6	2013	Interestingly, the validation at the protein level showed a strong expression of TXN, CXCL9, MT2A and SOD2 not only in macrophages of THRLBCL but also in the tumor cells of NLPHL and classical Hodgkin lymphoma (cHL).	thrlbcl	134-141	metallothionein 2A	Homo sapiens	93-97
23994556-4	2013	Cotreatment with 3-methylcholanthrene and dexamethasone, agonists of AHR and GR respectively, synergistically increased MT2A mRNA levels in HepG2 cells.	Methylcholanthrene	17-37	metallothionein 2A	Homo sapiens	120-124
23994556-4	2013	Cotreatment with 3-methylcholanthrene and dexamethasone, agonists of AHR and GR respectively, synergistically increased MT2A mRNA levels in HepG2 cells.	Dexamethasone	42-55	metallothionein 2A	Homo sapiens	120-124
24031039-6	2013	Two compounds, an acetamide and an acrylamide derivative, exhibited good binding affinities at both the human melatonin (MT) receptors and the serotonin 5-HT2C receptor subtype, with pKi values of 7.96 and 7.95 against MT1, 7.86 and 8.68 against MT2, and 6.64 and 6.44 against 5-HT2C, respectively.	acetamide	18-27	metallothionein 2A	Homo sapiens	246-249
24031039-6	2013	Two compounds, an acetamide and an acrylamide derivative, exhibited good binding affinities at both the human melatonin (MT) receptors and the serotonin 5-HT2C receptor subtype, with pKi values of 7.96 and 7.95 against MT1, 7.86 and 8.68 against MT2, and 6.64 and 6.44 against 5-HT2C, respectively.	Acrylamide	35-45	metallothionein 2A	Homo sapiens	246-249
23745599-5	2013	Melatonin plays a direct role in mononuclear cell activity, increasing zymosan-induced phagocytosis by stimulating MT2 melatonin receptors and increasing the expression of dectin-1.	Melatonin	0-9	metallothionein 2A	Homo sapiens	115-118
23745599-5	2013	Melatonin plays a direct role in mononuclear cell activity, increasing zymosan-induced phagocytosis by stimulating MT2 melatonin receptors and increasing the expression of dectin-1.	Zymosan	71-78	metallothionein 2A	Homo sapiens	115-118
23815579-1	2013	Melatonin, an endogenous ligand for melatonin receptor, plays an important role in modulating various physiological activities through acting on different subtypes MT1, MT2 or the binding site MT3.	Melatonin	0-9	metallothionein 2A	Homo sapiens	169-172
24157868-7	2013	MT2A overexpression induced chemoresistance to cytotoxic drugs through direct chelation of platinum-containing drugs and indirect action on p53 zinc-dependent activity.	Platinum	91-99	metallothionein 2A	Homo sapiens	0-4
23925449-0	2013	Mammalian MT1 and MT2 metallothioneins differ in their metal binding abilities.	Metals	22-27	metallothionein 2A	Homo sapiens	18-21
23870536-4	2013	It appears that the effect of melatonin on mast cells is two-fold: dependent (MT1 and MT2) and independent membrane receptors.	Melatonin	30-39	metallothionein 2A	Homo sapiens	86-89
23835914-5	2013	Zn(II) competition experiments with the metal ion chelator 4-(2-pyridylazo)resorcinol (PAR) in the presence of the cellular redox pair glutathione (GSH)/glutathione disulfide (GSSG) show that plant MTs from the subfamilies MT1, MT2, and MT3 are remarkably more affected by oxidative stress than those from the Ec subfamily and the well-characterized human MT2 form.	Zinc	0-6	metallothionein 2A	Homo sapiens	228-231
23835914-5	2013	Zn(II) competition experiments with the metal ion chelator 4-(2-pyridylazo)resorcinol (PAR) in the presence of the cellular redox pair glutathione (GSH)/glutathione disulfide (GSSG) show that plant MTs from the subfamilies MT1, MT2, and MT3 are remarkably more affected by oxidative stress than those from the Ec subfamily and the well-characterized human MT2 form.	Zinc	0-6	metallothionein 2A	Homo sapiens	356-359
23530731-7	2013	RESULTS: Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been reported to be effective as antidepressant drug.	agomelatine	9-20	metallothionein 2A	Homo sapiens	65-68
23397952-0	2013	The inhibition of TNF-alpha-induced leucocyte apoptosis by melatonin involves membrane receptor MT1/MT2 interaction.	Melatonin	59-68	metallothionein 2A	Homo sapiens	100-103
23632362-2	2013	Distinct in its mechanism, the drug is a melatonin agonist with a high affinity for the membrane receptors MT1 and MT2.	Melatonin	41-50	metallothionein 2A	Homo sapiens	115-118
23765220-1	2013	Melatonin exerts its actions through membrane MT1/MT2 melatonin receptors, which belong to the super family of G-protein-coupled receptors consisting of the typical seven transmembrane domains.	Melatonin	0-9	metallothionein 2A	Homo sapiens	50-53
23354312-5	2013	Since melatonin-induced p53 phosphorylation requires an intact p38 phosphorylation cascade and p38 can be activated by G proteins, we supposed that melatonin"s activities could be mediated by its G-protein-coupled membrane receptors, MT1 and MT2.	Melatonin	6-15	metallothionein 2A	Homo sapiens	242-245
23354312-5	2013	Since melatonin-induced p53 phosphorylation requires an intact p38 phosphorylation cascade and p38 can be activated by G proteins, we supposed that melatonin"s activities could be mediated by its G-protein-coupled membrane receptors, MT1 and MT2.	Melatonin	148-157	metallothionein 2A	Homo sapiens	242-245
23354312-6	2013	Here, we show that the activation of the p53-dependent DNA damage response by melatonin is indeed mediated by MT1 and MT2.	Melatonin	78-87	metallothionein 2A	Homo sapiens	118-121
23397952-11	2013	Blockade of melatonin membrane receptor MT1/MT2 or extracellular signal-regulated kinase (ERK) pathway with luzindole or PD98059, respectively, abolished the inhibitory effects of melatonin on leucocyte apoptosis evoked by TNF-alpha/CHX.	luzindole	108-117	metallothionein 2A	Homo sapiens	44-47
23397952-11	2013	Blockade of melatonin membrane receptor MT1/MT2 or extracellular signal-regulated kinase (ERK) pathway with luzindole or PD98059, respectively, abolished the inhibitory effects of melatonin on leucocyte apoptosis evoked by TNF-alpha/CHX.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	121-128	metallothionein 2A	Homo sapiens	44-47
23397952-11	2013	Blockade of melatonin membrane receptor MT1/MT2 or extracellular signal-regulated kinase (ERK) pathway with luzindole or PD98059, respectively, abolished the inhibitory effects of melatonin on leucocyte apoptosis evoked by TNF-alpha/CHX.	Melatonin	12-21	metallothionein 2A	Homo sapiens	44-47
23535335-1	2013	The pineal hormone melatonin exerts its influence in the periphery through activation of two specific trans-membrane receptors: MT1 and MT2.	Melatonin	19-28	metallothionein 2A	Homo sapiens	136-139
23466427-3	2013	The aim of this study was to determine whether there is an association between the -5 A/G single nucleotide polymorphism (SNP; rs28366003) in core promoter region and expression of metallothionein 2A (MT2A) gene and metal concentration in prostate cancer tissues.	Metals	181-186	metallothionein 2A	Homo sapiens	201-205
23466427-10	2013	The results of Spearman"s rank correlation showed that the expressions of MT2A and Cu, Pb and Ni concentrations were negatively correlated.	Copper	83-85	metallothionein 2A	Homo sapiens	74-78
23466427-10	2013	The results of Spearman"s rank correlation showed that the expressions of MT2A and Cu, Pb and Ni concentrations were negatively correlated.	Lead	87-89	metallothionein 2A	Homo sapiens	74-78
23466427-11	2013	On the basis of the results obtained in this study, we suggest that SNP polymorphism may affect the MT2A gene expression in prostate and this is associated with some metal accumulation.	Metals	166-171	metallothionein 2A	Homo sapiens	100-104
23584026-1	2013	Melatonin exerts many of its actions through the activation of two G protein-coupled receptors (GPCRs), named MT1 and MT2.	Melatonin	0-9	metallothionein 2A	Homo sapiens	118-121
23421923-7	2013	Metalation of human MT-2A is shown to be metal ion specific by comparing relative metal ion binding constants for Cd(2+) and Zn(2+).	Metals	41-46	metallothionein 2A	Homo sapiens	20-25
23421923-7	2013	Metalation of human MT-2A is shown to be metal ion specific by comparing relative metal ion binding constants for Cd(2+) and Zn(2+).	Metals	82-87	metallothionein 2A	Homo sapiens	20-25
23421923-7	2013	Metalation of human MT-2A is shown to be metal ion specific by comparing relative metal ion binding constants for Cd(2+) and Zn(2+).	Cadmium	114-116	metallothionein 2A	Homo sapiens	20-25
23421923-7	2013	Metalation of human MT-2A is shown to be metal ion specific by comparing relative metal ion binding constants for Cd(2+) and Zn(2+).	Zinc	125-127	metallothionein 2A	Homo sapiens	20-25
23131177-0	2013	Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor.	phenylpropylamides	32-50	metallothionein 2A	Homo sapiens	97-100
24174876-1	2013	BACKGROUND: Agomelatine is a novel antidepressant agonist to MT1 and MT2 subtypes of melatoninergic receptors (MT1 and MT2) and antagonist to 5-HT2C subtype of serotonergic (5-HT2C) receptors, which has shown antidepressant efficacy in short-term and long-term trials as well as in clinical practice.	agomelatine	12-23	metallothionein 2A	Homo sapiens	119-122
22823500-5	2013	Our findings indicate a novel role for MT1 and MT2 for increasing expression of the calcium-binding proteins calbindin D28K and parvalbumin.	Calcium	84-91	metallothionein 2A	Homo sapiens	47-50
22823500-10	2013	Knockdown of MT1 and MT2 led to an increase in glutamate toxicity, which was only partially reversed by melatonin treatment.	Glutamic Acid	47-56	metallothionein 2A	Homo sapiens	21-24
22823500-10	2013	Knockdown of MT1 and MT2 led to an increase in glutamate toxicity, which was only partially reversed by melatonin treatment.	Melatonin	104-113	metallothionein 2A	Homo sapiens	21-24
22823500-11	2013	Taken together, our findings suggest that the neuroprotection against glutamate toxicity exhibited by melatonin may depend on MT1 and MT2 but not GPR50.	Glutamic Acid	70-79	metallothionein 2A	Homo sapiens	134-137
22823500-11	2013	Taken together, our findings suggest that the neuroprotection against glutamate toxicity exhibited by melatonin may depend on MT1 and MT2 but not GPR50.	Melatonin	102-111	metallothionein 2A	Homo sapiens	134-137
24174876-1	2013	BACKGROUND: Agomelatine is a novel antidepressant agonist to MT1 and MT2 subtypes of melatoninergic receptors (MT1 and MT2) and antagonist to 5-HT2C subtype of serotonergic (5-HT2C) receptors, which has shown antidepressant efficacy in short-term and long-term trials as well as in clinical practice.	agomelatine	12-23	metallothionein 2A	Homo sapiens	69-72
25696959-4	2013	Melatonin has specific MT1 and MT2 receptors localized in all body cells.	Melatonin	0-9	metallothionein 2A	Homo sapiens	31-34
22946959-6	2013	Melatonin administration has been shown to inhibit insulin release by acting through both MT1 and MT2 melatonin receptors present in pancreatic beta-cells.	Melatonin	0-9	metallothionein 2A	Homo sapiens	98-101
22946959-8	2013	Melatonin exerts most of its beneficial actions by acting through MT1 and MT2 melatonin receptors present in various tissues of the body and some of the metabolic actions of melatonin have been blocked by melatonin antagonist like luzindole.	Melatonin	0-9	metallothionein 2A	Homo sapiens	74-77
22946959-8	2013	Melatonin exerts most of its beneficial actions by acting through MT1 and MT2 melatonin receptors present in various tissues of the body and some of the metabolic actions of melatonin have been blocked by melatonin antagonist like luzindole.	Melatonin	78-87	metallothionein 2A	Homo sapiens	74-77
22946959-8	2013	Melatonin exerts most of its beneficial actions by acting through MT1 and MT2 melatonin receptors present in various tissues of the body and some of the metabolic actions of melatonin have been blocked by melatonin antagonist like luzindole.	luzindole	231-240	metallothionein 2A	Homo sapiens	74-77
23262445-1	2012	Novel conformationally restricted analogues of agomelatine were synthesized and pharmacologically evaluated at MT1 and MT2 melatoninergic receptors.	agomelatine	47-58	metallothionein 2A	Homo sapiens	119-122
22995156-3	2012	Here we analyzed whether polymorphisms in MT genes MT1A and MT2A influence Cd-related kidney damage.	Cadmium	75-77	metallothionein 2A	Homo sapiens	60-64
23479460-6	2012	Recently it has been shown that melatonin exerts its antinociceptive effects through MT1 and MT2 melatonergic receptors located in the dorsal region of the spinal cord as well as in various parts of the brain concerned with pain modulation.	Melatonin	32-41	metallothionein 2A	Homo sapiens	93-96
22916801-7	2012	The melatonin message is translated through the interaction between the melatonin receptors (MT1 and MT2) and its coupling to G proteins, which are potential therapeutic targets in disorders ranging from insomnia, circadian sleep disorders, depression and cardiovascular diseases.	Melatonin	4-13	metallothionein 2A	Homo sapiens	101-104
22927210-2	2012	N-(Anilinoalkyl)amides are a versatile class of melatonin receptor ligands that include nonselective MT1/MT2 agonists and MT2-selective antagonists.	n-(anilinoalkyl)amides	0-22	metallothionein 2A	Homo sapiens	105-108
22927210-2	2012	N-(Anilinoalkyl)amides are a versatile class of melatonin receptor ligands that include nonselective MT1/MT2 agonists and MT2-selective antagonists.	n-(anilinoalkyl)amides	0-22	metallothionein 2A	Homo sapiens	122-125
22981465-5	2012	MT-1A and MT-2A expressions, particularly MT-1A, were found to be significantly increased with elevated levels of blood and urinary Cd levels.	Cadmium	132-134	metallothionein 2A	Homo sapiens	10-15
22981465-6	2012	In subjects with high urinary Cd levels, negative correlations between MT-1A and microalbumin, and between MT-2A and beta(2)-MG, were observed.	Cadmium	30-32	metallothionein 2A	Homo sapiens	107-112
21809392-1	2012	Melatonin inhibits growth and invasive capacity of colon cancer cells in vitro through its membrane (MT1 and MT2) and/or nuclear receptors (RORalpha).	Melatonin	0-9	metallothionein 2A	Homo sapiens	109-112
22391096-2	2012	We investigated whether genetic variation in metallothionein (MT)1A and MT2A associated with Cd induced bone loss in this study.	Cadmium	93-95	metallothionein 2A	Homo sapiens	72-76
22690618-1	2012	Ramelteon is a new class of sleep agent that selectively binds to the melatonin type 1 (MT1) and type 2 (MT2) receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABA-A receptors such as with traditional hypnotics benzodiazepines.	ramelteon	0-9	metallothionein 2A	Homo sapiens	105-108
22483286-5	2012	Recently ramelteon, a selective MT1, MT2 receptor agonist with greater efficacy of action in treating insomnia has been used clinically and has been found effective in improving sleep quality, sleep efficacy and also in reducing the sleep onset time when compared to melatonin or slow melatonin preparations.	ramelteon	9-18	metallothionein 2A	Homo sapiens	37-40
22245784-1	2012	Many of melatonin"s actions are mediated through interaction with the G-protein coupled membrane bound melatonin receptors type 1 and type 2 (MT1 and MT2, respectively) or, indirectly with nuclear orphan receptors from the RORalpha/RZR family.	Melatonin	8-17	metallothionein 2A	Homo sapiens	150-153
21328412-3	2012	This prospective study investigated the effects of metallothionein 2A (MT2A) -5 A/G single nucleotide polymorphism on the accumulation of Cd in human placenta and micronutrient transfer to the fetus in 95 pregnant women and their newborns.	Cadmium	138-140	metallothionein 2A	Homo sapiens	51-69
21328412-3	2012	This prospective study investigated the effects of metallothionein 2A (MT2A) -5 A/G single nucleotide polymorphism on the accumulation of Cd in human placenta and micronutrient transfer to the fetus in 95 pregnant women and their newborns.	Cadmium	138-140	metallothionein 2A	Homo sapiens	71-75
22222973-4	2012	Further, the effects of thermal treatment and the presence of denaturing agent such as urea on MT-1 and MT-2 isoforms were studied by CE-UV.	Urea	87-91	metallothionein 2A	Homo sapiens	104-108
22178664-2	2012	This paper presents the full 384-388-atom structures of the two native Zn(II)- and the Cd(II)-containing domains of human MT2, optimized with density functional theory.	Zinc	71-77	metallothionein 2A	Homo sapiens	122-125
22178664-2	2012	This paper presents the full 384-388-atom structures of the two native Zn(II)- and the Cd(II)-containing domains of human MT2, optimized with density functional theory.	cd(ii)	87-93	metallothionein 2A	Homo sapiens	122-125
23650464-4	2012	Melatonin acts mainly on MT1 and MT2 receptors, which are present in the SNC, regulating physiological and neuroendocrine functions, including circadian entrainment, referred to as the chronobiotic effet.	Melatonin	0-9	metallothionein 2A	Homo sapiens	33-36
22335516-7	2012	Agomelatine, a naphthalene bioisostere of melatonin, which combines a potent MT1 and MT2 agonism with 5-HT(2C) receptor antagonism, has been found to be effective in the treatment of depressive and anxiety symptoms associated with major depression, with rapid and beneficial effects on the regulation of sleep continuity and quality.	agomelatine	0-11	metallothionein 2A	Homo sapiens	85-88
22335516-7	2012	Agomelatine, a naphthalene bioisostere of melatonin, which combines a potent MT1 and MT2 agonism with 5-HT(2C) receptor antagonism, has been found to be effective in the treatment of depressive and anxiety symptoms associated with major depression, with rapid and beneficial effects on the regulation of sleep continuity and quality.	Melatonin	42-51	metallothionein 2A	Homo sapiens	85-88
22335516-8	2012	If substantiated by further evidence, the observation that melatonergic system dysfunctions contribute to the development of depression, as well as that the antidepressant action of agomelatine is linked to its binding properties to MT1/MT2 receptors, might open new avenues for the discovery of antidepressive agents.	agomelatine	182-193	metallothionein 2A	Homo sapiens	237-240
23226532-6	2012	Our results show that both melatonin membrane receptors, MT1 and MT2, are expressed in cultured primary Muller cells and are upregulated by elevated glucose levels.	Glucose	149-156	metallothionein 2A	Homo sapiens	65-68
22102540-4	2011	RESULTS: Agomelatine, an agonist of melatonergic MT1 and MT2 receptors and antagonist of 5-HT2 receptors, is associated with similar rates of sexual dysfunction compared with placebo and lower rates compared with other antidepressants.	agomelatine	9-20	metallothionein 2A	Homo sapiens	57-60
22047556-0	2011	Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.	4-phenyl-2-propionamidotetralin	116-147	metallothionein 2A	Homo sapiens	57-60
22047556-1	2011	New derivatives of 4-phenyl-2-propionamidotetralin (4-P-PDOT) were prepared and tested on cloned MT1 and MT2 receptors, with the purpose of merging previously reported pharmacophores for nonselective agonists and for MT2-selective antagonists.	4-phenyl-2-propionamidotetralin	19-50	metallothionein 2A	Homo sapiens	105-108
22047556-1	2011	New derivatives of 4-phenyl-2-propionamidotetralin (4-P-PDOT) were prepared and tested on cloned MT1 and MT2 receptors, with the purpose of merging previously reported pharmacophores for nonselective agonists and for MT2-selective antagonists.	4-phenyl-2-propionamidotetralin	19-50	metallothionein 2A	Homo sapiens	217-220
22047556-1	2011	New derivatives of 4-phenyl-2-propionamidotetralin (4-P-PDOT) were prepared and tested on cloned MT1 and MT2 receptors, with the purpose of merging previously reported pharmacophores for nonselective agonists and for MT2-selective antagonists.	4-p	52-55	metallothionein 2A	Homo sapiens	105-108
21999473-2	2011	The new antidepressant agomelatine is an agonist of melatonergic MT1/MT2 receptors as well as an antagonist of serotonergic 5-HT2C receptors.	agomelatine	23-34	metallothionein 2A	Homo sapiens	69-72
23983944-1	2011	Agomelatine (Valdoxan), a synthetic melatonergic receptor agonist at the MT1 and MT2 receptors, was first used in the management of sleep disorder.	agomelatine	0-11	metallothionein 2A	Homo sapiens	81-84
23983944-1	2011	Agomelatine (Valdoxan), a synthetic melatonergic receptor agonist at the MT1 and MT2 receptors, was first used in the management of sleep disorder.	agomelatine	13-21	metallothionein 2A	Homo sapiens	81-84
21991581-1	2011	Ferritin (Ft) interaction with the Zn-complexes of mammalian MT1, MT2 and MT3 metallothioneins (MT) leads to simultaneous Fe(II) and Zn(II) release.	Zinc	35-37	metallothionein 2A	Homo sapiens	66-69
21991581-1	2011	Ferritin (Ft) interaction with the Zn-complexes of mammalian MT1, MT2 and MT3 metallothioneins (MT) leads to simultaneous Fe(II) and Zn(II) release.	ammonium ferrous sulfate	122-128	metallothionein 2A	Homo sapiens	66-69
21991581-1	2011	Ferritin (Ft) interaction with the Zn-complexes of mammalian MT1, MT2 and MT3 metallothioneins (MT) leads to simultaneous Fe(II) and Zn(II) release.	Zinc	133-139	metallothionein 2A	Homo sapiens	66-69
21785817-11	2011	Treatment with 2.0 microM of Azacitidine (AZA), a demethylating agent, for 72 h restored p16INK4a transcript expression and induced growth inhibition in MT2 cells.	Azacitidine	29-40	metallothionein 2A	Homo sapiens	153-156
21785817-11	2011	Treatment with 2.0 microM of Azacitidine (AZA), a demethylating agent, for 72 h restored p16INK4a transcript expression and induced growth inhibition in MT2 cells.	Azacitidine	42-45	metallothionein 2A	Homo sapiens	153-156
21459362-5	2011	The mechanisms of action of melatonin include the involvement of membrane receptors (MT1, MT2), cytosolic binding sites (MT3 and calmodulin), and nuclear receptors of the RZR/ROR family.	Melatonin	28-37	metallothionein 2A	Homo sapiens	90-93
21585522-0	2011	Melatonin inhibits insulin secretion in rat insulinoma beta-cells (INS-1) heterologously expressing the human melatonin receptor isoform MT2.	Melatonin	0-9	metallothionein 2A	Homo sapiens	137-140
21916789-1	2011	INTRODUCTION: This article discusses agomelatine (Valdoxan( )/Thymanax( ); Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist.	agomelatine	37-48	metallothionein 2A	Homo sapiens	120-123
21916789-1	2011	INTRODUCTION: This article discusses agomelatine (Valdoxan( )/Thymanax( ); Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist.	agomelatine	50-58	metallothionein 2A	Homo sapiens	120-123
21585522-7	2011	On the basis of a specific radioimmunoassay, insulin secretion was found to be more strongly reduced in the clones expressing hMT2 than in INS-1 controls, when incubated with 1 or 100 nm melatonin.	Melatonin	187-196	metallothionein 2A	Homo sapiens	126-130
21678079-4	2011	Particular attention is paid to the Tg2576 Alzheimer disease mouse model and the preliminary results obtained in mice into which human Zn(7)MT-2A was injected, which suggest a reversal of the behavioral deficits while enhancing amyloid plaque load and gliosis.	Zinc	135-138	metallothionein 2A	Homo sapiens	140-145
21585522-8	2011	Similarly, cAMP and cGMP levels, measured by specific enzyme-linked immunosorbent assays (ELISAs), were reduced to a greater extent in hMT2 clones after melatonin treatment.	Cyclic AMP	11-15	metallothionein 2A	Homo sapiens	135-139
21585522-8	2011	Similarly, cAMP and cGMP levels, measured by specific enzyme-linked immunosorbent assays (ELISAs), were reduced to a greater extent in hMT2 clones after melatonin treatment.	Cyclic GMP	20-24	metallothionein 2A	Homo sapiens	135-139
21585522-8	2011	Similarly, cAMP and cGMP levels, measured by specific enzyme-linked immunosorbent assays (ELISAs), were reduced to a greater extent in hMT2 clones after melatonin treatment.	Melatonin	153-162	metallothionein 2A	Homo sapiens	135-139
21585522-9	2011	In hMT2-expressing cells, the inhibitory effect of melatonin on insulin secretion was blocked by pretreatment with pertussis toxin, demonstrating the coupling of the hMT2 to G(i) -proteins.	Melatonin	51-60	metallothionein 2A	Homo sapiens	3-7
21585522-9	2011	In hMT2-expressing cells, the inhibitory effect of melatonin on insulin secretion was blocked by pretreatment with pertussis toxin, demonstrating the coupling of the hMT2 to G(i) -proteins.	Melatonin	51-60	metallothionein 2A	Homo sapiens	166-170
21585522-10	2011	These results indicate that functional hMT2 expression leads to the inhibition of cyclic nucleotide signaling and a reduction in insulin release.	Nucleotides, Cyclic	82-99	metallothionein 2A	Homo sapiens	39-43
21767559-0	2011	The potential effect of metallothionein 2A -5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels.	Cadmium	89-96	metallothionein 2A	Homo sapiens	24-42
21767559-0	2011	The potential effect of metallothionein 2A -5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels.	Copper	113-119	metallothionein 2A	Homo sapiens	24-42
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Cadmium	164-166	metallothionein 2A	Homo sapiens	69-87
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Cadmium	164-166	metallothionein 2A	Homo sapiens	89-93
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Lead	168-170	metallothionein 2A	Homo sapiens	69-87
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Lead	168-170	metallothionein 2A	Homo sapiens	89-93
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Zinc	172-174	metallothionein 2A	Homo sapiens	69-87
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Zinc	172-174	metallothionein 2A	Homo sapiens	89-93
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Copper	179-181	metallothionein 2A	Homo sapiens	69-87
21767559-3	2011	The aim of this study was to investigate the association between the metallothionein 2A (MT2A) core promoter region -5 A/G single nucleotide polymorphism (SNP) and Cd, Pb, Zn and Cu levels in the blood samples.	Copper	179-181	metallothionein 2A	Homo sapiens	89-93
21767559-6	2011	As a result; highly statistically significant associations were detected between the -5 A/G core promoter region SNP in the MT2A gene and Cd, Pb and Zn levels (p=0.004, p=0.012 and p=0.002, respectively), but no association was found with Cu level (p=0.595).	Cadmium	138-140	metallothionein 2A	Homo sapiens	124-128
21767559-6	2011	As a result; highly statistically significant associations were detected between the -5 A/G core promoter region SNP in the MT2A gene and Cd, Pb and Zn levels (p=0.004, p=0.012 and p=0.002, respectively), but no association was found with Cu level (p=0.595).	Lead	142-144	metallothionein 2A	Homo sapiens	124-128
21767559-6	2011	As a result; highly statistically significant associations were detected between the -5 A/G core promoter region SNP in the MT2A gene and Cd, Pb and Zn levels (p=0.004, p=0.012 and p=0.002, respectively), but no association was found with Cu level (p=0.595).	Zinc	149-151	metallothionein 2A	Homo sapiens	124-128
21767559-6	2011	As a result; highly statistically significant associations were detected between the -5 A/G core promoter region SNP in the MT2A gene and Cd, Pb and Zn levels (p=0.004, p=0.012 and p=0.002, respectively), but no association was found with Cu level (p=0.595).	Copper	239-241	metallothionein 2A	Homo sapiens	124-128
22025877-4	2011	Melatonin exerts its physiological effects through specific membrane receptors, named melatonin-1 receptor (MT1), MT2 and MT3.	Melatonin	0-9	metallothionein 2A	Homo sapiens	114-117
21148743-0	2011	Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2.	Asbestos	85-93	metallothionein 2A	Homo sapiens	118-122
21148743-4	2011	The results of DNA microarray analysis showed that the expression of 139 genes was altered by long-term and low-level exposure to asbestos, and the profile was almost similar among the six sublines when compared with the original MT-2 cells that had never been exposed to asbestos.	Asbestos	130-138	metallothionein 2A	Homo sapiens	230-234
20737243-10	2011	Changes of iron content were significant by treatment and time (two-way ANOVA); mRNA relative abundance of MT2A changed significantly and paralleled those of copper concentration, but TfR transcripts did not change.	Copper	158-164	metallothionein 2A	Homo sapiens	107-111
21507333-0	2011	Evaluation of the effects of Quercetin and Kaempherol on the surface of MT-2 cells visualized by atomic force microscopy.	Quercetin	29-38	metallothionein 2A	Homo sapiens	72-76
21507333-0	2011	Evaluation of the effects of Quercetin and Kaempherol on the surface of MT-2 cells visualized by atomic force microscopy.	kaempferol	43-53	metallothionein 2A	Homo sapiens	72-76
21507333-1	2011	This study investigated the anti-viral effects of the polyphenolic compounds Quercetin and Kaempherol on the release of HTLV-1 from the surface of MT-2 cells.	polyphenolic compounds	54-76	metallothionein 2A	Homo sapiens	147-151
21507333-1	2011	This study investigated the anti-viral effects of the polyphenolic compounds Quercetin and Kaempherol on the release of HTLV-1 from the surface of MT-2 cells.	Quercetin	77-86	metallothionein 2A	Homo sapiens	147-151
21507333-1	2011	This study investigated the anti-viral effects of the polyphenolic compounds Quercetin and Kaempherol on the release of HTLV-1 from the surface of MT-2 cells.	kaempferol	91-101	metallothionein 2A	Homo sapiens	147-151
21507333-3	2011	MT-2 cells were fixed with 100% methanol on round glass lamina or cleaved mica and dried under UV light and laminar flow.	Methanol	32-40	metallothionein 2A	Homo sapiens	0-4
21507333-6	2011	Interestingly, cell-free viruses and budding structures visualized on the surface of cells were less common when MT-2 was incubated with Quercetin, and no particles were seen on the surface of cells incubated with Kaempherol.	Quercetin	137-146	metallothionein 2A	Homo sapiens	113-117
21453740-8	2011	Ramelteon, a synthetic analog of melatonin which has a longer half life and a stronger affinity for MT1 and MT2 melatonergic receptors, has been reportedly effective for initiating and improving sleep in both adult and elderly insomniacs without showing hangover, dependence, or cognitive impairment.	ramelteon	0-9	metallothionein 2A	Homo sapiens	108-111
20945374-7	2011	We analyzed the 2 h-acute toxicity of CuCl(2) in terms of actin depolymerization and metallothionein 2A (MT2A) and heat shock protein 70 (HSPA1A) genes induction.	cupric chloride	38-45	metallothionein 2A	Homo sapiens	85-103
20945374-7	2011	We analyzed the 2 h-acute toxicity of CuCl(2) in terms of actin depolymerization and metallothionein 2A (MT2A) and heat shock protein 70 (HSPA1A) genes induction.	cupric chloride	38-45	metallothionein 2A	Homo sapiens	105-109
21453740-8	2011	Ramelteon, a synthetic analog of melatonin which has a longer half life and a stronger affinity for MT1 and MT2 melatonergic receptors, has been reportedly effective for initiating and improving sleep in both adult and elderly insomniacs without showing hangover, dependence, or cognitive impairment.	Melatonin	33-42	metallothionein 2A	Homo sapiens	108-111
21453740-10	2011	The novel antidepressant agomelatine, a dual action agent with affinity for melatonin MT1 and MT2 receptors and 5-HT2c antagonistic properties, constitutes a new approach to the treatment of major depressive disorders.	agomelatine	25-36	metallothionein 2A	Homo sapiens	94-97
21453740-12	2011	Taken together, the evidence indicates that MT1/MT2 receptor agonists like ramelteon or agomelatine may be valuable pharmacological tools for insomnia and for depression-associated insomnia.	ramelteon	75-84	metallothionein 2A	Homo sapiens	48-51
21453740-12	2011	Taken together, the evidence indicates that MT1/MT2 receptor agonists like ramelteon or agomelatine may be valuable pharmacological tools for insomnia and for depression-associated insomnia.	agomelatine	88-99	metallothionein 2A	Homo sapiens	48-51
20707632-3	2010	In our mechanism of act, the G(i) protein-coupled metabotropic melatonin receptors MT1 and MT2 are the primary mediators of the physiological actions of melatonin.	Melatonin	63-72	metallothionein 2A	Homo sapiens	91-94
23861638-1	2011	Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors.	ramelteon	0-9	metallothionein 2A	Homo sapiens	89-92
20965250-0	2011	Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery.	Silicon	22-29	metallothionein 2A	Homo sapiens	71-83
20965250-2	2011	The study aim was to determine whether nanostructured porous silicon could sustain the release and prolong the duration of action of a model peptide Melanotan II (MTII).	Silicon	61-68	metallothionein 2A	Homo sapiens	149-161
20965250-2	2011	The study aim was to determine whether nanostructured porous silicon could sustain the release and prolong the duration of action of a model peptide Melanotan II (MTII).	Silicon	61-68	metallothionein 2A	Homo sapiens	163-167
20965250-3	2011	Thermally hydrocarbonized nanoporous silicon (THCPSi) microparticles (38-53 mum) were loaded with MTII.	Silicon	37-44	metallothionein 2A	Homo sapiens	98-102
20965250-3	2011	Thermally hydrocarbonized nanoporous silicon (THCPSi) microparticles (38-53 mum) were loaded with MTII.	thcpsi	46-52	metallothionein 2A	Homo sapiens	98-102
20965250-8	2011	In vivo, MTII loaded THCPSi induced an increase in the heart rate 2 h later than MTII solution, and the effect lasted 1 h longer.	thcpsi	21-27	metallothionein 2A	Homo sapiens	9-13
20965250-9	2011	In addition, MTII loaded THCPSi changed the water consumption after 150 min, when the immediate effect of MTII solution was already diminished.	thcpsi	25-31	metallothionein 2A	Homo sapiens	13-17
20965250-9	2011	In addition, MTII loaded THCPSi changed the water consumption after 150 min, when the immediate effect of MTII solution was already diminished.	thcpsi	25-31	metallothionein 2A	Homo sapiens	106-110
20965250-9	2011	In addition, MTII loaded THCPSi changed the water consumption after 150 min, when the immediate effect of MTII solution was already diminished.	Water	44-49	metallothionein 2A	Homo sapiens	13-17
21159615-2	2010	This study found that AZ960, a novel inhibitor of Jak2 kinase, effectively induced growth arrest and apoptosis of human T-cell lymphotropic virus type 1, HTLV-1-infected T cells (MT-1 and MT-2) in parallel with downregulation of the phosphorylated forms of Jak2 and Bcl-2 family proteins including Bcl-2 and Mcl-1.	5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile	22-27	metallothionein 2A	Homo sapiens	188-192
21159615-3	2010	Interestingly, AZ960 increased levels of Bcl-xL in MT-1 and MT-2 cells in association with accumulation of cAMP response element-binding protein bound to the Bcl-xL promoter as measured by chromatin immunoprecipitation assay.	5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile	15-20	metallothionein 2A	Homo sapiens	60-64
27877389-1	2011	Magnesium dititanate (MgTi2O5, MT2) has been synthesized since the early 1930s.	Magnesium titanium trioxide	0-20	metallothionein 2A	Homo sapiens	31-34
21377769-4	2011	We identified new series of compounds with affinity for the MT3 binding site in the nanomolar range, and singled out a selective ligand, (N-[2-(7-methylsulfamoyl-naphth-1-yl)ethyl]acetamide (17), with a Ki of 4.9 nM and selectivity of 1024 and 2040 versus MT1 and MT2 receptors respectively.	N-{2-[7-(Methylsulfamoyl)naphthalen-1-Yl]ethyl}acetamide	138-189	metallothionein 2A	Homo sapiens	264-267
21392858-0	2011	Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.	2-(phenylthio)benzo[b]thiophenes	64-96	metallothionein 2A	Homo sapiens	110-113
21392858-5	2011	The most selective compound, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl)ethyl)but-3-enamide (14), an MT2 ligand with affinity for the MT2 receptor similar to that of melatonin and a 220-fold preference over MT1 receptors, acts as a partial agonist.	CHEMBL1779810	29-107	metallothionein 2A	Homo sapiens	117-120
21392858-5	2011	The most selective compound, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl)ethyl)but-3-enamide (14), an MT2 ligand with affinity for the MT2 receptor similar to that of melatonin and a 220-fold preference over MT1 receptors, acts as a partial agonist.	CHEMBL1779810	29-107	metallothionein 2A	Homo sapiens	150-153
21392858-5	2011	The most selective compound, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl)ethyl)but-3-enamide (14), an MT2 ligand with affinity for the MT2 receptor similar to that of melatonin and a 220-fold preference over MT1 receptors, acts as a partial agonist.	Melatonin	182-191	metallothionein 2A	Homo sapiens	117-120
21392858-6	2011	In addition, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl)ethyl)propionamide (9), a nanomolar MT2 ligand with a good selectivity ratio (MT1/MT2=51) shows antagonist activity on both melatonin receptors.	CHEMBL1779805	13-90	metallothionein 2A	Homo sapiens	108-111
21392858-6	2011	In addition, N-(2-(5-fluoro-2-(4-fluorophenylthio)benzo[b]thiophen-3-yl)ethyl)propionamide (9), a nanomolar MT2 ligand with a good selectivity ratio (MT1/MT2=51) shows antagonist activity on both melatonin receptors.	CHEMBL1779805	13-90	metallothionein 2A	Homo sapiens	154-157
23861638-1	2011	Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors.	Melatonin	45-54	metallothionein 2A	Homo sapiens	89-92
20959363-0	2011	MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.	Melatonin	48-57	metallothionein 2A	Homo sapiens	0-3
20959363-0	2011	MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.	Nitric Oxide	61-73	metallothionein 2A	Homo sapiens	0-3
20730438-6	2010	DISCUSSION: The gene expression arrays and quantitative RT-PCR suggested that tea polyphenol inhibited the gene expression of metallothionein 2A (MT2A), transcription factor (MAFA), hairy and enhancer of split 1 (HES1), and jagged1 (JAG1) nearly twofold over controls.	Polyphenols	82-92	metallothionein 2A	Homo sapiens	126-144
20730438-6	2010	DISCUSSION: The gene expression arrays and quantitative RT-PCR suggested that tea polyphenol inhibited the gene expression of metallothionein 2A (MT2A), transcription factor (MAFA), hairy and enhancer of split 1 (HES1), and jagged1 (JAG1) nearly twofold over controls.	Polyphenols	82-92	metallothionein 2A	Homo sapiens	146-150
20730438-9	2010	Tea polyphenol inhibited the gene expression of HES1, JAG1, MT2A, and MAFA but upregulated the gene expression of BAX and downregulated that of (P)38.	Polyphenols	4-14	metallothionein 2A	Homo sapiens	60-64
20561054-3	2010	Although metallothionein-3 shares these metal clusters with the well-characterized metallothionein-1 and metallothionein-2, it shows distinct biological, structural and chemical properties.	Metals	9-14	metallothionein 2A	Homo sapiens	105-122
20544829-0	2010	Melatonin"s protective action against ischemic neuronal damage is associated with up-regulation of the MT2 melatonin receptor.	Melatonin	0-9	metallothionein 2A	Homo sapiens	103-106
20544829-2	2010	In the present study, we examined the relationship between the neuroprotective effects of melatonin and the activation of MT2 melatonin receptor in the hippocampal CA1 region (CA1) after transient cerebral ischemia.	Melatonin	90-99	metallothionein 2A	Homo sapiens	122-125
20544829-5	2010	In the melatonin-sham group, MT2 immunoreaction and protein levels were increased compared with the sham group, and MT2 immunoreactivity and its protein levels in the melatonin-ischemia group were similar to those in the melatonin-sham group.	Melatonin	7-16	metallothionein 2A	Homo sapiens	29-32
20544829-5	2010	In the melatonin-sham group, MT2 immunoreaction and protein levels were increased compared with the sham group, and MT2 immunoreactivity and its protein levels in the melatonin-ischemia group were similar to those in the melatonin-sham group.	Melatonin	167-176	metallothionein 2A	Homo sapiens	116-119
20544829-5	2010	In the melatonin-sham group, MT2 immunoreaction and protein levels were increased compared with the sham group, and MT2 immunoreactivity and its protein levels in the melatonin-ischemia group were similar to those in the melatonin-sham group.	Melatonin	167-176	metallothionein 2A	Homo sapiens	116-119
20544829-8	2010	The activation of MT2 melatonin receptor in the CA1 after melatonin treatment may be involved in the neuroprotective effect associated with melatonin after ischemic injury.	Melatonin	22-31	metallothionein 2A	Homo sapiens	18-21
20544829-8	2010	The activation of MT2 melatonin receptor in the CA1 after melatonin treatment may be involved in the neuroprotective effect associated with melatonin after ischemic injury.	Melatonin	58-67	metallothionein 2A	Homo sapiens	18-21
20836978-0	2010	[Tea polyphenol inhibits colorectal cancer with microsatellite instability by regulating the expressions of HES1, JAG1, MT2A and MAFA].	Polyphenols	5-15	metallothionein 2A	Homo sapiens	120-124
20836978-6	2010	The gene expression arrays and quantitative real-time PCR suggested that tea polyphenol inhibited the gene expressions of MT2A, MAFA, HES1 and JAG1 nearly two-fold over controls.	Polyphenols	77-87	metallothionein 2A	Homo sapiens	122-126
20836978-9	2010	Tea polyphenol inhibited the gene expressions of HES1, JAG1, MT2A and MAFA, up-regulated the gene expression of BAX and down-regulated that of P38.	Polyphenols	4-14	metallothionein 2A	Homo sapiens	61-65
20711450-3	2010	METHODOLOGY/PRINCIPAL FINDINGS: We now report that the major human-expressed metallothionein (MT) subtype, MT-2A, is capable of preventing the in vitro copper-mediated aggregation of Abeta1-40 and Abeta1-42.	Copper	152-158	metallothionein 2A	Homo sapiens	107-112
20646067-1	2010	Transthyretin (TTR), an amyloid-beta (Abeta) scavenger protein, and metallothioneins 2 and 3 (MT2 and MT3), low molecular weight metal-binding proteins, have recognized impacts in Abeta metabolism.	Metals	68-73	metallothionein 2A	Homo sapiens	94-97
20483362-0	2010	Letter to the editor: association between cadmium concentrations and -5 A/G MT2A polymorphism (how significant is it?	Cadmium	42-49	metallothionein 2A	Homo sapiens	76-80
20483363-0	2010	Response to letter to the editor: association between cadmium concentrations and -5 A/G MT2A polymorphism (how significant is it?	Cadmium	54-61	metallothionein 2A	Homo sapiens	88-92
19818760-8	2010	The enhanced expression of metallothionein-I and metallothionein-II mRNA in rotenone-treated control cells was significantly decreased in rotenone-treated PHGPx-ov cells, suggesting that the hydrogen peroxide that is formed by superoxide anions generated in mitochondria diffuse into the cytosol and induce metallothionein mRNA expression.	Rotenone	76-84	metallothionein 2A	Homo sapiens	49-67
20496895-0	2010	Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.	Nitrogen	9-10	metallothionein 2A	Homo sapiens	26-31
20496895-0	2010	Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.	Amides	41-46	metallothionein 2A	Homo sapiens	26-31
20082663-8	2010	Melatonin receptors (MT1 and MT2) were upregulated following treatment with melatonin.	Melatonin	76-85	metallothionein 2A	Homo sapiens	29-32
19900532-6	2010	MT-I and MT-II were up-regulated in response to both Zn and Cd exposure and, as expected, Cd represented the most potent inducer.	Zinc	53-55	metallothionein 2A	Homo sapiens	9-14
19900532-6	2010	MT-I and MT-II were up-regulated in response to both Zn and Cd exposure and, as expected, Cd represented the most potent inducer.	Cadmium	60-62	metallothionein 2A	Homo sapiens	9-14
19900532-6	2010	MT-I and MT-II were up-regulated in response to both Zn and Cd exposure and, as expected, Cd represented the most potent inducer.	Cadmium	90-92	metallothionein 2A	Homo sapiens	9-14
19900532-7	2010	Namely, 0.1microM Cd was able to up-regulate MT-I, and -II in a way comparable to 170microM Zn.	Cadmium	18-20	metallothionein 2A	Homo sapiens	45-58
20080417-10	2010	Further, melatonin receptor subtypes-MT1 and MT2 was noted on pars tuberalis, SCN and on lymphatic tissues suggesting a direct action of melatonin in modulation of immunity by photoperiod as well.	Melatonin	9-18	metallothionein 2A	Homo sapiens	45-48
20550024-2	2010	Ramelteon is a melatonin MT-1/MT-2 agonist approved for the treatment of insomnia.	ramelteon	0-9	metallothionein 2A	Homo sapiens	25-34
20550024-2	2010	Ramelteon is a melatonin MT-1/MT-2 agonist approved for the treatment of insomnia.	Melatonin	15-24	metallothionein 2A	Homo sapiens	25-34
20303360-3	2010	The aim of this study was to investigate the association between the -5 A/G metallothionein 2A (MT2A) single nucleotide polymorphism (SNP) and Cd, Zn and Cu levels in the renal cortex from autopsy cases.	Cadmium	143-145	metallothionein 2A	Homo sapiens	76-94
20303360-3	2010	The aim of this study was to investigate the association between the -5 A/G metallothionein 2A (MT2A) single nucleotide polymorphism (SNP) and Cd, Zn and Cu levels in the renal cortex from autopsy cases.	Cadmium	143-145	metallothionein 2A	Homo sapiens	96-100
20303360-3	2010	The aim of this study was to investigate the association between the -5 A/G metallothionein 2A (MT2A) single nucleotide polymorphism (SNP) and Cd, Zn and Cu levels in the renal cortex from autopsy cases.	Zinc	147-149	metallothionein 2A	Homo sapiens	76-94
20303360-3	2010	The aim of this study was to investigate the association between the -5 A/G metallothionein 2A (MT2A) single nucleotide polymorphism (SNP) and Cd, Zn and Cu levels in the renal cortex from autopsy cases.	Zinc	147-149	metallothionein 2A	Homo sapiens	96-100
20303360-3	2010	The aim of this study was to investigate the association between the -5 A/G metallothionein 2A (MT2A) single nucleotide polymorphism (SNP) and Cd, Zn and Cu levels in the renal cortex from autopsy cases.	Copper	154-156	metallothionein 2A	Homo sapiens	76-94
20303360-3	2010	The aim of this study was to investigate the association between the -5 A/G metallothionein 2A (MT2A) single nucleotide polymorphism (SNP) and Cd, Zn and Cu levels in the renal cortex from autopsy cases.	Copper	154-156	metallothionein 2A	Homo sapiens	96-100
20303360-7	2010	These results show that the core promoter region polymorphism of metallothionein 2A increases the accumulation of Cd in human renal cortex.	Cadmium	114-116	metallothionein 2A	Homo sapiens	65-83
19818760-8	2010	The enhanced expression of metallothionein-I and metallothionein-II mRNA in rotenone-treated control cells was significantly decreased in rotenone-treated PHGPx-ov cells, suggesting that the hydrogen peroxide that is formed by superoxide anions generated in mitochondria diffuse into the cytosol and induce metallothionein mRNA expression.	Rotenone	138-146	metallothionein 2A	Homo sapiens	49-67
19818760-8	2010	The enhanced expression of metallothionein-I and metallothionein-II mRNA in rotenone-treated control cells was significantly decreased in rotenone-treated PHGPx-ov cells, suggesting that the hydrogen peroxide that is formed by superoxide anions generated in mitochondria diffuse into the cytosol and induce metallothionein mRNA expression.	Hydrogen Peroxide	191-208	metallothionein 2A	Homo sapiens	49-67
19818760-8	2010	The enhanced expression of metallothionein-I and metallothionein-II mRNA in rotenone-treated control cells was significantly decreased in rotenone-treated PHGPx-ov cells, suggesting that the hydrogen peroxide that is formed by superoxide anions generated in mitochondria diffuse into the cytosol and induce metallothionein mRNA expression.	Superoxides	227-244	metallothionein 2A	Homo sapiens	49-67
19345008-5	2009	It was observed that the four lignite samples were considerably effective in removing Pb, Cd, Zn, and Cu ions from aqueous solutions, with the sample MT2 being the most effective.	Lead	86-88	metallothionein 2A	Homo sapiens	150-153
19880730-5	2009	Because luzindole and 4P-PDOT inhibited MT-induced luminescence, the action of this hormone is likely to be mediated through binding to the MT2 receptor subtype, which probably decreases the intracellular concentration of cyclic AMP (cAMP) because forskolin (a cAMP donor) strongly inhibits the light response to MT.	luzindole	8-17	metallothionein 2A	Homo sapiens	140-143
19880730-5	2009	Because luzindole and 4P-PDOT inhibited MT-induced luminescence, the action of this hormone is likely to be mediated through binding to the MT2 receptor subtype, which probably decreases the intracellular concentration of cyclic AMP (cAMP) because forskolin (a cAMP donor) strongly inhibits the light response to MT.	Cyclic AMP	222-232	metallothionein 2A	Homo sapiens	140-143
19880730-5	2009	Because luzindole and 4P-PDOT inhibited MT-induced luminescence, the action of this hormone is likely to be mediated through binding to the MT2 receptor subtype, which probably decreases the intracellular concentration of cyclic AMP (cAMP) because forskolin (a cAMP donor) strongly inhibits the light response to MT.	Cyclic AMP	234-238	metallothionein 2A	Homo sapiens	140-143
19880730-5	2009	Because luzindole and 4P-PDOT inhibited MT-induced luminescence, the action of this hormone is likely to be mediated through binding to the MT2 receptor subtype, which probably decreases the intracellular concentration of cyclic AMP (cAMP) because forskolin (a cAMP donor) strongly inhibits the light response to MT.	Colforsin	248-257	metallothionein 2A	Homo sapiens	140-143
19880730-5	2009	Because luzindole and 4P-PDOT inhibited MT-induced luminescence, the action of this hormone is likely to be mediated through binding to the MT2 receptor subtype, which probably decreases the intracellular concentration of cyclic AMP (cAMP) because forskolin (a cAMP donor) strongly inhibits the light response to MT.	Cyclic AMP	261-265	metallothionein 2A	Homo sapiens	140-143
19758108-1	2009	Agomelatine (beta-methyl-6-chloromelatonin), which is structurally homologous to melatonin, is a potent agonist of melatonin MT1 and MT2 receptors as well as an antagonist of serotonin 5-HT(2C) receptors.	agomelatine	0-11	metallothionein 2A	Homo sapiens	133-136
19758108-1	2009	Agomelatine (beta-methyl-6-chloromelatonin), which is structurally homologous to melatonin, is a potent agonist of melatonin MT1 and MT2 receptors as well as an antagonist of serotonin 5-HT(2C) receptors.	beta-methyl-6-chloromelatonin	13-42	metallothionein 2A	Homo sapiens	133-136
19711962-1	2009	A density functional theory study for the bis- and monothiophene complexes of Fe, Co, and Ni (MT2 and MT, T = thiophene, M = Fe, Co, Ni) was performed to understand their coordination geometries, bonding properties, vibration spectra and singlet excited state spectra.	Iron	78-80	metallothionein 2A	Homo sapiens	94-97
19711962-1	2009	A density functional theory study for the bis- and monothiophene complexes of Fe, Co, and Ni (MT2 and MT, T = thiophene, M = Fe, Co, Ni) was performed to understand their coordination geometries, bonding properties, vibration spectra and singlet excited state spectra.	Cobalt	82-84	metallothionein 2A	Homo sapiens	94-97
19711962-1	2009	A density functional theory study for the bis- and monothiophene complexes of Fe, Co, and Ni (MT2 and MT, T = thiophene, M = Fe, Co, Ni) was performed to understand their coordination geometries, bonding properties, vibration spectra and singlet excited state spectra.	Thiophenes	55-64	metallothionein 2A	Homo sapiens	94-97
19345008-5	2009	It was observed that the four lignite samples were considerably effective in removing Pb, Cd, Zn, and Cu ions from aqueous solutions, with the sample MT2 being the most effective.	Cadmium	90-92	metallothionein 2A	Homo sapiens	150-153
19345008-5	2009	It was observed that the four lignite samples were considerably effective in removing Pb, Cd, Zn, and Cu ions from aqueous solutions, with the sample MT2 being the most effective.	Zinc	94-96	metallothionein 2A	Homo sapiens	150-153
19345008-5	2009	It was observed that the four lignite samples were considerably effective in removing Pb, Cd, Zn, and Cu ions from aqueous solutions, with the sample MT2 being the most effective.	Copper	102-104	metallothionein 2A	Homo sapiens	150-153
19768947-2	2009	Ramelteon (Rozerem) is an orally active, highly selective melatonin MT1/MT2 receptor agonist.	ramelteon	0-9	metallothionein 2A	Homo sapiens	72-75
19556449-0	2009	Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.	ramelteon	135-144	metallothionein 2A	Homo sapiens	73-76
19556449-6	2009	Saturation binding experiments with 2-[(125)I]iodomelatonin revealed that the dissociation constants (K(d)) for the monkey MT(1) and MT(2) melatonin receptors were 19.9 and 70.4 pM, respectively.	)i]iodomelatonin	43-59	metallothionein 2A	Homo sapiens	133-138
21305148-0	2009	Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.	Ruthenium	47-56	metallothionein 2A	Homo sapiens	71-88
21305148-1	2009	The reaction of metallothionein-2 (MT-2) with the organometallic antitumour compound [Ru(eta(6)-p-cymene)Cl(2)(pta)], RAPTA-C, was investigated using ESI MS and ICP AES.	[ru(eta(6)-p-cymene)cl	85-107	metallothionein 2A	Homo sapiens	16-33
21305148-1	2009	The reaction of metallothionein-2 (MT-2) with the organometallic antitumour compound [Ru(eta(6)-p-cymene)Cl(2)(pta)], RAPTA-C, was investigated using ESI MS and ICP AES.	[ru(eta(6)-p-cymene)cl	85-107	metallothionein 2A	Homo sapiens	35-39
21305148-4	2009	These data, combined with ICP AES analysis, show that binding of both RAPTA-C and cisplatin to MT-2 requires the displacement of an equivalent amount of zinc, suggesting that Cys residues are the target binding sites for the two metallodrugs.	Cisplatin	82-91	metallothionein 2A	Homo sapiens	95-99
21305148-4	2009	These data, combined with ICP AES analysis, show that binding of both RAPTA-C and cisplatin to MT-2 requires the displacement of an equivalent amount of zinc, suggesting that Cys residues are the target binding sites for the two metallodrugs.	Cysteine	175-178	metallothionein 2A	Homo sapiens	95-99
21305148-5	2009	The competitive binding of RAPTA-C and cisplatin towards a mixture of ubiquitin (Ub) and MT-2 was also studied, showing that MT-2 can abstract RAPTA-C from Ub more efficiently than it can abstract cisplatin.	dichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II)	27-34	metallothionein 2A	Homo sapiens	89-93
21305148-5	2009	The competitive binding of RAPTA-C and cisplatin towards a mixture of ubiquitin (Ub) and MT-2 was also studied, showing that MT-2 can abstract RAPTA-C from Ub more efficiently than it can abstract cisplatin.	dichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II)	27-34	metallothionein 2A	Homo sapiens	125-129
21305148-5	2009	The competitive binding of RAPTA-C and cisplatin towards a mixture of ubiquitin (Ub) and MT-2 was also studied, showing that MT-2 can abstract RAPTA-C from Ub more efficiently than it can abstract cisplatin.	Cisplatin	39-48	metallothionein 2A	Homo sapiens	89-93
21305148-5	2009	The competitive binding of RAPTA-C and cisplatin towards a mixture of ubiquitin (Ub) and MT-2 was also studied, showing that MT-2 can abstract RAPTA-C from Ub more efficiently than it can abstract cisplatin.	Cisplatin	39-48	metallothionein 2A	Homo sapiens	125-129
21305148-5	2009	The competitive binding of RAPTA-C and cisplatin towards a mixture of ubiquitin (Ub) and MT-2 was also studied, showing that MT-2 can abstract RAPTA-C from Ub more efficiently than it can abstract cisplatin.	dichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II)	143-150	metallothionein 2A	Homo sapiens	125-129
19723097-4	2009	Melatonin is a neurohormone that regulates target cells via binding to specific high-affinity plasma membrane receptors, MT1/MT2.	Melatonin	0-9	metallothionein 2A	Homo sapiens	125-128
19768947-2	2009	Ramelteon (Rozerem) is an orally active, highly selective melatonin MT1/MT2 receptor agonist.	ramelteon	11-18	metallothionein 2A	Homo sapiens	72-75
19097988-8	2009	Ni-induced increases in MT2A mRNA and MRE-luciferase activity were sensitive to the Zn chelator, TPEN, supporting an important role for Zn in mediating the effect of Ni.	Zinc	84-86	metallothionein 2A	Homo sapiens	24-28
19097988-8	2009	Ni-induced increases in MT2A mRNA and MRE-luciferase activity were sensitive to the Zn chelator, TPEN, supporting an important role for Zn in mediating the effect of Ni.	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	97-101	metallothionein 2A	Homo sapiens	24-28
19097988-8	2009	Ni-induced increases in MT2A mRNA and MRE-luciferase activity were sensitive to the Zn chelator, TPEN, supporting an important role for Zn in mediating the effect of Ni.	Zinc	136-138	metallothionein 2A	Homo sapiens	24-28
19097988-10	2009	Although both N-acetyl cysteine (NAC) and ascorbic acid (AA) decreased Ni-induced increases in ROS, only NAC prevented Ni-induced increases in MT2A mRNA, suggesting a special role for interactions of Ni, thiols, and Zn release.	Acetylcysteine	105-108	metallothionein 2A	Homo sapiens	143-147
19440163-5	2009	Also associated with the onset or magnitude of anthracycline resistance were genes involved in drug transport (ABCB1, ABCC1), cell signaling and transcription (RDC1, CXCR4), cell proliferation or apoptosis (BMP7, CAV1), protection from reactive oxygen species (AKR1C2, AKR1C3, FTL, FTH, TXNRD1, MT2A), and structural or immune system proteins (IFI30, STMN1).	Anthracyclines	47-60	metallothionein 2A	Homo sapiens	295-299
19777735-2	2009	Agomelatine is an agonist of melatonergic MT1 and MT2 receptors and a serotonin 5-HT2C receptor antagonist.	agomelatine	0-11	metallothionein 2A	Homo sapiens	50-53
19711962-1	2009	A density functional theory study for the bis- and monothiophene complexes of Fe, Co, and Ni (MT2 and MT, T = thiophene, M = Fe, Co, Ni) was performed to understand their coordination geometries, bonding properties, vibration spectra and singlet excited state spectra.	bis- and monothiophene	42-64	metallothionein 2A	Homo sapiens	94-97
19827314-12	2009	The recently marketed agomelatine with a highly selective receptor binding profile (MT1 and MT2 agonism and 5HT2C antagonism) targets the desynchronised circadian rhytm in affective disorders and it has mainly antidepressive effect.	agomelatine	22-33	metallothionein 2A	Homo sapiens	92-95
18582600-10	2009	All the above results revealed that the mandarin fish MT-2 would be a useful biomarker for metal pollution.	Metals	91-96	metallothionein 2A	Homo sapiens	54-58
19329323-0	2009	Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands.	3-phenyltetrahydronaphthalenic	24-54	metallothionein 2A	Homo sapiens	84-87
19329323-5	2009	Moreover, we have achieved remarkable MT(2) selectivity over MT(1) (selectivity &gt;100) and have been able to further extend the RSA of the tetrahydrophthalenic series.	rabbit sperm membrane autoantigen	130-133	metallothionein 2A	Homo sapiens	38-43
19356627-3	2009	We demonstrated that KAT5 cells expressed eight functional MT1 and MT2 isoforms induced by cadmium.	Cadmium	91-98	metallothionein 2A	Homo sapiens	67-70
19356627-8	2009	Collectively, KAT5 cells express eight functional MT1 and MT2 isoforms in a pathway controlled by calcium and ERK1/2.	Calcium	98-105	metallothionein 2A	Homo sapiens	58-61
19175856-3	2009	Using CHO cells expressing human MT2 melatonin receptors, microtubule depolymerization prevents the loss in the number of high potency states of the receptor when compared to melatonin-treated cells.	Melatonin	37-46	metallothionein 2A	Homo sapiens	33-36
19116991-7	2009	Down-regulation of MT in MCF-7 cells by silencing the MT-2A gene (the most abundantly expressed of the 10 known functional MT isoforms) increased chemosensitivity of the cells to doxorubicin.	Doxorubicin	179-190	metallothionein 2A	Homo sapiens	54-59
18996371-5	2009	The MT2A upregulation correlated with resistance to Adriamycin (ADR)-driven apoptosis and with p53 inhibition.	Doxorubicin	52-62	metallothionein 2A	Homo sapiens	4-8
19026172-1	2008	AIM: Melatonin (MT) is a neurohormone produced and secreted primarily by the pineal gland in a circadian manner, and mainly acts through 2 receptor subtypes: MT1 and MT2 in humans.	Melatonin	5-14	metallothionein 2A	Homo sapiens	166-169
18507714-7	2008	These results indicate a novel role for 17-beta-estradiol and melatonin in AIS, controlling the coupling of G(S)alpha protein and MT2 receptor on human osteoblasts.	Estradiol	40-57	metallothionein 2A	Homo sapiens	130-133
18507714-7	2008	These results indicate a novel role for 17-beta-estradiol and melatonin in AIS, controlling the coupling of G(S)alpha protein and MT2 receptor on human osteoblasts.	Melatonin	62-71	metallothionein 2A	Homo sapiens	130-133
18544139-0	2008	The role of proline residues in the structure and function of human MT2 melatonin receptor.	Proline	12-19	metallothionein 2A	Homo sapiens	68-71
18544139-2	2008	In mammals, two G protein-coupled melatonin receptors (GPCR) mediate some melatonin"s actions: MT1 and MT2.	Melatonin	34-43	metallothionein 2A	Homo sapiens	103-106
18544139-4	2008	As TM segments of MT2 receptor display several interesting differences in expression of specific proline residues compared to other rhodopsin-like receptors (rGPCRs), we investigated the role of proline residues in the structure and function of this receptor.	Proline	97-104	metallothionein 2A	Homo sapiens	18-21
18544139-4	2008	As TM segments of MT2 receptor display several interesting differences in expression of specific proline residues compared to other rhodopsin-like receptors (rGPCRs), we investigated the role of proline residues in the structure and function of this receptor.	Proline	195-202	metallothionein 2A	Homo sapiens	18-21
18544139-8	2008	The impact of the performed mutations on the receptor structure was assessed by molecular dynamic simulations of MT2 receptors embedded in the fully hydrated phospholipid bilayer.	Phospholipids	158-170	metallothionein 2A	Homo sapiens	113-116
21089248-6	2008	Ramelteon, a hypnotic approved by the United States Food and Drug Administration (FDA) in July 2005, is a selective melatonin receptor (MT1 and MT2) agonist.	ramelteon	0-9	metallothionein 2A	Homo sapiens	144-147
18803406-0	2008	Interaction of metallothionein-2 with platinum-modified 5"-guanosine monophosphate and DNA.	Platinum	38-46	metallothionein 2A	Homo sapiens	15-32
18803406-0	2008	Interaction of metallothionein-2 with platinum-modified 5"-guanosine monophosphate and DNA.	5"-guanosine monophosphate	56-82	metallothionein 2A	Homo sapiens	15-32
18803406-4	2008	Immunochemical analysis of MT-2 showed that the monofunctional platinum-DNA adducts formed DNA- cis/ trans-Pt-MT cross-links and that platinated MT-2 was released from the DNA- trans-Pt-MT cross-links with time.	Platinum	63-71	metallothionein 2A	Homo sapiens	27-31
18586083-0	2008	Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells.	gallium nitrate	129-144	metallothionein 2A	Homo sapiens	45-63
18755257-0	2008	Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa).	Melatonin	0-9	metallothionein 2A	Homo sapiens	54-58
18755257-0	2008	Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa).	Cadmium	24-31	metallothionein 2A	Homo sapiens	54-58
18755257-5	2008	In this study we examine the possible role of melatonin in Cd-induced expression of several MT isoforms (MT-2A, MT-1X, MT-1F and MT-1E) in three human tumor cell lines (MCF-7, MDA-MB-231 and HeLa).	Cadmium	59-61	metallothionein 2A	Homo sapiens	105-110
18755257-6	2008	We found that, in all cell types, melatonin increases Cd-induced expression of MT-2A, which is considered to protect against Cd toxicity.	Melatonin	34-43	metallothionein 2A	Homo sapiens	79-84
18755257-6	2008	We found that, in all cell types, melatonin increases Cd-induced expression of MT-2A, which is considered to protect against Cd toxicity.	Cadmium	54-56	metallothionein 2A	Homo sapiens	79-84
18755257-6	2008	We found that, in all cell types, melatonin increases Cd-induced expression of MT-2A, which is considered to protect against Cd toxicity.	Cadmium	125-127	metallothionein 2A	Homo sapiens	79-84
18586083-6	2008	N-Acetyl-L-cysteine blocked gallium-induced MT2A and HO-1 expression and increased gallium"s cytotoxicity.	Gallium	28-35	metallothionein 2A	Homo sapiens	44-48
18586083-10	2008	We conclude that gallium nitrate induces cellular oxidative stress as an early event which then triggers the expression of HO-1 and MT2A through different pathways.	gallium nitrate	17-32	metallothionein 2A	Homo sapiens	132-136
18586083-2	2008	Using a DNA microarray to examine genes induced by gallium nitrate in CCRF-CEM cells, we found that gallium increased metallothionein-2A (MT2A) and heme oxygenase-1 (HO-1) gene expression and altered the levels of other stress-related genes.	gallium nitrate	51-66	metallothionein 2A	Homo sapiens	118-136
18586083-2	2008	Using a DNA microarray to examine genes induced by gallium nitrate in CCRF-CEM cells, we found that gallium increased metallothionein-2A (MT2A) and heme oxygenase-1 (HO-1) gene expression and altered the levels of other stress-related genes.	gallium nitrate	51-66	metallothionein 2A	Homo sapiens	138-142
18586083-2	2008	Using a DNA microarray to examine genes induced by gallium nitrate in CCRF-CEM cells, we found that gallium increased metallothionein-2A (MT2A) and heme oxygenase-1 (HO-1) gene expression and altered the levels of other stress-related genes.	Gallium	51-58	metallothionein 2A	Homo sapiens	118-136
18586083-2	2008	Using a DNA microarray to examine genes induced by gallium nitrate in CCRF-CEM cells, we found that gallium increased metallothionein-2A (MT2A) and heme oxygenase-1 (HO-1) gene expression and altered the levels of other stress-related genes.	Gallium	51-58	metallothionein 2A	Homo sapiens	138-142
18586083-3	2008	MT2A and HO-1 were increased after 6 and 16 h of incubation with gallium nitrate.	gallium nitrate	65-80	metallothionein 2A	Homo sapiens	0-4
18586083-6	2008	N-Acetyl-L-cysteine blocked gallium-induced MT2A and HO-1 expression and increased gallium"s cytotoxicity.	Acetylcysteine	0-19	metallothionein 2A	Homo sapiens	44-48
18583104-2	2008	Agomelatine, a naphthalene analog of melatonin, is both an agonist of human cloned melatonergic MT1 and MT2 receptors and a serotonin 5-HT2C receptor antagonist.	agomelatine	0-11	metallothionein 2A	Homo sapiens	104-107
18583104-2	2008	Agomelatine, a naphthalene analog of melatonin, is both an agonist of human cloned melatonergic MT1 and MT2 receptors and a serotonin 5-HT2C receptor antagonist.	Melatonin	37-46	metallothionein 2A	Homo sapiens	104-107
18815150-5	2008	In hepatomas, through its activation of MT1 and MT2 receptors, melatonin inhibits linoleic acid uptake, thereby preventing the formation of the mitogenic metabolite 1,3-hydroxyoctadecadienoic acid.	Melatonin	63-72	metallothionein 2A	Homo sapiens	48-51
18815150-5	2008	In hepatomas, through its activation of MT1 and MT2 receptors, melatonin inhibits linoleic acid uptake, thereby preventing the formation of the mitogenic metabolite 1,3-hydroxyoctadecadienoic acid.	Linoleic Acid	82-95	metallothionein 2A	Homo sapiens	48-51
18815150-5	2008	In hepatomas, through its activation of MT1 and MT2 receptors, melatonin inhibits linoleic acid uptake, thereby preventing the formation of the mitogenic metabolite 1,3-hydroxyoctadecadienoic acid.	1,3-hydroxyoctadecadienoic acid	165-196	metallothionein 2A	Homo sapiens	48-51
17692523-5	2008	RESULTS: For the peak pressures under the metatarsal heads (MT) the following order was found: MT-II&gt;MT-III&gt;MT-I&gt;MT-IV&gt;MT-V. A comparison of the insoles indicated that the neoprene insole resulted in the lowest peak pressures with significant load reductions under MT-III to MT-V (p&lt;0.00001).	Neoprene	184-192	metallothionein 2A	Homo sapiens	95-100
18937711-5	2008	The effect of melatonin against expression of MT1, MT2, and ERalpha-receptors mRNA was compared with RT-PCR.	Melatonin	14-23	metallothionein 2A	Homo sapiens	51-54
18298466-6	2008	Radioligand binding assays on recombinant human MT(1)/MT(2) receptors showed that both the melatonin and ramelteon were both high affinity, nonsubtype selective ligands.	Melatonin	91-100	metallothionein 2A	Homo sapiens	54-59
18298466-6	2008	Radioligand binding assays on recombinant human MT(1)/MT(2) receptors showed that both the melatonin and ramelteon were both high affinity, nonsubtype selective ligands.	ramelteon	105-114	metallothionein 2A	Homo sapiens	54-59
18254726-1	2008	Melatonin exerts its biological effects through at least two transmembrane G-protein-coupled receptors, MT1 and MT2, and a lower-affinity cytosolic binding site, designated MT3.	Melatonin	0-9	metallothionein 2A	Homo sapiens	112-115
18571301-3	2008	In addition to its relevant antioxidant activity, melatonin exerts many of its physiological actions by interacting with membrane MT1 and MT2 receptors and intracellular proteins such as quinone reductase 2, calmodulin, calreticulin and tubulin.	Melatonin	50-59	metallothionein 2A	Homo sapiens	138-141
17999152-6	2008	Calcium concentration of the growth medium was also shown to alter the accumulation of MT-1/2 protein and MT-1E, MT-1X, and MT-2A mRNAs.	Calcium	0-7	metallothionein 2A	Homo sapiens	124-129
18681045-7	2008	The molecular simulation model of MT-2 showed the interlayer space with the exchangeable cations and metallic silver atoms arrangement within the glycerol bilayer.	Glycerol	146-154	metallothionein 2A	Homo sapiens	34-38
17692523-6	2008	Furthermore, the impulse values under MT-II to MT-V were significantly lower with neoprene insoles (p&lt;0.0002).	Neoprene	82-90	metallothionein 2A	Homo sapiens	38-43
30764095-2	2008	Melatonergic MT1 and MT2 receptors exist in high concentrations in the suprachiasmatic nucleus of the hypothalamus and have been shown to be instrumental for the sleep-promoting and circadian rhythm-regulating effects of melatonin.	Melatonin	221-230	metallothionein 2A	Homo sapiens	21-24
17590860-5	2008	It was also shown that the RWPE-1 cells respond to Zn(+2) and Cd(+2) exposure by induction of the basally expressed MT mRNAs and the accumulation of high levels MT-1/2 protein (in excess of 10% of total protein).	Zinc	51-53	metallothionein 2A	Homo sapiens	161-167
17590860-5	2008	It was also shown that the RWPE-1 cells respond to Zn(+2) and Cd(+2) exposure by induction of the basally expressed MT mRNAs and the accumulation of high levels MT-1/2 protein (in excess of 10% of total protein).	Cadmium	62-64	metallothionein 2A	Homo sapiens	161-167
18194202-1	2008	Melatonin is known to inhibit insulin secretion from rodent beta-cells through interactions with cell-surface MT1 and/or MT2 receptors, but the function of this hormone in human islets of Langerhans is not known.	Melatonin	0-9	metallothionein 2A	Homo sapiens	121-124
30764095-5	2008	Ramelteon, which acts via MT1/MT2 melatonergic agonism, has been found clinically effective for improving total sleep time and sleep efficiency in insomniacs.	ramelteon	0-9	metallothionein 2A	Homo sapiens	30-33
30764095-6	2008	Agomelatine (Valdoxan , Servier) is another MT1/MT2 melatonergic agonist that also displays antagonist activity at 5-HT2C serotonin receptors.	agomelatine	0-11	metallothionein 2A	Homo sapiens	48-51
30764095-6	2008	Agomelatine (Valdoxan , Servier) is another MT1/MT2 melatonergic agonist that also displays antagonist activity at 5-HT2C serotonin receptors.	agomelatine	13-21	metallothionein 2A	Homo sapiens	48-51
30764095-6	2008	Agomelatine (Valdoxan , Servier) is another MT1/MT2 melatonergic agonist that also displays antagonist activity at 5-HT2C serotonin receptors.	servier	24-31	metallothionein 2A	Homo sapiens	48-51
17907131-0	2007	Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists.	10,11-dihydro-5h-dibenzo[a,d]	93-122	metallothionein 2A	Homo sapiens	135-138
18193062-3	2008	Using a tamoxifen-activatable Cre recombinase to excise a test segment of chromatin positioned between divergently transcribed metallothionein-IIa promoters, we found the degree of dynamic supercoiling to increase as transcription intensified, and it was very sensitive to the specific arrangement of promoters and cis elements.	Tamoxifen	8-17	metallothionein 2A	Homo sapiens	127-146
20050582-4	2008	Antinociceptive effects of melatonin are having the significant connection with the MT2 receptor stimulation and activation of the opioid system.	Melatonin	27-36	metallothionein 2A	Homo sapiens	84-87
18052314-2	2007	MT1 and MT2 receptor binding affinity and intrinsic activity have been modulated by the introduction of different substituents on the aniline nitrogen, on the benzene ring, and on the amide side chain.	aniline	134-141	metallothionein 2A	Homo sapiens	8-11
18052314-2	2007	MT1 and MT2 receptor binding affinity and intrinsic activity have been modulated by the introduction of different substituents on the aniline nitrogen, on the benzene ring, and on the amide side chain.	Nitrogen	142-150	metallothionein 2A	Homo sapiens	8-11
18052314-2	2007	MT1 and MT2 receptor binding affinity and intrinsic activity have been modulated by the introduction of different substituents on the aniline nitrogen, on the benzene ring, and on the amide side chain.	Benzene	159-166	metallothionein 2A	Homo sapiens	8-11
18052314-2	2007	MT1 and MT2 receptor binding affinity and intrinsic activity have been modulated by the introduction of different substituents on the aniline nitrogen, on the benzene ring, and on the amide side chain.	Amides	184-189	metallothionein 2A	Homo sapiens	8-11
18052314-6	2007	The phenyl derivative 3g is an MT2-selective partial agonist, with MT2 binding affinity higher than melatonin, showing promising sleep-promoting and antianxiety properties in animal models.	Melatonin	100-109	metallothionein 2A	Homo sapiens	31-34
18057785-6	2007	Metal responsive element-binding transcription factor-1 (MTF-1) is involved in sensing heavy metal load and the induced transcription of several protective genes, including metallothionein (MT)-I, MT-II, zinc transporter-1, and gamma-glutamylcysteine synthetase.	Metals	93-98	metallothionein 2A	Homo sapiens	197-202
17673155-2	2007	To better determine the role of MT in interprotein metal transfer, we describe a procedure that uses stable isotopically enriched (67)Zn(7) metallothionein 2 ((67)Zn(7)-MT-2) to quantitatively determine the stoichiometry of transfer of Zn from the protein to a recipient apo-metalloenzyme, apo-carbonic anhydrase (apo-CA) by directly coupled ion exchange high-performance liquid chromatography inductively coupled plasma mass spectrometry.	Zinc	163-165	metallothionein 2A	Homo sapiens	140-157
17581657-4	2007	Both butyramides 13 and 15, as well as the non-methoxy acetamide 12 exhibited micromolar binding affinities for both receptors being slightly MT(2) selective.	butyramide	5-16	metallothionein 2A	Homo sapiens	142-147
17581657-4	2007	Both butyramides 13 and 15, as well as the non-methoxy acetamide 12 exhibited micromolar binding affinities for both receptors being slightly MT(2) selective.	2-Methoxyacetamide	47-64	metallothionein 2A	Homo sapiens	142-147
17581657-5	2007	The methoxy acetamide 14 showed the best pharmacological profile exhibiting a five times higher affinity for MT(1) (K(i) = 49 nM) than for MT(2) (K(i) = 246 nM) receptor.	2-Methoxyacetamide	4-21	metallothionein 2A	Homo sapiens	139-144
17121968-5	2007	There were several conserved tripeptide sequences, such as C-X-C, C-C-X-C-C, and C-X-X-C (X designates AA excluding cysteine in MT-I and MT-II), and they are highly conserved in their evolution.	tripeptide K-26	29-39	metallothionein 2A	Homo sapiens	137-142
17917562-5	2007	Agomelatine (S-20098), a compound with agonistic properties at MT1 and MT2 receptors and antagonistic properties at the 5-HT2C receptor, has been shown preclinically to exhibit robust antidepressant effects in several experimental paradigms.	agomelatine	0-11	metallothionein 2A	Homo sapiens	71-74
17917562-5	2007	Agomelatine (S-20098), a compound with agonistic properties at MT1 and MT2 receptors and antagonistic properties at the 5-HT2C receptor, has been shown preclinically to exhibit robust antidepressant effects in several experimental paradigms.	agomelatine	13-20	metallothionein 2A	Homo sapiens	71-74
17482720-0	2007	Further structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5.	Lactams	38-44	metallothionein 2A	Homo sapiens	60-65
17121968-5	2007	There were several conserved tripeptide sequences, such as C-X-C, C-C-X-C-C, and C-X-X-C (X designates AA excluding cysteine in MT-I and MT-II), and they are highly conserved in their evolution.	c-x-x-c	81-88	metallothionein 2A	Homo sapiens	137-142
17121968-6	2007	By homologous comparative modeling, we predicted the molecular spatial structures of yak MT-I and MT-II, which are composed of alpha- and beta-domains that are linked by the conserved tripeptide Lys(30)-Lys(31)-Ser(32) (KKS).	tripeptide K-26	184-194	metallothionein 2A	Homo sapiens	98-103
17121968-6	2007	By homologous comparative modeling, we predicted the molecular spatial structures of yak MT-I and MT-II, which are composed of alpha- and beta-domains that are linked by the conserved tripeptide Lys(30)-Lys(31)-Ser(32) (KKS).	Lysine	195-198	metallothionein 2A	Homo sapiens	98-103
17121968-6	2007	By homologous comparative modeling, we predicted the molecular spatial structures of yak MT-I and MT-II, which are composed of alpha- and beta-domains that are linked by the conserved tripeptide Lys(30)-Lys(31)-Ser(32) (KKS).	Lysine	203-206	metallothionein 2A	Homo sapiens	98-103
17121968-6	2007	By homologous comparative modeling, we predicted the molecular spatial structures of yak MT-I and MT-II, which are composed of alpha- and beta-domains that are linked by the conserved tripeptide Lys(30)-Lys(31)-Ser(32) (KKS).	Serine	211-214	metallothionein 2A	Homo sapiens	98-103
17485079-0	2007	Induction of functional MT1 and MT2 isoforms by calcium in anaplastic thyroid carcinoma cells.	Calcium	48-55	metallothionein 2A	Homo sapiens	32-35
17485079-4	2007	Therefore, a common pathway initiated by a rapid rise in calcium and followed by calcium-mediated activation of ERK is involved in the transcriptional induction of functional MT1 and MT2 isoforms and in the progression of the cell cycle in thyroid cancer cells exposed to cadmium.	Calcium	57-64	metallothionein 2A	Homo sapiens	183-186
17485079-4	2007	Therefore, a common pathway initiated by a rapid rise in calcium and followed by calcium-mediated activation of ERK is involved in the transcriptional induction of functional MT1 and MT2 isoforms and in the progression of the cell cycle in thyroid cancer cells exposed to cadmium.	Calcium	81-88	metallothionein 2A	Homo sapiens	183-186
17485079-4	2007	Therefore, a common pathway initiated by a rapid rise in calcium and followed by calcium-mediated activation of ERK is involved in the transcriptional induction of functional MT1 and MT2 isoforms and in the progression of the cell cycle in thyroid cancer cells exposed to cadmium.	Cadmium	272-279	metallothionein 2A	Homo sapiens	183-186
17308060-0	2007	Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate.	Gallium	50-57	metallothionein 2A	Homo sapiens	143-161
17224279-5	2007	Chemical and functional characteristics analysis of the recombinant human MT2A exhibited intact metal binding ability, hydroxyl radical scavenging ability and significant protective role against DNA damage caused by UVC radiation.	Metals	96-101	metallothionein 2A	Homo sapiens	74-78
17224279-5	2007	Chemical and functional characteristics analysis of the recombinant human MT2A exhibited intact metal binding ability, hydroxyl radical scavenging ability and significant protective role against DNA damage caused by UVC radiation.	Hydroxyl Radical	119-135	metallothionein 2A	Homo sapiens	74-78
17413472-12	2007	RESULTS: The MT2 mRNA expression on the concave side of the paravertebral muscle was higher than that on the convex side in AIS and CS groups (P &lt; 0.05), but the MT1 mRNA expression showed no significant difference (P &gt; 0.05).	Cesium	132-134	metallothionein 2A	Homo sapiens	13-16
17316165-7	2007	Our results indicate that MT(2) in the humans, similar to MT(1), may indeed be involved in transmitting melatonin"s effects in the retina, and AD pathology may impair MT(2) expression.	Melatonin	104-113	metallothionein 2A	Homo sapiens	26-31
17389558-0	2007	Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.	ramelteon	71-80	metallothionein 2A	Homo sapiens	138-141
17308060-0	2007	Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate.	gallium nitrate	231-246	metallothionein 2A	Homo sapiens	143-161
17308060-5	2007	Gallium-resistant cells were found to display a marked increase in gene expression for metallothionein-2A and the zinc transporter ZnT-1.	Gallium	0-7	metallothionein 2A	Homo sapiens	87-105
17308060-7	2007	Gallium nitrate induced metallothionein-2A and ZnT-1 expression in cells.	gallium nitrate	0-15	metallothionein 2A	Homo sapiens	24-42
17584130-10	2007	The non-specific "superpotent" MC agonist, PT-141, which is the carboxylate derivative of MT-II, has reached phase II human trials.	Methylcholanthrene	31-33	metallothionein 2A	Homo sapiens	90-95
17363595-3	2007	Here, we report that the levels of MT-1 and MT-2A are drastically reduced in primary human hepatocellular carcinomas (HCCs) and in diethylnitrosamine-induced liver tumors in mice, which is primarily due to transcriptional repression.	Diethylnitrosamine	131-149	metallothionein 2A	Homo sapiens	44-49
18020480-2	2007	Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (melatonin 1a) and MT(2) (melatonin 1b) receptors, the two major melatonin receptor subtypes found in mammals.	Melatonin	0-9	metallothionein 2A	Homo sapiens	141-146
17584130-10	2007	The non-specific "superpotent" MC agonist, PT-141, which is the carboxylate derivative of MT-II, has reached phase II human trials.	Platinum	43-45	metallothionein 2A	Homo sapiens	90-95
17762828-0	2007	[Sites and mechanisms of action of melatonin in mammals: the MT1 and MT2 receptors].	Melatonin	35-44	metallothionein 2A	Homo sapiens	69-72
17762828-5	2007	Inhibition of the production of AMPc by a Gi/Go protein is one of the principal signalling pathways of the MT1 and MT2 receptors, although many other signal transduction pathways are also brought into play according to the cell type studied (PKC, Ca2+, K+ channels or GMPc in the case of MT2, etc.).	ampc	32-36	metallothionein 2A	Homo sapiens	115-118
17762828-5	2007	Inhibition of the production of AMPc by a Gi/Go protein is one of the principal signalling pathways of the MT1 and MT2 receptors, although many other signal transduction pathways are also brought into play according to the cell type studied (PKC, Ca2+, K+ channels or GMPc in the case of MT2, etc.).	ampc	32-36	metallothionein 2A	Homo sapiens	288-291
17762828-6	2007	Numerous factors or physiological stimuli are capable of influencing the number and functional status of the MT1 and MT2 receptors, such as melatonin, the photoperiod, the circadian clock or the phenomena of receptor dimerisation.	Melatonin	140-149	metallothionein 2A	Homo sapiens	117-120
17762828-7	2007	Melatonin has numerous physiological effects for which the mechanisms of action and the specific role of the MT1 and MT2 receptors have not yet been clearly elucidated.	Melatonin	0-9	metallothionein 2A	Homo sapiens	117-120
17762828-8	2007	However, selective pharmacological tools for each of the two receptor subtypes are currently being identified, notably in the Servier Group, for the purpose of furthering our knowledge of the functionality and physiological role of the MT1 and MT2 receptors in the central and peripheral structures.	servier	126-133	metallothionein 2A	Homo sapiens	244-247
17197111-1	2007	The pineal hormone melatonin produces most of its biological effects via G protein-coupled receptors MT1 and MT2.	Melatonin	19-28	metallothionein 2A	Homo sapiens	109-112
17197111-3	2007	Recent research points to a putative role of MT1/MT2 dimerization as a mechanism that could determine the receptor-mediated biological effects of melatonin.	Melatonin	146-155	metallothionein 2A	Homo sapiens	49-52
17197111-7	2007	Hence, we propose that a prolonged treatment with classical antidepressant drugs alters the brain ratio of MT1/MT2 receptors to enable the endogenous melatonin, which is secreted during the night, to further improve the antidepressant effects.	Melatonin	150-159	metallothionein 2A	Homo sapiens	111-114
16806025-2	2006	METHODS: GST-MT-2a fusion protein was expressed after IPTG induction and further purified with Glutathione Sepharose 4B.	Isopropyl Thiogalactoside	54-58	metallothionein 2A	Homo sapiens	13-18
17213040-2	2006	Melatonin and its receptors MT1 and MT2, which belong to the family of G protein-coupled receptors, are impaired in Alzheimer"s disease (AD) with severe consequences to neuropathology and clinical symptoms.	Melatonin	0-9	metallothionein 2A	Homo sapiens	36-39
16928133-8	2006	The elaborated "optimized" models are employed to explore the details of protein-ligand interactions for melatonin and a number of its analogs with known affinity to MT(1) and MT(2) receptors.	Melatonin	105-114	metallothionein 2A	Homo sapiens	176-181
16806025-2	2006	METHODS: GST-MT-2a fusion protein was expressed after IPTG induction and further purified with Glutathione Sepharose 4B.	Glutathione	95-106	metallothionein 2A	Homo sapiens	13-18
16806025-2	2006	METHODS: GST-MT-2a fusion protein was expressed after IPTG induction and further purified with Glutathione Sepharose 4B.	Sepharose	107-119	metallothionein 2A	Homo sapiens	13-18
16889730-8	2006	RESULTS: The MT2 mRNA expression of paravertebral muscles on concave side was higher than that on convex side in AIS and CS groups (P &lt; 0.05), but the MT1 mRNA expression showed no significant difference (P &gt; 0.05).	Cesium	121-123	metallothionein 2A	Homo sapiens	13-16
16621216-11	2006	In conclusion, MT-2 is the main isoform induced by smoking, suggesting that this isoform could be involved in placental cadmium and zinc retention.	Cadmium	120-127	metallothionein 2A	Homo sapiens	15-19
16565513-0	2006	Metallothionein-1 and -2 expression in cadmium- or arsenic-derived human malignant urothelial cells and tumor heterotransplants and as a prognostic indicator in human bladder cancer.	Cadmium	39-46	metallothionein 2A	Homo sapiens	0-24
16565513-0	2006	Metallothionein-1 and -2 expression in cadmium- or arsenic-derived human malignant urothelial cells and tumor heterotransplants and as a prognostic indicator in human bladder cancer.	Arsenic	51-58	metallothionein 2A	Homo sapiens	0-24
16719502-3	2006	We found that both genistin and its glycosides similarly up-regulated the transcription of several metallothionein (MT) antioxidant genes (MT1A, MT2A, MT1E, and MT1X), as well as the glucose 6-phosphate dehydrogenase (G6PD) gene in HepG2 cells.	Glycosides	36-46	metallothionein 2A	Homo sapiens	145-149
16680370-4	2006	Recombinant MT2A proteins were loaded onto 12% sodium dodecylsulfate-polyacrylamide gel and separated by electrophoresis, the recombinant protein was visualized by Coomassie blue staining and the 33 kDa recombinant GST-MT2A fusion protein band was cut out from the gel.	Sodium Dodecyl Sulfate	47-68	metallothionein 2A	Homo sapiens	12-16
16680370-4	2006	Recombinant MT2A proteins were loaded onto 12% sodium dodecylsulfate-polyacrylamide gel and separated by electrophoresis, the recombinant protein was visualized by Coomassie blue staining and the 33 kDa recombinant GST-MT2A fusion protein band was cut out from the gel.	polyacrylamide	69-83	metallothionein 2A	Homo sapiens	12-16
16680370-4	2006	Recombinant MT2A proteins were loaded onto 12% sodium dodecylsulfate-polyacrylamide gel and separated by electrophoresis, the recombinant protein was visualized by Coomassie blue staining and the 33 kDa recombinant GST-MT2A fusion protein band was cut out from the gel.	Coomassie blue	164-178	metallothionein 2A	Homo sapiens	12-16
16493670-2	2006	Mammalian metallothioneins I and II (MT-I&amp;II) have significant neuroprotective functions, but the precise mechanisms underlying these effects are still unknown.	Adenosine Monophosphate	42-45	metallothionein 2A	Homo sapiens	10-35
16636651-0	2006	The role of metallothionein IIa in defending lens epithelial cells against cadmium and TBHP induced oxidative stress.	Cadmium	75-82	metallothionein 2A	Homo sapiens	12-31
16636651-0	2006	The role of metallothionein IIa in defending lens epithelial cells against cadmium and TBHP induced oxidative stress.	tert-Butylhydroperoxide	87-91	metallothionein 2A	Homo sapiens	12-31
16636651-4	2006	Here, we examined the ability of metallothionein IIa (MTIIa) to protect human lens epithelial cells against cadmium and tertiary butyl hydroperoxide (TBHP)-induced oxidative stress.	Cadmium	108-115	metallothionein 2A	Homo sapiens	33-52
16636651-4	2006	Here, we examined the ability of metallothionein IIa (MTIIa) to protect human lens epithelial cells against cadmium and tertiary butyl hydroperoxide (TBHP)-induced oxidative stress.	Cadmium	108-115	metallothionein 2A	Homo sapiens	54-59
16636651-4	2006	Here, we examined the ability of metallothionein IIa (MTIIa) to protect human lens epithelial cells against cadmium and tertiary butyl hydroperoxide (TBHP)-induced oxidative stress.	n-Butylhydroperoxide	129-148	metallothionein 2A	Homo sapiens	33-52
16636651-4	2006	Here, we examined the ability of metallothionein IIa (MTIIa) to protect human lens epithelial cells against cadmium and tertiary butyl hydroperoxide (TBHP)-induced oxidative stress.	n-Butylhydroperoxide	129-148	metallothionein 2A	Homo sapiens	54-59
16636651-4	2006	Here, we examined the ability of metallothionein IIa (MTIIa) to protect human lens epithelial cells against cadmium and tertiary butyl hydroperoxide (TBHP)-induced oxidative stress.	tert-Butylhydroperoxide	150-154	metallothionein 2A	Homo sapiens	33-52
16636651-4	2006	Here, we examined the ability of metallothionein IIa (MTIIa) to protect human lens epithelial cells against cadmium and tertiary butyl hydroperoxide (TBHP)-induced oxidative stress.	tert-Butylhydroperoxide	150-154	metallothionein 2A	Homo sapiens	54-59
16636651-8	2006	RESULTS: Analysis of the over expressing cell lines revealed an approximate 3-4 fold increase in MTIIa expression relative to control cells, resulting in as much as 20% protection against cadmium-induced oxidative stress (p&lt;0.001).	Cadmium	188-195	metallothionein 2A	Homo sapiens	97-102
16636651-9	2006	The MTIIa over expressing cells were also significantly more resistant to TBHP treatment while control cells exhibited significant shrinking and rounding-up following 3-6 h TBHP treatment, no changes were observed in TBHP-treated over expressing cells.	tert-Butylhydroperoxide	74-78	metallothionein 2A	Homo sapiens	4-9
16636651-9	2006	The MTIIa over expressing cells were also significantly more resistant to TBHP treatment while control cells exhibited significant shrinking and rounding-up following 3-6 h TBHP treatment, no changes were observed in TBHP-treated over expressing cells.	tert-Butylhydroperoxide	173-177	metallothionein 2A	Homo sapiens	4-9
16636651-9	2006	The MTIIa over expressing cells were also significantly more resistant to TBHP treatment while control cells exhibited significant shrinking and rounding-up following 3-6 h TBHP treatment, no changes were observed in TBHP-treated over expressing cells.	tert-Butylhydroperoxide	173-177	metallothionein 2A	Homo sapiens	4-9
16636651-12	2006	In addition, TBHP induced the expression of MTIIa, heme oxygenase-1, thioredoxin reductase-1, and MnSOD in both normal and MTIIa over-expressed cell lines.	tert-Butylhydroperoxide	13-17	metallothionein 2A	Homo sapiens	44-49
16636651-12	2006	In addition, TBHP induced the expression of MTIIa, heme oxygenase-1, thioredoxin reductase-1, and MnSOD in both normal and MTIIa over-expressed cell lines.	tert-Butylhydroperoxide	13-17	metallothionein 2A	Homo sapiens	123-128
16636651-13	2006	Interestingly the latter three genes were induced at 2-3 fold higher levels in TBHP-treated MTIIa over-expressing cells, compared to treated control cells (p=0.001, p=0.02, and p=0.01, respectively).	tert-Butylhydroperoxide	79-83	metallothionein 2A	Homo sapiens	92-97
16636651-14	2006	CONCLUSIONS: These data indicate that over-expression of MTIIa in human lens epithelial cells results in protection against cadmium and TBHP-induced oxidative stress.	Cadmium	124-131	metallothionein 2A	Homo sapiens	57-62
16636651-14	2006	CONCLUSIONS: These data indicate that over-expression of MTIIa in human lens epithelial cells results in protection against cadmium and TBHP-induced oxidative stress.	tert-Butylhydroperoxide	136-140	metallothionein 2A	Homo sapiens	57-62
16635021-0	2006	Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade.	Melatonin	0-9	metallothionein 2A	Homo sapiens	134-137
16635021-4	2006	Co-exposure of hAMSCs to osteogenic medium supplemented with melatonin and either pertussis toxin or the melatonin receptor antagonists, luzindole or 4P-PDOT (MT2 receptor selective), inhibited the melatonin-induced increase in ALP activity, indicating the involvement of melatonin receptors, in particular, MT2 receptors.	Melatonin	61-70	metallothionein 2A	Homo sapiens	159-162
16635021-4	2006	Co-exposure of hAMSCs to osteogenic medium supplemented with melatonin and either pertussis toxin or the melatonin receptor antagonists, luzindole or 4P-PDOT (MT2 receptor selective), inhibited the melatonin-induced increase in ALP activity, indicating the involvement of melatonin receptors, in particular, MT2 receptors.	Melatonin	61-70	metallothionein 2A	Homo sapiens	308-311
16635021-4	2006	Co-exposure of hAMSCs to osteogenic medium supplemented with melatonin and either pertussis toxin or the melatonin receptor antagonists, luzindole or 4P-PDOT (MT2 receptor selective), inhibited the melatonin-induced increase in ALP activity, indicating the involvement of melatonin receptors, in particular, MT2 receptors.	Melatonin	105-114	metallothionein 2A	Homo sapiens	159-162
16716945-0	2006	Construction of an additional metal-binding site in human metallothionein-2.	Metals	30-35	metallothionein 2A	Homo sapiens	58-75
16716945-1	2006	We have constructed a new metal-binding site in the human metallothionein-2 (hMT-2), using the protein as a scaffold to investigate the structure and function of metal-binding.	Metals	26-31	metallothionein 2A	Homo sapiens	58-75
16716945-1	2006	We have constructed a new metal-binding site in the human metallothionein-2 (hMT-2), using the protein as a scaffold to investigate the structure and function of metal-binding.	Metals	26-31	metallothionein 2A	Homo sapiens	77-82
16716945-1	2006	We have constructed a new metal-binding site in the human metallothionein-2 (hMT-2), using the protein as a scaffold to investigate the structure and function of metal-binding.	Metals	58-63	metallothionein 2A	Homo sapiens	77-82
16716945-2	2006	Potential metal-binding sites were designed within hMT-2 on the basis of structures generated by homology modeling.	Metals	10-15	metallothionein 2A	Homo sapiens	51-56
16716945-3	2006	Amino acid residues D11, C13, C26 and S28 in the beta-domain of hMT-2 (hMT-2beta) were found, by computer search, to form a potential tetrahedral Cys4 metal-binding site.	Metals	151-156	metallothionein 2A	Homo sapiens	64-69
16716945-4	2006	Six mutant proteins were constructed with the following amino acid substitutions: D11C, S28C and D11C/S28C in hMT-2 and the same mutations in hMT-2beta, respectively.	d11c	97-101	metallothionein 2A	Homo sapiens	110-115
16290939-3	2006	Shifting the methoxy group from position 5 to 2 of the 7a-azaindole ring led to a substantial reduction of MT1 binding when MT2 recognition was maintained.	7a-azaindole	55-67	metallothionein 2A	Homo sapiens	124-127
16402917-4	2006	Expression of MT2A (MT isoform 2A), but not MT1A or MT1B RNA, was significantly inducible by rotenone (up to 7-fold), t-BHP (t-butyl hydroperoxide; 5-fold) and CdCl2 (50-fold), but not ZnCl2.	Rotenone	93-101	metallothionein 2A	Homo sapiens	14-18
16402917-4	2006	Expression of MT2A (MT isoform 2A), but not MT1A or MT1B RNA, was significantly inducible by rotenone (up to 7-fold), t-BHP (t-butyl hydroperoxide; 5-fold) and CdCl2 (50-fold), but not ZnCl2.	tert-Butylhydroperoxide	118-123	metallothionein 2A	Homo sapiens	14-18
16402917-4	2006	Expression of MT2A (MT isoform 2A), but not MT1A or MT1B RNA, was significantly inducible by rotenone (up to 7-fold), t-BHP (t-butyl hydroperoxide; 5-fold) and CdCl2 (50-fold), but not ZnCl2.	tert-Butylhydroperoxide	125-146	metallothionein 2A	Homo sapiens	14-18
16402917-4	2006	Expression of MT2A (MT isoform 2A), but not MT1A or MT1B RNA, was significantly inducible by rotenone (up to 7-fold), t-BHP (t-butyl hydroperoxide; 5-fold) and CdCl2 (50-fold), but not ZnCl2.	Cadmium Chloride	160-165	metallothionein 2A	Homo sapiens	14-18
16402917-4	2006	Expression of MT2A (MT isoform 2A), but not MT1A or MT1B RNA, was significantly inducible by rotenone (up to 7-fold), t-BHP (t-butyl hydroperoxide; 5-fold) and CdCl2 (50-fold), but not ZnCl2.	zinc chloride	185-190	metallothionein 2A	Homo sapiens	14-18
16402917-5	2006	Myxothiazol treatment did not elevate either ROS or MT2A levels, which supports a ROS-related mechanism for rotenone-induced MT2A expression.	myxothiazol	0-11	metallothionein 2A	Homo sapiens	125-129
16402917-5	2006	Myxothiazol treatment did not elevate either ROS or MT2A levels, which supports a ROS-related mechanism for rotenone-induced MT2A expression.	Reactive Oxygen Species	82-85	metallothionein 2A	Homo sapiens	125-129
16402917-5	2006	Myxothiazol treatment did not elevate either ROS or MT2A levels, which supports a ROS-related mechanism for rotenone-induced MT2A expression.	Rotenone	108-116	metallothionein 2A	Homo sapiens	125-129
16402917-6	2006	To evaluate the role of MT2A expression, MT2A and MT1B were overexpressed in HeLa cells and treated with rotenone.	Rotenone	105-113	metallothionein 2A	Homo sapiens	41-45
16402917-7	2006	Compared with control and MT1B-overexpressing cells, ROS production was significantly lower and cell viability higher in MT2A-overexpressing HeLa cells when ROS production was enhanced by treatment with t-BHP.	Reactive Oxygen Species	53-56	metallothionein 2A	Homo sapiens	121-125
16402917-7	2006	Compared with control and MT1B-overexpressing cells, ROS production was significantly lower and cell viability higher in MT2A-overexpressing HeLa cells when ROS production was enhanced by treatment with t-BHP.	Reactive Oxygen Species	157-160	metallothionein 2A	Homo sapiens	121-125
16402917-7	2006	Compared with control and MT1B-overexpressing cells, ROS production was significantly lower and cell viability higher in MT2A-overexpressing HeLa cells when ROS production was enhanced by treatment with t-BHP.	tert-Butylhydroperoxide	203-208	metallothionein 2A	Homo sapiens	121-125
16508136-3	2006	We recently found that MT-1 is involved in the metabolism or detoxification of toxic metals, such as cadmium; on the other hand, MT-2 is responsible for the homeostasis of essential metals such as copper, in experimental models such as Long Evans Cinnamon (LEC) rats.	Copper	197-203	metallothionein 2A	Homo sapiens	129-133
16436935-4	2006	Binding studies performed in vitro proved that agomelatine is a high-affinity agonist at both the melatonin MT1 and MT2 receptor types.	agomelatine	47-58	metallothionein 2A	Homo sapiens	116-119
16283523-6	2005	Real-time RT-PCR confirmed the effect of copper on the levels of MT2A, HSPA1A, CYP1A1 and HMOX1 expression.	Copper	41-47	metallothionein 2A	Homo sapiens	65-69
16303211-3	2006	Aromatic amino acid substitution at the N-terminus in conjuction with the expansion of the 23-membered cyclic lactam MT-II scaffold to a 26-membered scaffold by addition of a Gly residue in position 10 leads to melanotropin peptides with enhanced receptor selectivity.	Amino Acids, Aromatic	0-19	metallothionein 2A	Homo sapiens	117-122
16303211-3	2006	Aromatic amino acid substitution at the N-terminus in conjuction with the expansion of the 23-membered cyclic lactam MT-II scaffold to a 26-membered scaffold by addition of a Gly residue in position 10 leads to melanotropin peptides with enhanced receptor selectivity.	Glycine	175-178	metallothionein 2A	Homo sapiens	117-122
16687314-2	2006	In humans, appropriate clinical trials confirm the efficacy of melatonin or melatoninergic agonists for the MT1 and MT2 receptor subtypes in circadian rhythm sleep disorders only.	Melatonin	63-72	metallothionein 2A	Homo sapiens	116-119
16687314-4	2006	Among these is a recently developed treatment concept for depression, which has been validated by the clinical efficacy of agomelatine, an agent having both MT1 and MT2 agonist and 5-HT2C antagonist activity.	agomelatine	123-134	metallothionein 2A	Homo sapiens	165-168
16687315-1	2006	In mammals, the circadian hormone melatonin targets two seven-transmembrane-spanning receptors, MT1 and MT2, of the G protein-coupled receptor (GPCR) super-family.	Melatonin	34-43	metallothionein 2A	Homo sapiens	104-107
16687315-6	2006	Formation of MT1/MT2 heterodimers remains to be shown in native tissues but is suggested by the documented co-expression of MT1 and MT2 in many melatonin-sensitive tissues, such as the hypothalamic suprachiasmatic nuclei, retina, arteries, and adipose tissue.	Melatonin	144-153	metallothionein 2A	Homo sapiens	17-20
16687315-6	2006	Formation of MT1/MT2 heterodimers remains to be shown in native tissues but is suggested by the documented co-expression of MT1 and MT2 in many melatonin-sensitive tissues, such as the hypothalamic suprachiasmatic nuclei, retina, arteries, and adipose tissue.	Melatonin	144-153	metallothionein 2A	Homo sapiens	132-135
16600086-3	2006	RESULTS: The basal MT-1A, IE, IF, IX and MT-2A expression level in workers exposed to cadmium were significantly higher than those in the control group (P &lt; 0.05).	Cadmium	86-93	metallothionein 2A	Homo sapiens	41-46
16600086-4	2006	The basal MT-1A, IE, IF, IX and MT-2A expression level would be significantly increased with the increase of the blood cadmium (BCd) level (P &lt; 0.05).	Cadmium	119-126	metallothionein 2A	Homo sapiens	32-37
16600086-4	2006	The basal MT-1A, IE, IF, IX and MT-2A expression level would be significantly increased with the increase of the blood cadmium (BCd) level (P &lt; 0.05).	bcd	128-131	metallothionein 2A	Homo sapiens	32-37
16600086-5	2006	There was a trend of increase for the mRNA expression of the basal MT-1A, 1E, IF, IX, MT-2A, especially for the mRNA expression of MT-1A and MT-2A (P &lt; 0.05) with the increase of the level of the urine cadmium (UCd).	Cadmium	205-212	metallothionein 2A	Homo sapiens	86-91
16600086-5	2006	There was a trend of increase for the mRNA expression of the basal MT-1A, 1E, IF, IX, MT-2A, especially for the mRNA expression of MT-1A and MT-2A (P &lt; 0.05) with the increase of the level of the urine cadmium (UCd).	Cadmium	205-212	metallothionein 2A	Homo sapiens	141-146
16402917-9	2006	MT2A overexpression in rotenone-treated cells also significantly reduced or delayed apoptosis induction, as measured by caspase 3/7 activity and cytosolic nucleosome enrichment.	Rotenone	23-31	metallothionein 2A	Homo sapiens	0-4
16402917-10	2006	We conclude that MT2A offers significant protection against the main death-causing consequences of rotenone-induced complex I deficiency in HeLa cells.	Rotenone	99-107	metallothionein 2A	Homo sapiens	17-21
16033772-2	2005	Treatment of the cells with sulforaphane at non-toxicity concentration (0-20 microM) resulted in coordinate increases in the induction of MT-I and MT-II mRNA, followed by corresponding increases in MT protein expression.	sulforaphane	28-40	metallothionein 2A	Homo sapiens	147-152
16087360-4	2005	The results showed that transient overexpression of human MT1A, MT2 and MT3 genes dynamically affected cell viability, and the effect was influenced by zinc and cadmium ions.	Cadmium	161-168	metallothionein 2A	Homo sapiens	64-67
16087360-7	2005	Out of the three MTs, MT1A was more efficient than MT2 and MT3 in its resistance to cadmium (10 microM), and MT3 together with zinc showed more cell growth inhibition than MT1 and MT2.	Cadmium	84-91	metallothionein 2A	Homo sapiens	51-54
15380218-1	2004	N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide 3a was synthesized as an orally bioavailable agonist at MT1 and MT2 melatonin receptors with significantly low vasoconstrictive activity.	N-(2-(2-(4-phenylbutyl)benzofuran-4-yl)cyclopropylmethyl)acetamide	0-66	metallothionein 2A	Homo sapiens	131-134
15992934-2	2005	Some of these effects are mediated by the interactions of melatonin with the two melatonin MT1 and MT2 receptors.	Melatonin	58-67	metallothionein 2A	Homo sapiens	99-102
15725085-7	2005	HO-1 exerts an anti-apoptotic effect in ischaemic cells, and MT-2A chelates ATO intracellularly.	Arsenic Trioxide	76-79	metallothionein 2A	Homo sapiens	61-66
15725085-8	2005	Inhibition of HO-1 with tin protoporphyrin enhances ROS in MM cells in ATO, and addition of N-acetylcysteine increases MT-2A.	Acetylcysteine	92-108	metallothionein 2A	Homo sapiens	119-124
16093418-5	2005	Centrally elicited stimulation of vagal and sympathetic pathways induces release of melatonin, which acts at MT2 receptors to increase mucosal electrolyte secretion.	Melatonin	84-93	metallothionein 2A	Homo sapiens	109-112
15913560-1	2005	To better understand the mechanism of interactions between G-protein-coupled melatonin receptors and their ligands, our previously reported homology model of human MT2 receptor with docked 2-iodomelatonin was further refined and used to select residues within TM3, TM6, and TM7 potentially important for receptor-ligand interactions.	2-iodomelatonin	189-204	metallothionein 2A	Homo sapiens	164-167
15913560-3	2005	Our data demonstrate that residues N268 and A275 in TM6 as well as residues V291 and L295 in TM7 are essential for 2-iodomelatonin binding to the hMT2 receptor, while TM3 residues M120, G121, V124, and I125 may participate in binding of other receptor agonists and/or antagonists.	2-iodomelatonin	115-130	metallothionein 2A	Homo sapiens	146-150
16217123-4	2005	Activation of MT2 melatonin receptors phase shift circadian rhythms of neuronal firing in the suprachiasmatic nucleus, inhibit dopamine release in retina, induce vasodilation and inhibition of leukocyte rolling in arterial beds, and enhance immune responses.	Dopamine	127-135	metallothionein 2A	Homo sapiens	14-17
16217123-5	2005	The melatonin-mediated responses elicited by activation of MT1 and MT2 native melatonin receptors are dependent on circadian time, duration and mode of exposure to endogenous or exogenous melatonin, and functional receptor sensitivity.	Melatonin	4-13	metallothionein 2A	Homo sapiens	67-70
16217123-5	2005	The melatonin-mediated responses elicited by activation of MT1 and MT2 native melatonin receptors are dependent on circadian time, duration and mode of exposure to endogenous or exogenous melatonin, and functional receptor sensitivity.	Melatonin	78-87	metallothionein 2A	Homo sapiens	67-70
15962362-3	2005	An inducible MT-II regulatory system was constructed, which allowed controlled expression of protein upon addition of ZnSO4 (100 micromol/L) as an external inducer.	Zinc Sulfate	118-123	metallothionein 2A	Homo sapiens	13-18
15952241-1	2005	Melatonin is a hormone exerting its multiple actions mainly through two G-protein-coupled receptors MT(1) and MT(2).	Melatonin	0-9	metallothionein 2A	Homo sapiens	110-115
15882436-4	2005	In addition, anti-oxidants such as hydroxyl-radical excluders and capturers of superoxide and inhibitors of superoxide production effectively reduced the size of the apoptotic fraction in MT-2 cells cultured with chrysotile-A.	Hydroxyl Radical	35-51	metallothionein 2A	Homo sapiens	188-192
15882436-4	2005	In addition, anti-oxidants such as hydroxyl-radical excluders and capturers of superoxide and inhibitors of superoxide production effectively reduced the size of the apoptotic fraction in MT-2 cells cultured with chrysotile-A.	Superoxides	79-89	metallothionein 2A	Homo sapiens	188-192
15882436-4	2005	In addition, anti-oxidants such as hydroxyl-radical excluders and capturers of superoxide and inhibitors of superoxide production effectively reduced the size of the apoptotic fraction in MT-2 cells cultured with chrysotile-A.	Superoxides	108-118	metallothionein 2A	Homo sapiens	188-192
15698955-5	2005	Titration with Cd2+ ions demonstrates that metal-binding affinities of individual clusters of MT-2 and MT-3 are decreasing in the following order: four-metal cluster of MT-2>three-metal cluster of MT-2 approximately four-metal cluster of MT-3>three-metal cluster of MT-3>extra metal-binding sites of MT-3.	Metals	43-48	metallothionein 2A	Homo sapiens	94-98
15698955-5	2005	Titration with Cd2+ ions demonstrates that metal-binding affinities of individual clusters of MT-2 and MT-3 are decreasing in the following order: four-metal cluster of MT-2>three-metal cluster of MT-2 approximately four-metal cluster of MT-3>three-metal cluster of MT-3>extra metal-binding sites of MT-3.	Metals	43-48	metallothionein 2A	Homo sapiens	169-173
15698955-5	2005	Titration with Cd2+ ions demonstrates that metal-binding affinities of individual clusters of MT-2 and MT-3 are decreasing in the following order: four-metal cluster of MT-2>three-metal cluster of MT-2 approximately four-metal cluster of MT-3>three-metal cluster of MT-3>extra metal-binding sites of MT-3.	Metals	43-48	metallothionein 2A	Homo sapiens	169-173
15698955-5	2005	Titration with Cd2+ ions demonstrates that metal-binding affinities of individual clusters of MT-2 and MT-3 are decreasing in the following order: four-metal cluster of MT-2>three-metal cluster of MT-2 approximately four-metal cluster of MT-3>three-metal cluster of MT-3>extra metal-binding sites of MT-3.	Metals	152-157	metallothionein 2A	Homo sapiens	94-98
15698955-5	2005	Titration with Cd2+ ions demonstrates that metal-binding affinities of individual clusters of MT-2 and MT-3 are decreasing in the following order: four-metal cluster of MT-2>three-metal cluster of MT-2 approximately four-metal cluster of MT-3>three-metal cluster of MT-3>extra metal-binding sites of MT-3.	Metals	152-157	metallothionein 2A	Homo sapiens	169-173
15698955-5	2005	Titration with Cd2+ ions demonstrates that metal-binding affinities of individual clusters of MT-2 and MT-3 are decreasing in the following order: four-metal cluster of MT-2>three-metal cluster of MT-2 approximately four-metal cluster of MT-3>three-metal cluster of MT-3>extra metal-binding sites of MT-3.	Metals	152-157	metallothionein 2A	Homo sapiens	169-173
15617532-7	2005	The results indicate that MT2 may be involved in mediating the effects of melatonin in the human hippocampus, and this mechanism may be heavily impaired in AD.	Melatonin	74-83	metallothionein 2A	Homo sapiens	26-29
15809517-2	2005	The goal of this study was to assess the effect of 17beta-estradiol (10 nM) exposure for 1 (E1) or 6 (E6) days on density and function of hMT1 and hMT2 melatonin receptors expressed in Chinese hamster ovary (CHO) cells (CHO-MT1/CHO-MT2 cells).	Estradiol	51-67	metallothionein 2A	Homo sapiens	147-151
15583813-5	2005	Functional studies of the MT-2A isoform by down-regulating expression of this gene with MT-2A antisense oligonucleotide in CNE2 cells, showed a reduction in cell viability and proliferation.	Oligonucleotides	104-119	metallothionein 2A	Homo sapiens	26-31
15583813-5	2005	Functional studies of the MT-2A isoform by down-regulating expression of this gene with MT-2A antisense oligonucleotide in CNE2 cells, showed a reduction in cell viability and proliferation.	Oligonucleotides	104-119	metallothionein 2A	Homo sapiens	88-93
15501061-0	2004	Tetrahydroisoquinoline derivatives as melatonin MT2 receptor antagonists.	1,2,3,4-tetrahydroisoquinoline	0-22	metallothionein 2A	Homo sapiens	48-51
15522910-1	2004	The hormone melatonin phase shifts circadian rhythms generated by the mammalian biological clock, the suprachiasmatic nucleus (SCN) of the hypothalamus, through activation of G protein-coupled MT2 melatonin receptors.	Melatonin	12-21	metallothionein 2A	Homo sapiens	193-196
15522910-2	2004	This study demonstrated that pretreatment with physiological concentrations of melatonin (30-300 pM or 7-70 pg/mL) decreased the number of hMT2 melatonin receptors heterologously expressed in mammalian cells in a time and concentration-dependent manner.	Melatonin	79-88	metallothionein 2A	Homo sapiens	139-143
15522910-3	2004	Furthermore, hMT2-GFP melatonin receptors heterologously expressed in immortalized SCN2.2 cells or in non-neuronal mammalian cells were internalized upon pretreatment with both physiological (300 pM or 70 pg/mL) and supraphysiological (10 nM or 2.3 ng/mL) concentrations of melatonin.	Melatonin	22-31	metallothionein 2A	Homo sapiens	13-17
15522910-4	2004	The decrease in MT2 melatonin receptor number induced by melatonin (300 pM for 1 h) was reversible and reached almost full recovery after 8 h; however, after treatment with 10 nM melatonin full recovery was not attained even after 24 h. This recovery process was partially protein synthesis dependent.	Melatonin	20-29	metallothionein 2A	Homo sapiens	16-19
15522910-4	2004	The decrease in MT2 melatonin receptor number induced by melatonin (300 pM for 1 h) was reversible and reached almost full recovery after 8 h; however, after treatment with 10 nM melatonin full recovery was not attained even after 24 h. This recovery process was partially protein synthesis dependent.	Melatonin	57-66	metallothionein 2A	Homo sapiens	16-19
15522910-6	2004	We conclude that in vivo the nightly secretion of melatonin desensitizes endogenous MT2 melatonin receptors in the mammalian SCN thereby providing a temporally integrated profile of sensitivity of the mammalian biological clock to a melatonin signal.	Melatonin	50-59	metallothionein 2A	Homo sapiens	84-87
15522910-6	2004	We conclude that in vivo the nightly secretion of melatonin desensitizes endogenous MT2 melatonin receptors in the mammalian SCN thereby providing a temporally integrated profile of sensitivity of the mammalian biological clock to a melatonin signal.	Melatonin	88-97	metallothionein 2A	Homo sapiens	84-87
15525337-2	2004	Modeling has been combined with site-directed mutagenesis to investigate the role of the specific amino acid residues within the transmembrane domains (TM) numbers V, VI and VII of hMT2 receptor in the interaction with 2-iodomelatonin.	2-iodomelatonin	219-234	metallothionein 2A	Homo sapiens	181-185
15525337-5	2004	In the case of TM VI, the substitution G271T caused substantial decrease in 2-iodomelatonin binding to the hMT2 receptor.	2-iodomelatonin	76-91	metallothionein 2A	Homo sapiens	107-111
15178055-1	2004	Coupled HPLC-ICP-MS has been used to quantitatively study the effects of GSSG and GSH on the ability of metallothionein (MTII) to donate essential and non-essential metals to apo-carbonic anhydrase.	Glutathione Disulfide	73-77	metallothionein 2A	Homo sapiens	121-125
15293992-4	2004	Binding affinity at human cloned MT1 and MT2 receptors was measured by 2-[125I]iodomelatonin displacement assay and intrinsic activity by the GTPgammaS test.	2-(125I)Iodomelatonin	71-92	metallothionein 2A	Homo sapiens	41-44
15293992-7	2004	N-(8-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide (4c) and -butyramide (4d) were the most selective MT2 receptor antagonists of the series, with MT2 receptor affinity comparable to that of melatonin and as such among the highest reported in the literature for MLT receptor antagonists.	n-(8-methoxy-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide	0-78	metallothionein 2A	Homo sapiens	129-132
15293992-7	2004	N-(8-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide (4c) and -butyramide (4d) were the most selective MT2 receptor antagonists of the series, with MT2 receptor affinity comparable to that of melatonin and as such among the highest reported in the literature for MLT receptor antagonists.	n-(8-methoxy-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide	0-78	metallothionein 2A	Homo sapiens	174-177
15293992-7	2004	N-(8-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide (4c) and -butyramide (4d) were the most selective MT2 receptor antagonists of the series, with MT2 receptor affinity comparable to that of melatonin and as such among the highest reported in the literature for MLT receptor antagonists.	butyramide	89-99	metallothionein 2A	Homo sapiens	129-132
15293992-7	2004	N-(8-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-ylmethyl)propionamide (4c) and -butyramide (4d) were the most selective MT2 receptor antagonists of the series, with MT2 receptor affinity comparable to that of melatonin and as such among the highest reported in the literature for MLT receptor antagonists.	butyramide	89-99	metallothionein 2A	Homo sapiens	174-177
15293992-8	2004	The acetamide derivative 4b produced a noticeable reduction of GTPgammaS binding at MT2 receptor, thus being among the few inverse agonists described.	acetamide	4-13	metallothionein 2A	Homo sapiens	84-87
15178055-0	2004	Metal donation and apo-metalloenzyme activation by stable isotopically labeled metallothionein.	Metals	0-5	metallothionein 2A	Homo sapiens	79-94
15178055-1	2004	Coupled HPLC-ICP-MS has been used to quantitatively study the effects of GSSG and GSH on the ability of metallothionein (MTII) to donate essential and non-essential metals to apo-carbonic anhydrase.	Glutathione Disulfide	73-77	metallothionein 2A	Homo sapiens	104-119
15203165-2	2004	The binding affinity of these compounds for human MT(1) and MT(2) receptors was determined using 2-[(125)I]-iodomelatonin as the radioligand.	]-iodomelatonin	106-121	metallothionein 2A	Homo sapiens	60-65
15177448-1	2004	Considering the recent challenge to the medicinal chemists for the development of selective melatonin receptor ligands, an attempt has been made to explore physicochemical requirements of benzofuran derivatives for binding with human MT1 and MT2 receptor subtypes and also to explore selectivity requirements.	benzofuran	188-198	metallothionein 2A	Homo sapiens	242-245
15178055-1	2004	Coupled HPLC-ICP-MS has been used to quantitatively study the effects of GSSG and GSH on the ability of metallothionein (MTII) to donate essential and non-essential metals to apo-carbonic anhydrase.	Glutathione Disulfide	82-85	metallothionein 2A	Homo sapiens	104-119
15178055-1	2004	Coupled HPLC-ICP-MS has been used to quantitatively study the effects of GSSG and GSH on the ability of metallothionein (MTII) to donate essential and non-essential metals to apo-carbonic anhydrase.	Glutathione Disulfide	82-85	metallothionein 2A	Homo sapiens	121-125
15178055-2	2004	Stable isotopically labeled (67)Zn(3)Cd(4) MTII was used to enable Zn donated from MTII to be differentiated from extraneous sources of Zn.	zn(3)cd	32-39	metallothionein 2A	Homo sapiens	43-47
15178055-2	2004	Stable isotopically labeled (67)Zn(3)Cd(4) MTII was used to enable Zn donated from MTII to be differentiated from extraneous sources of Zn.	zn(3)cd	32-39	metallothionein 2A	Homo sapiens	83-87
15178055-2	2004	Stable isotopically labeled (67)Zn(3)Cd(4) MTII was used to enable Zn donated from MTII to be differentiated from extraneous sources of Zn.	Zinc	32-34	metallothionein 2A	Homo sapiens	83-87
15178055-2	2004	Stable isotopically labeled (67)Zn(3)Cd(4) MTII was used to enable Zn donated from MTII to be differentiated from extraneous sources of Zn.	Zinc	67-69	metallothionein 2A	Homo sapiens	43-47
15178055-2	2004	Stable isotopically labeled (67)Zn(3)Cd(4) MTII was used to enable Zn donated from MTII to be differentiated from extraneous sources of Zn.	Zinc	67-69	metallothionein 2A	Homo sapiens	83-87
15178055-3	2004	Transfer of both (67)Zn and Cd from MTII to apo-carbonic anhydrase was noted in the absence of either GSSG or GSH.	Zinc	21-23	metallothionein 2A	Homo sapiens	36-40
15178055-3	2004	Transfer of both (67)Zn and Cd from MTII to apo-carbonic anhydrase was noted in the absence of either GSSG or GSH.	Cadmium	28-30	metallothionein 2A	Homo sapiens	36-40
15178055-5	2004	Thereafter, a gradual increase in the (67)Zn content at the expense of Cd was noted over 24-h indicating continued interaction and exchange between MTII and the enzyme commensurate with the relative preferences shown by the proteins for these two metals.	Zinc	42-44	metallothionein 2A	Homo sapiens	148-152
14700558-2	2004	All sulfur analogues show a decreased binding affinity at human MT1 and MT2 receptors and a reduced potency as melatonin agonists on the Xenopus melanophore assay.	Sulfur	4-10	metallothionein 2A	Homo sapiens	72-75
14980664-2	2004	The binding affinity of these compounds for human MT(1) and MT(2) receptors was determined using 2-[(125)I]-iodomelatonin as the radioligand.	]-iodomelatonin	106-121	metallothionein 2A	Homo sapiens	60-65
14966866-6	2004	With MT overexpression, we observed an acute buffering effect manifested as a dampening of stimulus-induced increases in [Zn2+]i.	Zinc	122-126	metallothionein 2A	Homo sapiens	5-7
15013015-0	2004	4-Substituted anilides as selective melatonin MT2 receptor agonists.	4-substituted anilides	0-22	metallothionein 2A	Homo sapiens	46-49
14604781-7	2003	Moreover, MT-II treatment significantly increases survival of dopaminergic neurons exposed to 6-hydroxydopamine (6-OHDA) and protects significantly hippocampal neurons from amyloid beta-peptide-induced neurotoxicity.	Oxidopamine	113-119	metallothionein 2A	Homo sapiens	10-15
14964369-1	2004	As part of a project studying the interactions between farming practices, soil erosion processes, and fate of agricultural pollutants into runoff waters, we conducted a pilot study to investigate the relationship between metal contents and metallothionein-2A (MT-2A) as a bioindicator of metal exposure.	Metals	221-226	metallothionein 2A	Homo sapiens	240-258
14964369-1	2004	As part of a project studying the interactions between farming practices, soil erosion processes, and fate of agricultural pollutants into runoff waters, we conducted a pilot study to investigate the relationship between metal contents and metallothionein-2A (MT-2A) as a bioindicator of metal exposure.	Metals	221-226	metallothionein 2A	Homo sapiens	260-265
14964369-1	2004	As part of a project studying the interactions between farming practices, soil erosion processes, and fate of agricultural pollutants into runoff waters, we conducted a pilot study to investigate the relationship between metal contents and metallothionein-2A (MT-2A) as a bioindicator of metal exposure.	Metals	240-245	metallothionein 2A	Homo sapiens	260-265
14964369-9	2004	Although still preliminary, in the absence of longer monitoring, this study shows that MT-2A gene expression is a useful tool to complement chemical analysis in assessing metal elements in water.	Metals	171-176	metallothionein 2A	Homo sapiens	87-92
14964369-9	2004	Although still preliminary, in the absence of longer monitoring, this study shows that MT-2A gene expression is a useful tool to complement chemical analysis in assessing metal elements in water.	Water	189-194	metallothionein 2A	Homo sapiens	87-92
14604781-7	2003	Moreover, MT-II treatment significantly increases survival of dopaminergic neurons exposed to 6-hydroxydopamine (6-OHDA) and protects significantly hippocampal neurons from amyloid beta-peptide-induced neurotoxicity.	Oxidopamine	94-111	metallothionein 2A	Homo sapiens	10-15
14555400-7	2003	It was shown that acute exposure to either As(3+) or Cd(2+) increased the levels of mRNAs for the MT-1E, MT-1X, and MT-2A genes, whereas extended exposure only increased these mRNAs following exposure to Cd(2+).	Arsenic(3+) ion	43-49	metallothionein 2A	Homo sapiens	116-121
14555400-7	2003	It was shown that acute exposure to either As(3+) or Cd(2+) increased the levels of mRNAs for the MT-1E, MT-1X, and MT-2A genes, whereas extended exposure only increased these mRNAs following exposure to Cd(2+).	Cadmium	53-55	metallothionein 2A	Homo sapiens	116-121
14521627-0	2003	Melatonin prevents apoptosis and enhances HSP27 mRNA expression induced by heat shock in HL-60 cells: possible involvement of the MT2 receptor.	Melatonin	0-9	metallothionein 2A	Homo sapiens	130-133
14521627-3	2003	This effect of melatonin is saturable at nanomolar concentrations and appears to be mediated by the MT2 subtype melatonin receptor.	Melatonin	15-24	metallothionein 2A	Homo sapiens	100-103
14521627-4	2003	The high affinity melatonin receptor agonist, 2-iodomelatonin, reproduced the melatonin effect while it was fully blocked by the selective MT2 antagonist 4-phenyl-2-propionamidotetraline.	2-iodomelatonin	46-61	metallothionein 2A	Homo sapiens	139-142
14521627-4	2003	The high affinity melatonin receptor agonist, 2-iodomelatonin, reproduced the melatonin effect while it was fully blocked by the selective MT2 antagonist 4-phenyl-2-propionamidotetraline.	Melatonin	18-27	metallothionein 2A	Homo sapiens	139-142
14521627-4	2003	The high affinity melatonin receptor agonist, 2-iodomelatonin, reproduced the melatonin effect while it was fully blocked by the selective MT2 antagonist 4-phenyl-2-propionamidotetraline.	4-phenyl-2-propionamidotetraline	154-186	metallothionein 2A	Homo sapiens	139-142
14521627-5	2003	The melatonin response to heat shock-induced apoptosis was pertussis toxin sensitive and, interestingly, the non-selective MT1/MT2 melatonin receptor ligand luzindole was found to display agonistic activity.	Melatonin	4-13	metallothionein 2A	Homo sapiens	127-130
14521627-5	2003	The melatonin response to heat shock-induced apoptosis was pertussis toxin sensitive and, interestingly, the non-selective MT1/MT2 melatonin receptor ligand luzindole was found to display agonistic activity.	luzindole	157-166	metallothionein 2A	Homo sapiens	127-130
14550308-6	2003	Because metallothioneins are associated with cell proliferation and CR, the PKCmu-MT 2A interaction may contribute to CR and/or AI in PC.	Chromium	118-120	metallothionein 2A	Homo sapiens	82-87
15009533-0	2004	Biological and conformational study of beta-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity.	beta-substituted prolines	39-64	metallothionein 2A	Homo sapiens	68-73
15127941-0	2003	Chimeric NDP-MSH and MTII melanocortin peptides with agouti-related protein (AGRP) Arg-Phe-Phe amino acids possess agonist melanocortin receptor activity.	arg-phe-phe amino acids	83-106	metallothionein 2A	Homo sapiens	21-25
12957828-5	2003	We also review melatonin-mediated responses through activation of melatonin receptors (MT1, MT2, and MT3) highlighting their involvement in modulation of CNS, hypothalamic-hypophyseal-gonadal axis, cardiovascular, and immune functions.	Melatonin	15-24	metallothionein 2A	Homo sapiens	92-95
12957828-7	2003	Activation of the MT2 melatonin receptor phase shifts circadian rhythms generated within the SCN, inhibits dopamine release in the retina, induces vasodilation, enhances splenocyte proliferation and inhibits leukocyte rolling in the microvasculature.	Dopamine	107-115	metallothionein 2A	Homo sapiens	18-21
12764576-2	2003	Melatonin exerts its multiple roles mainly through two seven transmembrane domain, G-coupled receptors, namely MT1 or MT2 receptors.	Melatonin	0-9	metallothionein 2A	Homo sapiens	118-121
14531843-0	2003	Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5.	Lactams	40-46	metallothionein 2A	Homo sapiens	62-67
12823612-3	2003	Additionally, MT2 expression in human ventricular specimens was analysed, as melatonin was shown to affect myocyte function.	Melatonin	77-86	metallothionein 2A	Homo sapiens	14-17
12858341-6	2003	These effects were reversed by overexpression of metallothionein IIa, a gene highly responsive to cadmium and other metals.	Cadmium	98-105	metallothionein 2A	Homo sapiens	49-68
12716893-1	2003	The robust induction of metallothionein-I and II (MT-I and MT-II) genes by several heavy metals such as zinc and cadmium requires the specific transcription factor metal-responsive transcription factor 1 (MTF1).	Cadmium	113-120	metallothionein 2A	Homo sapiens	24-48
12764576-3	2003	A pharmacological characterization of these human cloned melatonin hMT1 and hMT2 receptors stably expressed in HEK-293 or CHO cells is presented using a 2-[125I]-iodo-melatonin binding assay and a [35S]-GTPgammaS functional assay.	CAV protocol	122-125	metallothionein 2A	Homo sapiens	76-80
12764576-3	2003	A pharmacological characterization of these human cloned melatonin hMT1 and hMT2 receptors stably expressed in HEK-293 or CHO cells is presented using a 2-[125I]-iodo-melatonin binding assay and a [35S]-GTPgammaS functional assay.	Melatonin	57-66	metallothionein 2A	Homo sapiens	76-80
12764576-3	2003	A pharmacological characterization of these human cloned melatonin hMT1 and hMT2 receptors stably expressed in HEK-293 or CHO cells is presented using a 2-[125I]-iodo-melatonin binding assay and a [35S]-GTPgammaS functional assay.	Sulfur-35	198-201	metallothionein 2A	Homo sapiens	76-80
12519889-8	2003	However, cortisol production stimulated by 100 nM ACTH was significantly inhibited by low melatonin concentrations (0.1-100 nM); this inhibitory effect was reversed by the mt1/MT2 melatonin antagonist luzindole.	Hydrocortisone	9-17	metallothionein 2A	Homo sapiens	176-179
12622835-4	2003	Both the MT1 and MT2 melatonin receptors are present in the retina and retinal melatonin does not contribute to circulating levels, suggesting that retinal melatonin acts locally as a neurohormone and/or neuromodulator.	Melatonin	21-30	metallothionein 2A	Homo sapiens	17-20
12614479-8	2003	Reduction in cell death was significant following treatment with melatonin at 10(-3), 10(-4), or 10(-5) m. Reverse transcription-polymerase chain reaction showed that human mt1 and MT2 membrane receptors were not expressed in the cultured neuronal cells.	Melatonin	65-74	metallothionein 2A	Homo sapiens	181-184
12604667-0	2003	Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 melatonin receptors.	Melatonin	23-32	metallothionein 2A	Homo sapiens	115-119
12566070-7	2003	Preincubation overnight with 150 microM zinc sulfate or 5 microM cadmium chloride induced a 20- to 30-fold increase of MT2A mRNA; high levels of MT2A mRNA were maintained during the subsequent challenge period with AA, even after the zinc was removed.	Zinc Sulfate	40-52	metallothionein 2A	Homo sapiens	119-123
12566070-7	2003	Preincubation overnight with 150 microM zinc sulfate or 5 microM cadmium chloride induced a 20- to 30-fold increase of MT2A mRNA; high levels of MT2A mRNA were maintained during the subsequent challenge period with AA, even after the zinc was removed.	Zinc Sulfate	40-52	metallothionein 2A	Homo sapiens	145-149
12566070-7	2003	Preincubation overnight with 150 microM zinc sulfate or 5 microM cadmium chloride induced a 20- to 30-fold increase of MT2A mRNA; high levels of MT2A mRNA were maintained during the subsequent challenge period with AA, even after the zinc was removed.	Cadmium Chloride	65-81	metallothionein 2A	Homo sapiens	119-123
12556398-9	2003	Cd(2+) and Zn(2+) induced metallothionein IIa to five times higher levels than metallothionein Ig.	Cadmium	0-2	metallothionein 2A	Homo sapiens	26-45
12556398-9	2003	Cd(2+) and Zn(2+) induced metallothionein IIa to five times higher levels than metallothionein Ig.	Zinc	11-13	metallothionein 2A	Homo sapiens	26-45
12943203-2	2003	These new melatonin analogues were evaluated on human receptors MT1 and MT2 and have a similar affinity to that of melatonin itself.	Melatonin	10-19	metallothionein 2A	Homo sapiens	72-75
12538005-0	2003	Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands.	3-phenyl tetrahydronaphthalenic	24-55	metallothionein 2A	Homo sapiens	85-88
12519889-8	2003	However, cortisol production stimulated by 100 nM ACTH was significantly inhibited by low melatonin concentrations (0.1-100 nM); this inhibitory effect was reversed by the mt1/MT2 melatonin antagonist luzindole.	Melatonin	90-99	metallothionein 2A	Homo sapiens	176-179
12519889-8	2003	However, cortisol production stimulated by 100 nM ACTH was significantly inhibited by low melatonin concentrations (0.1-100 nM); this inhibitory effect was reversed by the mt1/MT2 melatonin antagonist luzindole.	Melatonin	180-189	metallothionein 2A	Homo sapiens	176-179
12519889-8	2003	However, cortisol production stimulated by 100 nM ACTH was significantly inhibited by low melatonin concentrations (0.1-100 nM); this inhibitory effect was reversed by the mt1/MT2 melatonin antagonist luzindole.	luzindole	201-210	metallothionein 2A	Homo sapiens	176-179
12173077-2	2002	The mRNA for MT-2A, a major metallothionein isoform in humans, was detected in subcutaneous fat using a specific antisense oligonucleotide probe.	Oligonucleotides	123-138	metallothionein 2A	Homo sapiens	13-18
12153718-0	2002	Interactions of arsenic with human metallothionein-2.	Arsenic	16-23	metallothionein 2A	Homo sapiens	35-52
12153718-3	2002	MALDI-TOF-MS revealed that the structure of the adduct formed by arsenic and hMT-2 (As-hMT-2) was not homogeneous.	Arsenic	65-72	metallothionein 2A	Homo sapiens	87-92
12153718-4	2002	The maximum molar ratio of arsenic to hMT-2 was found to be more than 6:1 on ICP-AES, UV absorption spectroscopy and MALDI-TOF-MS.	Arsenic	27-34	metallothionein 2A	Homo sapiens	38-43
12153718-5	2002	The ratio of the number of sulfhydryl groups in hMT-2 that bound arsenic was 3:1, which is the same as the ratios reported previously for arsenic-glutathione and arsenic-phytochelatin complexes.	Arsenic	65-72	metallothionein 2A	Homo sapiens	48-53
12153718-5	2002	The ratio of the number of sulfhydryl groups in hMT-2 that bound arsenic was 3:1, which is the same as the ratios reported previously for arsenic-glutathione and arsenic-phytochelatin complexes.	Arsenic	138-145	metallothionein 2A	Homo sapiens	48-53
12153718-5	2002	The ratio of the number of sulfhydryl groups in hMT-2 that bound arsenic was 3:1, which is the same as the ratios reported previously for arsenic-glutathione and arsenic-phytochelatin complexes.	Glutathione	146-157	metallothionein 2A	Homo sapiens	48-53
12153718-5	2002	The ratio of the number of sulfhydryl groups in hMT-2 that bound arsenic was 3:1, which is the same as the ratios reported previously for arsenic-glutathione and arsenic-phytochelatin complexes.	Arsenic	138-145	metallothionein 2A	Homo sapiens	48-53
12385685-4	2002	AZT-Val, AZT-Leu, AZT-iLeu, AZT-Phen, AZT-Ac and AZT-Iso have shown a similar or higher selectivity index than that of AZT itself, in one or both of the different cell cultures used (PBMC and MT2).	AZT-Val	0-7	metallothionein 2A	Homo sapiens	192-195
12385685-4	2002	AZT-Val, AZT-Leu, AZT-iLeu, AZT-Phen, AZT-Ac and AZT-Iso have shown a similar or higher selectivity index than that of AZT itself, in one or both of the different cell cultures used (PBMC and MT2).	3'-azido-3'-deoxy-5'-O-isonicotinoylthymidine	49-56	metallothionein 2A	Homo sapiens	192-195
12385685-4	2002	AZT-Val, AZT-Leu, AZT-iLeu, AZT-Phen, AZT-Ac and AZT-Iso have shown a similar or higher selectivity index than that of AZT itself, in one or both of the different cell cultures used (PBMC and MT2).	Zidovudine	0-3	metallothionein 2A	Homo sapiens	192-195
11888668-2	2002	The mt1 receptor, but not the MT2 receptor, is expressed in human breast tumor cell lines, and melatonin-induced growth suppression can be mimicked by the mt1 and MT2 agonist, AMMTC, and blocked by the antagonist, CBPT.	Melatonin	95-104	metallothionein 2A	Homo sapiens	163-166
12042074-2	2002	Hexamethylene-bisacetamide (HMBA), which induces differentiation and activates protein kinase C (PKC), synergistically augments the induction of both MT-I and MT-II mRNAs in response to heme-hemopexin, but attenuates the induction of HO-1.	hexamethylene bisacetamide	0-26	metallothionein 2A	Homo sapiens	159-164
12042074-2	2002	Hexamethylene-bisacetamide (HMBA), which induces differentiation and activates protein kinase C (PKC), synergistically augments the induction of both MT-I and MT-II mRNAs in response to heme-hemopexin, but attenuates the induction of HO-1.	hexamethylene bisacetamide	28-32	metallothionein 2A	Homo sapiens	159-164
12042074-2	2002	Hexamethylene-bisacetamide (HMBA), which induces differentiation and activates protein kinase C (PKC), synergistically augments the induction of both MT-I and MT-II mRNAs in response to heme-hemopexin, but attenuates the induction of HO-1.	Heme	186-190	metallothionein 2A	Homo sapiens	159-164
11814364-1	2002	We have previously established that ATP binds to mammalian metallothionein-2 (MT).	Adenosine Triphosphate	36-39	metallothionein 2A	Homo sapiens	59-76
12541977-3	2002	After a series of optimization, the separation and determination of MT1 and MT2 were obtained within 10 min by using the phosphate buffer system consisting of 0.02 mol/L Na2HPO4 and 0.02 mol/L NaH2PO4 (pH 7.0), and UV detection at 200 nm.	Phosphates	121-130	metallothionein 2A	Homo sapiens	76-79
12541977-3	2002	After a series of optimization, the separation and determination of MT1 and MT2 were obtained within 10 min by using the phosphate buffer system consisting of 0.02 mol/L Na2HPO4 and 0.02 mol/L NaH2PO4 (pH 7.0), and UV detection at 200 nm.	sodium phosphate	170-177	metallothionein 2A	Homo sapiens	76-79
12541977-3	2002	After a series of optimization, the separation and determination of MT1 and MT2 were obtained within 10 min by using the phosphate buffer system consisting of 0.02 mol/L Na2HPO4 and 0.02 mol/L NaH2PO4 (pH 7.0), and UV detection at 200 nm.	sodium phosphate	193-200	metallothionein 2A	Homo sapiens	76-79
11814364-1	2002	We have previously established that ATP binds to mammalian metallothionein-2 (MT).	Adenosine Triphosphate	36-39	metallothionein 2A	Homo sapiens	78-80
11814364-2	2002	The interaction between ATP and MT and the associated conformational change of the protein affect the sulfhydryl reactivity and zinc transfer potential of MT [Jiang, L.-J., Maret, W., and Vallee, B. L. (1998) The ATP-metallothionein complex.	Adenosine Triphosphate	24-27	metallothionein 2A	Homo sapiens	32-34
11814364-2	2002	The interaction between ATP and MT and the associated conformational change of the protein affect the sulfhydryl reactivity and zinc transfer potential of MT [Jiang, L.-J., Maret, W., and Vallee, B. L. (1998) The ATP-metallothionein complex.	Adenosine Triphosphate	24-27	metallothionein 2A	Homo sapiens	155-157
11814364-2	2002	The interaction between ATP and MT and the associated conformational change of the protein affect the sulfhydryl reactivity and zinc transfer potential of MT [Jiang, L.-J., Maret, W., and Vallee, B. L. (1998) The ATP-metallothionein complex.	Adenosine Triphosphate	213-216	metallothionein 2A	Homo sapiens	32-34
11814364-2	2002	The interaction between ATP and MT and the associated conformational change of the protein affect the sulfhydryl reactivity and zinc transfer potential of MT [Jiang, L.-J., Maret, W., and Vallee, B. L. (1998) The ATP-metallothionein complex.	Adenosine Triphosphate	213-216	metallothionein 2A	Homo sapiens	155-157
11814364-9	2002	(35)Cl NMR spectroscopy has further identified chloride as an additional biological MT ligand, which can interfere with the interaction of ATP with MT.	Chlorides	47-55	metallothionein 2A	Homo sapiens	84-86
11814364-9	2002	(35)Cl NMR spectroscopy has further identified chloride as an additional biological MT ligand, which can interfere with the interaction of ATP with MT.	Chlorides	47-55	metallothionein 2A	Homo sapiens	148-150
11814364-9	2002	(35)Cl NMR spectroscopy has further identified chloride as an additional biological MT ligand, which can interfere with the interaction of ATP with MT.	Adenosine Triphosphate	139-142	metallothionein 2A	Homo sapiens	84-86
11814364-9	2002	(35)Cl NMR spectroscopy has further identified chloride as an additional biological MT ligand, which can interfere with the interaction of ATP with MT.	Adenosine Triphosphate	139-142	metallothionein 2A	Homo sapiens	148-150
11814364-10	2002	(1)H NMR/TOCSY spectra demonstrate that ATP binding affects the N- and C-terminal amino acids of the MT molecule.	Adenosine Triphosphate	40-43	metallothionein 2A	Homo sapiens	101-103
11814364-12	2002	Moreover, this technique demonstrates that the otherwise nearly linear MT molecule bends by about 20 degrees at its central hinge region between the domains in the presence of ATP.	Adenosine Triphosphate	176-179	metallothionein 2A	Homo sapiens	71-73
11814364-14	2002	The interaction suggests a mechanism for the cellular translocation, retention, and reactivity of the ATP*MT complex in the mitochondrial intermembrane space.	Adenosine Triphosphate	102-105	metallothionein 2A	Homo sapiens	106-108
11502567-5	2001	Exposure of human umbilical vein endothelial cells (HUVEC) to increasing concentrations of glucose resulted in a rapid dose-dependent increase in MT-2 and ET-1 mRNA expression.	Glucose	91-98	metallothionein 2A	Homo sapiens	146-159
12187490-7	2002	Expression of MT I and MT II mRNA was increased by both phagocytosis and hydrogen peroxide, however MT III was not induced by either stress.	Hydrogen Peroxide	73-90	metallothionein 2A	Homo sapiens	23-28
11693492-2	2001	Treatment of the cells with 100 microM As3+ for 4 h resulted in a significant increase in the MT-1 and MT-2 proteins immediately preceding and following removal of the stress.	as3+	39-43	metallothionein 2A	Homo sapiens	103-107
11502567-7	2001	Preincubation of the cells with the specific ET(B) antagonist BQ-788 blocked MT-2 mRNA expression more effectively than the ET(A) inhibitor TBC-11251.	BQ 788	62-68	metallothionein 2A	Homo sapiens	77-81
11502567-10	2001	These results demonstrate that an increase in extracellular glucose in HUVEC can lead to a rapid dose-dependent increase in MT-2 mRNA expression and to perinuclear localization of MT protein with changes to the cytoskeleton.	Glucose	60-67	metallothionein 2A	Homo sapiens	124-128
11520198-0	2001	2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.	2-n-acylaminoalkylindoles	0-25	metallothionein 2A	Homo sapiens	102-105
11520198-0	2001	2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.	Melatonin	116-125	metallothionein 2A	Homo sapiens	102-105
11520198-3	2001	Quantitative structure-activity relationship studies showed that 4-methoxy-2-(N-acylaminomethyl)indoles, with a benzyl group in position 1, were selective MT2 antagonists and, in particular, N-[(1-p-chlorobenzyl-4-methoxy-1H-indol-2-yl)methyl]propanamide (12) behaved as a pure antagonist at MT1 and MT2 receptors, with a 148-fold selectivity for MT2.	4-methoxy-2-(n-acylaminomethyl)indoles	65-103	metallothionein 2A	Homo sapiens	155-158
11520198-3	2001	Quantitative structure-activity relationship studies showed that 4-methoxy-2-(N-acylaminomethyl)indoles, with a benzyl group in position 1, were selective MT2 antagonists and, in particular, N-[(1-p-chlorobenzyl-4-methoxy-1H-indol-2-yl)methyl]propanamide (12) behaved as a pure antagonist at MT1 and MT2 receptors, with a 148-fold selectivity for MT2.	4-methoxy-2-(n-acylaminomethyl)indoles	65-103	metallothionein 2A	Homo sapiens	300-303
11520198-3	2001	Quantitative structure-activity relationship studies showed that 4-methoxy-2-(N-acylaminomethyl)indoles, with a benzyl group in position 1, were selective MT2 antagonists and, in particular, N-[(1-p-chlorobenzyl-4-methoxy-1H-indol-2-yl)methyl]propanamide (12) behaved as a pure antagonist at MT1 and MT2 receptors, with a 148-fold selectivity for MT2.	4-methoxy-2-(n-acylaminomethyl)indoles	65-103	metallothionein 2A	Homo sapiens	300-303
11520198-4	2001	We present a topographical model that suggests a lipophilic group, located out of the plane of the indole ring of MLT, as the key feature of the MT2 selective antagonists.	indole	99-105	metallothionein 2A	Homo sapiens	145-148
11306562-1	2001	The metal-regulatory transcription factor 1 (MTF-1) is a key regulator of heavy metal-induced transcription of metallothionein I and II and other genes in mammals and other metazoans.	Metals	4-9	metallothionein 2A	Homo sapiens	111-135
11421579-3	2001	We have recently shown that the exogenous administration of the antioxidant protein zinc-metallothionein-II (Zn-MT-II) significantly decreased the clinical symptoms, mortality, and leukocyte infiltration of the CNS during EAE.	zinc-metallothionein-ii	84-107	metallothionein 2A	Homo sapiens	112-117
11515845-18	2001	Lower levels of MTIIa in NRs may indicate a diminished efficiency of GR regulation in steroid-refractory patients.	Steroids	86-93	metallothionein 2A	Homo sapiens	16-21